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ABSTRACT 
Cocrystals have gained tremendous interest in pharmaceutical development due to their 
potential to increase bioavailability.  Dissolution could be a major determinant for oral 
bioavailability, however, its mechanism for these cocrystalline materials has not been well 
recognized.  Lacking knowledge of the dissolution mechanism can lead to misinterpretation of in 
vitro and in vivo behavior.  The purpose of this dissertation is to provide a mechanistic 
understanding of the dissolution behavior of cocrystals to rationalize the selection process and 
improve in vivo predictions.   
 Cocrystals usually contain components with different physicochemical properties, such as 
ionization, diffusivity, and micellar solubilization and each of these properties can impact their 
rates of dissolution.  The main focus of this dissertation is to develop mass transport analyses to 
evaluate the roles of these properties on dissolution under varying solution conditions.  The 
different diffusivities between the cocrystal components led to the development of two different 
analyses, the surface saturation and interfacial equilibrium models to describe the dissolution 
process of cocrystals.  Better agreement with the experimental data makes the surface saturation 
model the preferred choice for flux predictions.     
This dissertation has demonstrated that the dissolution of cocrystals with ionizable 
components is dictated by the pH at the dissolving solid surface.  This interfacial pH is influenced 
by both the cocrystal properties and solution composition.  Depending on solution conditions, both 
carbamazepine and ketoconazole cocrystals can exhibit higher, equal, or lower dissolution rates 
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compared to their parent drugs.  The carbamazepine cocrystals studied here maintain both 
dissolution advantage and thermodynamic stability because of their diffusivity advantage.  The pH 
dependence of ketoconazole dissolution is mitigated through cocrystallization with acidic 
coformers.  Similar to pharmaceutical salts, cocrystals also exhibit common coformer effect in 
which the dissolution rates decrease with increasing coformer solution concentration.  By 
incorporating the independently determined values of physicochemical properties of cocrystal 
components and solution composition into the mass transport analyses, the flux of cocrystals as a 
function of bulk pH, surfactant, coformer and buffer concentration can be accurately predicted.  
These mass transport analyses provide the fundamental knowledge of cocrystal dissolution and the 
opportunity to predict and rationalize the design of cocrystals for optimal oral absorption.   
 
 
 
 
 
 
 
 
 
 
 1 
 
CHAPTER 1  
INTRODUCTION 
Solubility is one of the important physicochemical properties that needs to be evaluated 
during the drug discovery and development process, since it is a significant factor that affects the 
dissolution rate and consequently, the oral absorption of the drug1.  This is particularly important 
for drugs that fall into the Biopharmaceutics Classification System (BCS) class II compounds, 
where solubility is likely the limiting factor for oral absorption due to the low solubility and high 
permeability properties of the drugs1, 2.  Despite the importance of solubility, the number of poorly 
water soluble drugs is increasing due to the need of larger and more lipophilic molecules for the 
newly discovered drug targets1, 3.  Currently, the number of poorly water soluble drugs accounts 
for 40% of the marketed drugs and 75% of the drugs that are under development1.  As a result, the 
enhancement of aqueous solubility has remained a challenge for the successful development of 
drug products in the pharmaceutical industry1, 3.  Many strategies have been employed to overcome 
this challenge and these include both formulation and solid state approaches1, 4.  Formulation 
strategies include but are not limited to the use of cosolvents, surfactants, complexation agents and 
lipid systems1.  While formulation approaches rely mainly on the use of excipients for improving 
solubility, solid state approaches focus on the solid structure modifications of the active 
pharmaceutical ingredients (APIs) and these include amorphous forms, polymorphs, solvates, 
hydrates, formation of salts and cocrystals4.  Each of these solid forms displays unique 
physicochemical properties that can influence the performance of the pharmaceutical materials5.   
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 Among the solid state approaches, cocrystals are an emerging class of engineered solid 
forms in pharmaceutical research and development, which have generated tremendous interest due 
to their potential advantages over other solid forms3, 4, 6.  Polymorphism offers limited number of 
crystalline structures since there is only a few number of different crystal forms that can be 
identified for a given API 7.  Cocrystal engineering provides opportunities to produce a large 
diversity of crystal forms due to the abundance of coformers available for formation3, 4, 8.  Unlike 
salt formation which is limited to only ionizable compounds, cocrystallization is possible for 
nonionizable compounds.  Cocrystals have high crystal lattice energy and thus offer better stability 
for formulations compared to amorphous and solvated drugs1, 7.  More importantly, cocrystals offer 
large solubility range and versatility in fine-tuning the solubility of the parent drugs9-12. 
Cocrystal engineering can generate a variety of crystal forms with physicochemical 
properties that are distinct from the APIs and these properties include but are not limited to 
crystallinity, melting point, physical and chemical stability, mechanical properties, solubility, 
dissolution and bioavailability4.  Among these properties, solubility and dissolution are of 
particular interest due to their importance in the oral absorption of drugs1, 2.  Cocrystals have the 
potential to improve aqueous solubility of pharmaceutical compounds that can translate into higher 
dissolution rate and thus better bioavailability3.  Consequently, a thorough understanding of the 
solubility and dissolution mechanisms of cocrystals is necessary to interpret their in vivo 
performance. 
  Cocrystal solubility is dependent on not only its own properties, but also the solution 
conditions such as pH, solubilizing agents and coformer concentration10, 12, 13.  Depending on the 
solution conditions, the same cocrystal can exhibit higher, equal or lower solubility compared to 
the parent drug.  This solubility phenomenon results in transition points that are important for 
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evaluating the thermodynamic stability of cocrystals.  At the transition point, the solubility of the 
drug and cocrystal are equal, but below or above, cocrystal can have higher solubility.  These 
transition points can be defined as the eutectic point, pHmax, S
* and critical stabilization 
concentration (CSC)10, 12, 14-16.  The solubility product behavior of cocrystal in which the solubility 
of the cocrystal decreases with increasing coformer concentration can lead to a transition point 
also known as the eutectic point15.  The existence of pHmax is due to the different solubility pH 
dependence between the drug and cocrystal14, 17.  The preferential solubilization of the drug over 
the coformer by solubilizing agent can lead to a transition point that is characterized by a 
solubilizing agent concentration (CSC) and a solubility value (S*)10, 16.  The existence of these 
transition points makes the thermodynamic stability of cocrystals controllable through varying 
solution conditions.  Knowledge of these transition points can be useful for fine tuning the 
solubility advantages of cocrystals to modulate their dissolution rates. 
 Dissolution studies of cocrystals have been evaluated in different media3, 8, 18-21, however, 
a fundamental understanding of the dissolution mechanism is still lacking to explain the different 
behavior.  Properties of both cocrystal and solution have been shown to be important parameters 
for determining the solubility of cocrystals, but their roles on dissolution remain to be established.  
Cocrystals usually contain components with different physicochemical properties, such as 
ionization, diffusivity and micellar solubilization.  It has been shown that the pH at the dissolving 
surface of ionizable compounds during dissolution could be different from the bulk solution pH22-
24.  Knowing that the cocrystal components can be ionizable, it is important to evaluate how these 
properties could affect the pH microenvironment within the diffusion layer because of the pH 
dependent solubility of the cocrystals.  Diffusion coefficient is another parameter that influences 
dissolution and for most cocrystals, the components can have different diffusivities because of the 
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difference in molecular size and hydrophobicity.  Being able to identify the roles of the different 
properties of cocrystal components can help to establish the dissolution mechanism of cocrystals. 
 One of the prerequisites for successful oral formulation development is to select the solid 
form with optimal physicochemical properties that can lead to desired bioperformance and the 
selection process is based on the thorough understanding of these properties.  The two important 
properties that influence bioavailability are solubility and dissolution.  Since the solubility 
mechanisms of cocrystals have been established, the focus of this dissertation is dissolution.  This 
chapter provides the fundamental principles and concepts that are essential for understanding the 
dissolution behavior of cocrystals.  A statement of research objectives is also included in this 
chapter to give an overview of this dissertation.         
Cocrystal Design and Synthesis 
 Cocrystals are crystalline materials that contain two or more different molecular 
components in the same crystal lattice with well-defined stoichiometric ratios and these 
components are usually APIs and coformers that are both solids at room temperature7, 25, 26.  The 
design of cocrystals is based on the principles of crystal engineering and concepts of 
supramolecular chemistry, in which the components are selected based on favorable 
intermolecular interactions27, 28.  The supramolecular synthons responsible for the formation of 
cocrystals include non-covalent interactions, such as hydrogen bonds, π-π interactions and Vander 
Waals forces7, 26.  Among these interactions, hydrogen bonding is the most important and common 
interaction7, 26.  Supramolecular synthons can be classified into two categories, homosynthons, 
which are interactions between identical functional moieties, whereas heterosynthons are 
interactions between different functional moieties29, 30.  Heterosynthons are important interactions 
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for cocrystal design because they are energetically favored over homosynthons28.  The common 
hydrogen bond synthons of cocrystals are shown in Figure 1.126.  
 
Figure 1.1.  Common supramolecular synthons formed between carboxylic acids and amide 
groups26. 
 
Various techniques have been developed to synthesize cocrystals, which include, but are 
not limited to solution crystallization, mechanical grinding and melt crystallization3.  Among these 
techniques, reaction crystallization method (RCM) offers several advantages over other methods31.  
RCM is not only suitable for high throughput screening of cocrystals, but also good for large scale 
synthesis31.  The mechanism of RCM is based on generating supersaturation in solution with 
respect to only one solid phase, which is the cocrystal31.  Because of the solubility product 
behavior, supersaturation of incongruently saturated cocrystals can be generated in solution by 
increasing concentration of one component in excess to the stoichiometric ratio13, 31.  The synthesis 
of cocrystals can be guided by solubility phase diagrams similar to the one shown in Figure 1.232.  
The diagram indicates the regions of thermodynamic stability of the cocrystal and its components, 
which is very important for identifying the solution conditions that favor the formation of 
cocrystals31, 32.  Among the four regions shown in Figure 1.2, solution concentrations in both region 
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II and IV are supersaturated with respect to the cocrystal.  However, only pure cocrystal can form 
in region IV because region II is also supersaturated with respect to drug.   
 
Figure 1.2.  Schematic phase solubility diagram indicating thermodynamic stability regions and 
formation pathway of cocrystal.  Lines represent solubility of drug A, coformer B, and cocrystal 
AB.  Cocrystal solubility decreases with coformer concentration [B]T.  Subscript T represents total 
concentrations.  Arrows represent a path along which cocrystal is the only phase that can 
crystallize.  Region I: solution is supersaturated with respect to drug, and cocrystal can convert to 
drug.  Region II: solution is supersaturated with respect to both drug and cocrystal, and both can 
crystallize.  Region III: solution is below saturation of drug, cocrystal, and coformer.  Region IV: 
solution is supersaturated with respect to cocrystal, and cocrystal can crystallize32. 
   
Cocrystal solubility 
 Solubility is determined by two important parameters, lattice and solvation energy.  Lattice 
energy refers to the intermolecular forces of the solute and solvation energy is the interaction 
between the solute and solvent molecules in solution1.  The solubility mechanism involves the 
breaking of intermolecular bonds of the solid form and then follows by the formation of solvent-
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solute bonds1, 9.  Therefore, the strategies for enhancing solubility are to reduce the intermolecular 
forces of the solute and/or maximize the solvation energy1.  It is important to know the primary 
barrier for solubility in order to determine what strategy to use for enhancing solubility1.  Studies 
have shown that the main barrier for cocrystal aqueous solubility is the solvation energy because 
of the hydrophobic nature of the drug9.  Consequently, the aqueous solubility of cocrystals can be 
modulated through solution interactions, such as ionization, complexation and micellar 
solubilization9.  The common solution phase interactions of cocrystals are illustrated in Figure 1.3 
9.  
 
Figure 1.3.  Cocrystal solution phase interactions and associated equilibria for a 1:1 cocrystal RHA 
with a non-ionizable drug (R) and an ionizable coformer (HA) in micellar solution9. 
 
Ionization  
The solubility pH dependence of a poorly water soluble drug can be modified via 
cocrystallization with coformers of different ionization properties, such as acidic, basic, 
amphoteric and zwitterionic12.  Mathematical models have been developed to predict the solubility 
pH dependence of cocrystals based on the chemical equilibria of both components in solution12.  
Consider a 1:1 cocrystal with R as the non-ionizable drug and HA as the acidic coformer, the 
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chemical equilibria in solution include cocrystal dissociation and coformer ionization, which can 
be described as follows: 
𝑅𝐻𝐴𝑠𝑜𝑙𝑖𝑑 ⇋ 𝑅𝑎𝑞 + 𝐻𝐴𝑎𝑞             (1.1) 
𝐾𝑠𝑝 = [𝑅]𝑎𝑞[𝐻𝐴]𝑎𝑞                 (1.2) 
𝐻𝐴𝑎𝑞  ⇋  𝐻
+ + 𝐴𝑎𝑞
−
                (1.3) 
𝐾𝑎 =
[𝐻+][𝐴−]𝑎𝑞
[𝐻𝐴]𝑎𝑞
              (1.4) 
where Ksp is the solubility product, Ka is the ionization constant of the coformer and subscript aq 
denotes the aqueous phase12.  By applying mass balance for each component in solution, the total 
drug and coformer concentrations can be expressed as12: 
[𝑅]𝑇 = [𝑅]𝑎𝑞               (1.5) 
[𝐴]𝑇 = [𝐻𝐴]𝑎𝑞 + [𝐴
−]𝑎𝑞             (1.6) 
By combining the mass balance equations with the equilibrium constants, the total drug 
concentration can be expressed as12: 
[𝑅]𝑇 =  
𝐾𝑠𝑝
[𝐴]𝑇
(1 + 
𝐾𝑎
[𝐻+]
)             (1.7) 
When cocrystal is in equilibrium with solution under stoichiometric conditions, the cocrystal 
solubility is equal to the total drug concentration, as well as the total coformer concentration12:  
𝑆𝑐𝑜𝑐𝑟𝑦𝑠𝑡𝑎𝑙 =  [𝑅]𝑇 = [𝐴]𝑇             (1.8) 
By combining equations 1.7 and 1.8, the stoichiometric solubility of a 1:1 cocrystal with 
nonionizable drug and monoacidic coformer can be expressed as follow12: 
 9 
 
𝑆𝑐𝑜𝑐𝑟𝑦𝑠𝑡𝑎𝑙 =  √𝐾𝑠𝑝 (1 +
𝐾𝑎
[𝐻+]
)              (1.9) 
Solubility equations for cocrystals of varying ionization properties and stoichiometries can be 
derived in a similar manner12.  The development of these mathematical models can give a priori 
predictions of the solubility pH dependence of pharmaceutical cocrystals.  The ability of cocrystals 
in modulating the pH dependent solubility of the parent drugs is demonstrated in Figure 1.4.  
Depending on the ionization properties of the coformers, the solubility behavior of cocrystals as a 
function of pH can be very different from that of the parent drug.  For example, a non-ionizable 
drug exhibits no pH dependent solubility as shown in Figure 1.4, (a) and (b).  However, the 
cocrystal of this drug with diacidic coformer leads to increase in solubility as a function of pH, 
whereas the cocrystal with amphoteric coformer results in a U-shaped solubility curve.  The 
solubility behavior is also predicted for cocrystals of a basic drug (Figure 1.4, c) and a zwitterionic 
drug (Figure 1.4, d) with acidic coformers. 
(a)                                                                           (b) 
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(c)                                                                              (d) 
 
Figure 1.4.  Theoretical solubility-pH profiles for (a) 2:1 R2H2A cocrystal, (b) 2:1 R2HAB 
cocrystal, (c) 2:1 B2H2A cocrystal and (d) 1:1 
–ABH+H2X cocrystal calculated using previously 
developed equations12.  Drug and coformer pKa values and cocrystal Ksp are included in each 
graph.  
 
Transition point: pHmax 
 A transition point, pHmax can exist if the solubility curve of the drug intersects with that of 
the cocrystal at a given pH value.  This transition point is an important parameter for determining 
the stability region of cocrystals.  An example demonstrating this transition point is shown in 
Figure 1.5 for a dibasic drug, ketoconazole and its cocrystals with diacidic coformers33.  At pHmax, 
the solubility of the drug is the same as the cocrystals.  Below pHmax, the drug has higher solubility, 
but above it, the cocrystal solubility is higher.  By changing the solution pH, the 
thermodynamically stable cocrystal (below pHmax) can become unstable in solution (above pHmax).  
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Figure 1.5.  Solubility pH dependence of ketoconazole ( ), ketoconazole-adipic acid ( ), 
ketoconazole-succinic acid ( ) and ketoconazole-fumaric acid ( ).  The transition point, 
pHmax, is at the intersection between the drug and cocrystal solubility curves.  Solid lines represent 
the theoretical predictions and the symbols are the experimental data33. 
 
Micellar solubilization 
 Surfactants are common excipients used in pharmaceutical formulation development to 
enhance the solubility of poorly water soluble drugs34.  Studies have shown that the behavior of 
cocrystals in surfactant solution is different from that of the single components10, 35, 36.  A schematic 
representation of micellar solubilization of cocrystal is demonstrated in Figure 1.6.  The 
solubilization process involves several equilibria between the cocrystal solid phase and its 
components in the aqueous and micellar pseudophases35.  As shown in Figure 1.6, surfactant can 
solubilize the cocrystal components to different extents because of the different hydrophobicity 
between the components.  The hydrophobic drug is preferentially solubilized in the micelles, while 
the hydrophilic coformer is mostly in the aqueous phase.  Because of the differential solubilization 
between the cocrystal components, the solubility dependence on surfactant concentration of the 
cocrystal is different from the drug.  The solubility of hydrophobic drug usually exhibits linear 
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dependence on surfactant concentration, while the cocrystal solubility exhibits nonlinear 
dependence.  The linear dependent solubility of a nonionizable drug in surfactant solution can be 
described as 
𝑆𝑑𝑟𝑢𝑔 =  𝑆0(1 + 𝐾𝑠
𝑅[𝑀])           (1.10) 
and the nonlinear dependent solubility of 1:1 cocrystal RHA with nonionizable drug and acidic 
coformer in surfactant solution is described as  
𝑆𝑐𝑜𝑐𝑟𝑦𝑠𝑡𝑎𝑙 =  √𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑀]) (1 + 𝐾𝑠𝐻𝐴[𝑀] +
𝐾𝑎
[𝐻+]
)       (1.11) 
where 𝑆0 is the intrinsic solubility of the drug, 𝐾𝑠
𝑅 and 𝐾𝑠
𝐻𝐴 are the solubilization constants of the 
drug and coformer respectively, and M is the micellar surfactant concentration, which is equal to 
the total surfactant concentration minus the critical micellar concentration (CMC) 35. 
 
Figure 1.6.  Schematic illustration of the equilibria between the cocrystal phase and its components 
in the aqueous and micellar pseudophases. This scheme represents micellar solubilization of one 
cocrystal component (for instance drug), leading to excess coformer in the aqueous pseudophase 
and in this way stabilizing the cocrystal phase35. 
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Transition point: CSC 
 Solubilizing agents such as surfactants, polymers and lipids can induce transition point for 
cocrystals with higher solubility than the parent drug under the assumption that these agents 
preferentially solubilize the drug over the coformer.  This transition point is characterized by a 
solubilizing agent concentration (i.e. CSC) required to achieve equivalent solubility between the 
drug and cocrystal, and a solubility value (S*)10, 16.  Similar to pHmax, CSC marks the stability 
region for cocrystals in solution containing solubilizing agents.  Below the CSC, cocrystal is the 
thermodynamically unstable phase relative to the less soluble drug10.  Above the CSC, cocrystal 
becomes thermodynamically stable because it is less soluble than the drug10.   
Surfactants can impart stability to the otherwise unstable cocrystals and the effectiveness 
of stabilization is dependent on the relative magnitude of the micellar solubilization constants 
between the components10, 35.  As demonstrated in Figure 1.7, the greater the difference in micellar 
solubilization between the drug and coformer, the lower the surfactant concentration required to 
achieve the CSC value10, 35.  The existence of CSC is due to the preferential solubilization, so it 
will disappear if the solubilization of the drug is the same as the coformer as shown in Figure 1.710, 
35.     
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Figure 1.7.  Schematic representation of the cocrystal (RHA) and drug (R) solubility with respect 
to the total surfactant concentration.  Ks
R and Ks
HA are the solubilization constants for R and HA, 
respectively.  CMC is the critical micellar concentration and CSC is the critical stabilization 
concentration35.  
 
Eutectic point measurement 
 Dissolution is the common method used in evaluating the solubility of cocrystals 3, 8, 21, 37.  
However, this method usually fails to capture the true dissolution concentration time profile 
because cocrystals are supersaturating drug delivery systems and may lead to drug crystallization 
during dissolution9.  Because of the solution mediated phase transformation, the thermodynamic 
solubility of cocrystals can be underestimated using the kinetic measurements.  To address this 
problem, the eutectic point measurement has been developed to determine the thermodynamic 
equilibrium solubility of cocrystals15.  At the eutectic point, the solid phases of both drug and 
cocrystal are in equilibrium with solution, and the solution concentrations of drug and coformer 
are dependent on the solution conditions, such as temperature, pH, solvent and additives15.  The 
eutectic point can be established by following the flowchart illustrated in Figure 1.8.  By measuring 
the solution concentrations of the cocrystal components ([drug]eu and [coformer]eu) at the eutectic 
point, the thermodynamic solubility of the cocrystal can be determined15.   
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Figure 1.8.  Flowchart of representative methods used to determine the equilibrium solution 
concentrations of cocrystal components at the eutectic point.  In this case, the solid phases at 
equilibrium are cocrystal and solid drug15, 32.  
 
Cocrystal dissolution and bioavailability 
 There are numerous examples in the literature trying to demonstrate the advantage of 
cocrystals over the parent drugs by comparing the solubility, dissolution and bioavailability data3.  
However, cocrystals do not always exhibit better performance than the parent compounds and the 
in vitro dissolution data does not always correlate well with the in vivo data8, 18, 21, 38.  Experimental 
designs and interpretation of the results can be improved by understanding the solubility and 
dissolution mechanisms of cocrystals.  This section includes a few examples of cocrystal 
dissolution and bioavailability studies from the literature. 
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Carbamazepine 
Carbamazepine (CBZ) is a BCS II antiepileptic drug that is known to have four different 
anhydrous polymorphs, as well as hydrates and solvates39, 40.  It has limited bioavailability because 
of its poor water solubility, so it usually requires higher doses to achieve the desired 
pharmacological effect41.  Cocrystallization offers advantage for improving aqueous solubility of 
CBZ over salt formation due to its neutral property.  Many cocrystals have been discovered for 
CBZ and some have been demonstrated to have improved solubility15, 38, 42.  CBZ cocrystals are 
excellent examples for which the solubility pH dependence of neutral compounds can be tailored 
through cocrystallization with different coformers.  Among these cocrystals, CBZ saccharin (CBZ-
SAC) has been studied intensively and its performance has been compared with the marketed 
product, Tegretol41.  The dissolution studies of CBZ-SAC were performed in stimulated gastric 
fluid at 37°C with different particle sizes and the results showed that the dissolution rate increased 
with smaller particle sizes41.  It was concluded that the smaller particle size of CBZ-SAC can 
prevent the conversion of cocrystal to the more stable drug form in solution; however, such 
statement was not conclusive because only one dissolution medium was studied and the solid phase 
analyses were performed only on particle size of 500 µm or greater41.  The pharmacokinetic studies 
performed in dogs showed no statistical difference in pharmacokinetic parameters between the 
cocrystal and Tegretol, which is shown in Figure 1.941.  This comparable result is likely due to the 
transformation of cocrystal back to the parent drug, which could potentially cause by the increased 
solubility of the cocrystal at higher pH environment in the intestine43.  In addition, the cocrystal 
capsule is formulated differently from the marketed product.  To improve in vivo performance, the 
formulations of poorly water soluble drugs usually contain additives that can solubilize the drug.  
CBZ-SAC may have better in vivo performance if it is formulated the same as the marketed 
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product.  In conclusion, this study has demonstrated the need to understand the effect of particle 
size and solution environment on cocrystal solubility and dissolution.   
 
Figure 1.9.  Average plasma time curves of CBZ concentrations from a cross-over experiment in 
fasted beagle dogs (n = 4) given oral doses of 200 mg of the active drug as Tegretol tablets and 
CBZ-SAC41.  
 
Indomethacin 
Indomethacin (IND) is a nonsteroidal drug with anti-inflammatory, antipyretic and 
analgesic properties, which belongs to the BCS class II compounds44.  The two polymorphic forms 
of IND are α and γ, with the γ form being thermodynamically stable at room temperature44.  IND 
is a weakly acidic drug with a pKa value of 4.5 and its γ form has a solubility of 2.5-4 µg/ml in 
water.  This low solubility could be the potential cause for low and erratic bioavailability44.  To 
improve the solubility and dissolution of IND, it was cocrystallized with SAC. The powder 
dissolution study indicated that the dissolution of the cocrystal was higher in pH 7.4 phosphate 
buffer compared to the γ form44.  The conversion of the cocrystal to the γ form was noticed during 
dissolution, but in-depth understanding of the dissolution behavior is lacking44.   
The dissolution and bioavailability of IND-SAC were evaluated and compared to the 
marketed product Indomee18.  In vitro dissolution studies were performed in both pH 7.4 phosphate 
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buffer and 0.1 M HCl with 0.5% Tween 80 at pH 1.218.  The results indicated that IND-SAC 
exhibited higher dissolution rate in both dissolution media compared to IND, but displayed 
comparable dissolution rate as the marketed product18.  This study demonstrated the pH effect on 
the dissolution of IND-SAC, in which the dissolution rate increased at high pH due to the acidity 
of IND and SAC11, 18.  Bioavailability of IND, IND-SAC and marketed product were evaluated in 
beagle dogs.  The cocrystal was prepared in hard gelatin capsules containing only lactose, whereas 
the marketed product contained more additives18.  As shown in Figure 1.10, the AUC and Cmax of 
IND-SAC were higher than IND, but similar to the marketed product18.  Again, this similar 
bioavailability between the cocrystal and the marketed product is potentially due to the additives 
used in the marketed product to optimize the formulation18.   
 
Figure 1.10.  Plasma concentration vs. time profiles for IND after oral administration of various 
formulations in beagle dogs: (●) IND–SAC cocrystal (ground); (■) 1:1 Physical mixture of IND 
(γ) and SAC; (▲) Indomee®.  Error bars show standard deviation18. 
 
Meloxicam 
Meloxicam is a BCS class II non-steroidal anti-inflammatory and antipyretic drug45.  It has 
a solubility of 0.012 mg/mL in water and its solubility is pH dependent due to its ionization 
property45.  Meloxicam has five polymorphic forms and it can exist in four different tautomeric 
forms depending on the solution environment45.  The cation form is the dominate species under 
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acidic conditions; the zwitterion or enol form exists in neutral conditions; and the anion form 
presences in basic conditions45.  Meloxicam has an acidic pKa of 4.18 and a basic pKa of 1.09
46.  
Because of its low solubility, the therapeutic onset time of meloxicam is long.  Several cocrystals 
with different carboxylic acids as coformers have been discovered to improve the solubility and 
thus decrease the onset time of meloxicam45.     
 As one of the cocrystals, the kinetic solubility and bioavailability of meloxicam-aspirin 
cocrystal were evaluated47.  The cocrystal did not exhibit any solubility advantage in water at room 
temperature compared to the parent drug47.  However, the cocrystal showed a 44 fold solubility 
enhancement in pH 7.4 phosphate buffer at 37°C compared to the parent drug47.  The oral 
bioavailability of the cocrystal was 69%, whereas the parent drug was only 16%47.   
 A more recent study evaluated the correlation between the in vitro dissolution data and in 
vivo performance of meloxicam cocrystals8.  The in vitro dissolution of meloxicam and its 12 
cocrystals were performed in pH 6.5 phosphate buffer solutions at 37°C and the pharmacokinetic 
studies were performed using Sprague-Dawley rats, in which the rats were dosed with cocrystals 
suspended in 5% polyethylene glycol 400 (PEG 400) and 95% methylcellulose solutions8.  All the 
cocrystals exhibited faster dissolution rates at early time points, but eventually equilibrated to 
similar dissolution rate as meloxicam due to conversion8.  The pharmacokinetic study showed 
similar behavior as the dissolution8.  The correlation between the in vitro dissolution rates and in 
vivo absorption rates of the cocrystals was determined using linear regression analysis with a R2 
of 0.7067, which is shown Figure 1.118.  However, such correlation is not very accurate due to the 
following reasons.  First, phosphate buffer is not a very good representation of the physiological 
conditions.  The gastric intestinal (GI) tract contains bile salts, which are natural surfactants that 
can improve bioavailability by increasing dissolution rate48.  Second, the dissolution studies were 
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performed using pure cocrystals, whereas the pharmacokinetic studies used cocrystal suspensions 
in PEG 400 and methylcellulose solutions.  These polymers may have an impact on the solubility 
of the cocrystals.  To have better IVIV correlation, the dissolution studies should be conducted in 
physiological relevant conditions.  
 
Figure 1.11.  Correlation between in vitro dissolution rates and in vivo absorption rates of 
meloxicam and its cocrystals8. 
 
Lamotrigine 
 Lamotrigine is a BCS class II anticonvulsant drug, which exhibits poor water solubility 
(0.17 mg/mL at 25°C) and dissolution rate49.  Despite the fact that lamotrigine is a weak base with 
a pKa of 5.7, its aqueous solubility is still very low in 0.1 M HCl (4.1 mg/mL)
49.  Novel crystal 
forms of lamotrigine have been discovered to improve the solubility, which include three 
cocrystals, one cocrystal hydrate, three salt forms, two solvates and one hydrated form49.  Some of 
these crystal forms were selected to determine their dissolution rates and pharmacokinetic 
behavior49.  As shown in Figure 1.12, Lamotrigine methylparaben form II cocrystal exhibited 
lower maximal concentration during dissolution in water compared to the parent drug; however, it 
was able to achieve higher maximal concentration during dissolution in 0.1 M HCl solution49.  This 
different dissolution behavior is most likely due to the pH effect on dissolution.  However, the 
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authors stated that the dissolution profiles in acidic conditions were not affected by pH because 
there was no significant change in the final pH of the solution49.  Although the pH in the bulk 
solution did not change, the pH at the dissolving surface can be different and this interfacial pH is 
the determining factor for the dissolution behavior.   
(a)                                                                        (b) 
  
Figure 1.12.  Dissolution profiles in water (a) and 0.1 M HCl (b) of lamotrigine and its crystal 
forms.  2: lamotrigine methylparaben cocrystal form II; 3: lamotrigine nicotinamide cocrystal; 4: 
lamotrigine nicotinamide cocrystal monohydrate; 5: lamotrigine saccharin salt49. 
 
The mechanism of dissolution 
 Dissolution is defined as the “the mixing of two phases with the formation of one new 
homogeneous phase”, and this process involves five major steps: 1) the wetting of drug particle 
surface by water; 2) the breakdown of solid state bonds; 3) the solvation of drug molecules with 
water; 4) the diffusion of drug molecules away from the dissolving surface into the well-stirred 
bulk solution and 5) the convection within the well-stirred bulk solution50.  In most cases, the first 
three steps happen instantaneously and thus, diffusion is usually the rate limiting step that 
determines the dissolution rate51.   
 Dissolution is the prerequisite of drug absorption for almost all drugs that are given orally 
and the purpose of in vitro dissolution studies is to provide a fast and inexpensive way to predict 
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in vivo performance of drugs50, 52.  Thus, it is essential to understand the mechanism of dissolution 
and the development of mechanistic models for the dissolution process can be very beneficial50.  
The first diffusion controlled dissolution experiment was conducted by Noyes and Whitney in 
1897 and based on their observations, they proposed the dissolution mechanism to be the diffusion 
from the thin film of saturated solution that surrounded the dissolving substances50, 51, 53.  In 1904, 
Nernst and Brunner modified the Noyes and Whitney model and postulated the existence of a 
diffusion layer adhering to the dissolving surface50, 51, 54, 55.  Based on the concept of diffusion layer 
and Fick’s first law, they derived the Nernst-Brunner equation54, 55,  
𝑑𝑀
𝑑𝑡
=
𝐷𝑆
ℎ
(𝐶𝑠 − 𝐶𝑡)            (1.12) 
where dM/dt is the rate of dissolution, D is the diffusion coefficient of the drug, S is the surface 
area of the drug, h is the thickness of the diffusion layer, Cs and Ct are the solubility of the drug 
and the concentration of the drug in the bulk solution at time t, respectively50.  Based on this 
equation, the rate of dissolution is influenced by diffusion, surface area, solubility and thickness 
of the unstirred boundary layer.     
Rotating disk dissolution 
 Intrinsic dissolution rate (IDR) is a useful tool to characterize drugs and it has been used 
to determine the relationship between dissolution rate and crystalline form, as well as to study the 
effect of surfactants and pH on the dissolution of poorly soluble drugs56.  IDR has recently been 
suggested to use for BCS classification because its correlation with in vivo dissolution rate is better 
compared to solublity56.  IDR is defined as the dissolution rate of pure drug substance when 
extrinsic factors, such as surface area, agitation, pH, ionic strength and temperature of the 
dissolution medium, are held constant56, 57.  IDR can be measured by dissolution methods such as 
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the fixed disk system and rotating disk system57.  Rotating disk system is the commonly used 
method and it is also known as the “Wood’s apparatus”57.  One advantage of using this apparatus 
is that the hydrodynamic boundary layer has been well defined.  According to Levich model58, the 
thickness of the diffusion boundary layer for rotating disk is defined as:  
ℎ = 1.612𝐷1/3𝑣1/6𝜔−1/2           (1.13) 
where 𝑣 is the kinematic viscosity of the medium and 𝜔 is the angular velocity in radians per unit 
time58.   
The rate of dissolution can be expressed in terms of flux, which is defined as the amount 
of material flowing through a unit cross section of a barrier in a unit time52.  According to Fick’s 
first law, flux is described as follow:  
𝐽 = −𝐷
𝑑𝐶
𝑑𝑥
              (1.14) 
where J is the flux and 
𝑑𝐶
𝑑𝑥
 is the concentration gradient within the diffusion layer52.  Combining 
equations 1.12, 1.13 & 1.14, the equation describing the flux of drug substance across the diffusion 
layer for rotating disk system can be derived as22  
𝐽 = 0.62𝐷2/3𝑣−1/6𝜔1/2𝐶𝑠           (1.15) 
This equation is based on the assumption that dissolution is conducted under sink conditions, 
where Ct is equal to zero
22. 
Mass transport analyses of carboxylic acids 
Rotating disk dissolution apparatus has been used to examine the effect of pH on the 
dissolution kinetics of three carboxylic acids, benzoic acid, 2-naphthoic acid and indomethacin 
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under unbuffered conditions22.  Mass transport model has been developed to describe the 
dissolution process with simultaneous diffusion and chemical reactions within the hydrodynamic 
boundary layer adjacent to the dissolving surface22.  The chemical reactions happening at the 
dissolving surface during dissolution can alter the pH microenvironment and cause the pH at the 
interface to be different from that of the bulk solution22.  The development of the mass transport 
model allows the prediction of this interfacial pH and the flux that depends on this pH.   
The dissolution pH dependence of the three carboxylic acids confirms that the pH at the 
dissolving solid surface is different from the bulk solution22.  These carboxylic acids liberate 
hydrogen ions that can lower the pH at the dissolving solid surface compared to the bulk solution.  
The ionization of these acids also results in a buffer effect at the interface such that the interfacial 
pH remains relatively constant regardless of bulk pH changes as shown in Figure 1.13 (a)22.  
Interfacial pH dictates the dissolution behavior of these acids.  As shown in Figure 1.13 (b), the 
flux values of all three acids increase with bulk pH, but they all reach constant values at the 
buffering regions where there are minimal changes in interfacial pH22.  Knowledge of interfacial 
pH is essential for understanding the dissolution behavior of ionizable compounds.  The difficulty 
in accessing interfacial pH experimentally emphasizes the importance of performing mass 
transport analyses for ionizable compounds.  The mass transport models for predicting interfacial 
pH and flux consider the properties of the dissolving compounds, such as solubility, pKa values, 
and diffusion coefficients, and as well as the composition of the dissolution media, such as buffer 
species, bulk pH, et al22-24.     
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(a)                                                                (b) 
 
Figure 1.13.  (a) Interfacial pH as a function of bulk pH for 1: indomethacin, 2: 2-naphthoic acid 
and 3: benzoic acid.  (b) Flux ratios as a function of bulk pH for indomethacin (▲), 2-naphthoic 
acid (■) and benzoic acid (●)22.   
 
Statement of dissertation research 
 Although the dissolution rates of cocrystals have been widely studied3, 8, 18-21, not many 
have considered the mechanism of the dissolution process59-61.  Due to the lack of knowledge in 
this area, the purpose of this dissertation research is to provide a mechanistic understanding of the 
dissolution behavior of cocrystals under the influence of different solution conditions, such as pH 
and the presence of surfactant, coformer and buffer.  The main objective of this research is to 
develop mass transport models that incorporate the important physicochemical properties of the 
cocrystals to explain their dissolution behavior under different solution conditions.  These mass 
transport analyses can not only guide the development process of cocrystals, but also provide 
useful insights for predicting their in vivo performance.  
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  Chapter 2 of this thesis studies the dissolution behavior of two carbamazepine cocrystals 
under the influence of pH and micellar solubilization.  The purpose of this chapter is to provide a 
mechanistic understanding of the dissolution behavior of cocrystals through mass transport 
analyses.  It has been shown that the pH at the dissolving surface of ionizable drug is different 
from the bulk solution22-24.  This interfacial pH is important for determining the dissolution rate 
and can be predicted by developing mass transport models22-24.  In this chapter, mass transport 
models are developed by applying Fick’s law of diffusion to dissolution with simultaneous 
chemical reactions in the hydrodynamic boundary layer adjacent to the dissolving cocrystal surface 
to predict the interfacial pH and flux of the cocrystals.  The predictive powers of these models are 
evaluated by comparing the theoretical predictions of cocrystal flux with the experimental data as 
a function of pH and surfactant concentration.  This chapter also discusses the important roles of 
cocrystal physicochemical properties, such as solubility, diffusivity, ionization, micellar 
solubilization in determining the interfacial pH and rates of dissolution.  
 Chapter 3 provides a mechanistic analysis and comparison of the dissolution behavior of 
carbamazepine to its two cocrystals under the combination effect of pH and surfactant.  In this 
chapter, a simple mathematical equation is derived based on the mass transport analyses of both 
drug and cocrystal to describe the dissolution advantage of cocrystal, which is defined as the flux 
of the cocrystal over that of the drug.  The dissolution advantage is dependent on both the solubility 
and diffusion coefficient advantages of the cocrystal.  If the diffusion coefficient of the drug is the 
same as that of the cocrystal, the cocrystal dissolution advantage is equal to the solubility 
advantage.  This chapter evaluates the cocrystal dissolution advantage under the conditions where 
the diffusivity of the drug is different from that of the cocrystal.  Having a diffusivity advantage 
can be beneficial because it requires lower or even no solubility advantage to maintain higher 
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cocrystal dissolution rate.  The developed mass transport models can be used to evaluate the 
dissolution conditions where the cocrystals can display both dissolution advantage and 
thermodynamic stability.  
 Chapter 4 evaluates the influence of excess coformer on the dissolution rates of cocrystals.  
Similar to pharmaceutical salts, cocrystals also exhibit solubility product behavior.  This behavior 
leads to the suppression of salt dissociation in the presence of excess counter ion, which is known 
as the common ion effect.  The solubility of cocrystal has also been shown to decrease in the 
presence of excess coformer.  Using salts as an analogy, the influence of excess coformer on the 
solubility and dissolution rates of cocrystals is defined as the common coformer effect.  Excess 
coformer can potentially be accumulated in the intestinal lumen if the permeation of the drug is 
faster than the coformer.  The excess coformer in the intestine can affect the dissolution rate if the 
cocrystal has not completely dissolved.  Evaluating the common coformer effect on the dissolution 
of cocrystals can provide insights on how the differential permeations between the cocrystal 
components could impact the oral absorption.  Another important purpose of this chapter is to 
validate the surface saturation model developed in Chapter 2 to describe the dissolution mechanism 
of cocrystals.  By varying the coformer concentration in the bulk solution, the surface 
concentration of coformer can be the same as or higher than the drug concentration. 
Chapter 5 investigates and compares the pH effect on the dissolution of a dibasic drug, 
ketoconazole to its three cocrystals with diacidic coformers.  Because of its basicity, the oral 
absorption of ketoconazole can be impaired for patients with elevated stomach pH.  However, in 
vivo performance can be improved under acidic conditions.  One of the objectives of this chapter 
is to examine the potential of cocrystallizing ketoconazole with acidic coformers in enhancing 
bioavailability.  This is achieved by evaluating and comparing the dissolution pH dependence of 
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ketoconazole to its cocrystals.  In this chapter, the mass transport models are expanded to include 
cocrystals with components of diverse ionization properties, specifically for cocrystals with 
dibasic drugs and diacidic coformers.  The mass transport analyses result in a cubic equation and 
an eighth order polynomial equation for predicting the interfacial pH for the dissolution of the 
diabasic drug and its cocrystals with diacidic coformers, respectively.   Based on the interfacial 
pH predictions, the dissolution pH dependence of both ketoconazole and its cocrystals are 
predicted and compared to the experimental data.  The mechanistic understanding of cocrystal 
dissoluiton provides useful information for the selection process and formulation development. 
Chapter 6 studies the effect of buffer on the dissolution rate of a 1:1 cocrystal, 
carbamazepine-salicylic acid.  This chapter extends the mass transport model developed in Chapter 
2 to include the chemical reactions between the acidic coformer and the basic buffer species within 
the hydrodynamic boundary layer.  In the presence of monoprotic buffer, a seventh order 
polynomial equation is required to predict the interfacial pH for the dissolution of 1:1 cocrystals 
with nonionizable drug and monoacidic coformer.  The impact of buffer on the dissolution of 
cocrystals is evaluated using the mass transport model as a function of bulk pH and buffer 
concentration.  The predictive power of this mass transport model is evaluated by comparing the 
theoretical flux predictions with the experimental data obtained in different acetate and phosphate 
buffer concentrations.  A constant surfactant concentration (150 mM sodium lauryl sulfate) is used 
in all dissolution studies to prevent or minimize the cocrystal conversion.  
 The last chapter of this thesis concludes with the significant findings and future directions 
of this research.  Chapter 2 of this thesis is published in Molecular Pharmaceutics 2016, 13(3), 
1030-46.  A manuscript of Chapter 5 is currently being prepared for publication.  
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CHAPTER 2   
MECHANISTIC ANALYSIS OF COCRYSTAL DISSOLUTION AS A FUNCTION OF 
pH AND MICELLAR SOLUBILIZATION* 
Abstract  
The purpose of this work is to provide a mechanistic understanding of the dissolution 
behavior of cocrystals under the influence of ionization and micellar solubilization.  Mass transport 
models were developed by applying Fick’s Law of diffusion to dissolution with simultaneous 
chemical reactions in the hydrodynamic boundary layer adjacent to the dissolving cocrystal surface 
to predict the pH at the dissolving solid-liquid interface (i.e. interfacial pH) and the flux of 
cocrystals. To evaluate the predictive power of these models, dissolution studies of 
carbamazepine-saccharin (CBZ-SAC) and carbamazepine-salicylic acid (CBZ-SLC) cocrystals 
were performed at varied pH and surfactant concentrations above the critical stabilization 
concentration (CSC), where the cocrystals were thermodynamically stable.  The findings in this 
work demonstrate the pH dependent dissolution behavior of cocrystals with ionizable components 
is dependent on interfacial pH.  This mass transport analysis demonstrates the importance of pH, 
cocrystal solubility, diffusivity, and micellar solubilization on the dissolution rates of cocrystals.  
 
 
 
* This Chapter is published in Molecular Pharmaceutics, 2016, 13 (3), 1030-1046, 
http://pubs.acs.org/doi/full/10.1021/acs.molpharmaceut.5b00862. 
 36 
 
Introduction  
The enhancement of aqueous solubility has remained a challenge for the successful 
development of new drug products in the pharmaceutical industry as the number of poorly water 
soluble drugs is increasing.  Many strategies have been employed to overcome this challenge by 
modifying the solid structure of the drug and these include amorphous forms, polymorphism, 
solvates, hydrates, salts and cocrystals1, 2.  Among these approaches, cocrystalline solids have 
generated tremendous interest due to their potential advantages over other solid forms, such as 
their diversity in formation and large solubility range2-4.  Due to their potential of increasing the 
bioavailability of drugs, many studies have been carried out to understand the solubility and 
dissolution behavior of cocrystals3, 5-9.  The solubility behavior of cocrystals has been studied10-13 
and detailed mechanisms of how solution interactions such as ionization and micellar 
solubilization affect the solubility of cocrystals have been identified by Rodriguez and 
coworkers14-17.  Although there are many dissolution studies of cocrystals in the literature3, 5-9, only 
a few have considered the mechanism of dissolution12, 18, 19.  A detailed mechanistic understanding 
of how physicochemical properties of cocrystal components affect the dissolution behavior still 
remains to be explored.  It is essential to understand the dissolution mechanism of cocrystals 
because such knowledge can provide a better understanding of the oral absorption of drugs from 
the cocrystalline solids. 
 An important consideration for cocrystals is the possibility that solution mediated phase 
transformation (eg: precipitation of less soluble drug) can occur during dissolution for cocrystals 
with higher solubility than their parent drugs.  This phenomenon has been observed in a number 
of studies in the literature12, 19-21.  Rapid conversion back to the parent compound makes the 
measurement of cocrystal dissolution challenging.  Dissolution experiments have been carried out 
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at low temperature to decrease the dissolution rates of highly soluble cocrystals to capture the 
intrinsic dissolution rates; however, phase transformation was still observed20.  It has also been 
shown that surfactants can thermodynamically stabilize cocrystals due to differences in micellar 
solubilization between the drug and coformer17, 22, 23.  The critical stabilization concentration 
(CSC) has been defined as the surfactant concentration required to achieve equivalent solubility 
of the cocrystal and parent drug17.  Cocrystals are thermodynamically unstable below the CSC and 
crystallization of pure drug can occur, but thermodynamically stable at or above the CSC17.  
Therefore, solid phase transformation can be prevented by performing cocrystal dissolution at or 
above the CSC. 
 Cocrystal usually contains a hydrophobic drug and a hydrophilic coformer that have very 
different physicochemical properties such as ionization, hydrophobicity, and diffusivity.  These 
properties can have very significant effects on the dissolution rates of cocrystals.  The ionizable 
components can undergo simultaneous chemical reactions at the dissolving surface with the 
chemical species coming from the bulk solution during dissolution.  Consequently, the pH at the 
dissolving surface is not necessarily equivalent to the bulk solution24.  The first and most important 
step for determining the dissolution rate of cocrystal with ionizable components is to model the 
pH at the dissolving surface.  Interfacial pH is affected by the degree of ionization of the 
component at the interface, which is determined by the concentration and pKa value of the 
ionizable component24.  For single component dissolution, the concentration at the dissolving 
surface is dictated by the solubility of that component.  Diffusivity can also influence the 
concentrations of the components at the dissolving surface for multi-component dissolution with 
different component diffusion coefficients.  The faster diffusing component can lead to a decrease 
in concentration of that component at the dissolving surface25.  The dissolution of cocrystal is a 
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multi-component system with different component diffusivities.  Therefore, the concentration of 
the faster diffusing cocrystal component will have a dependence on the difference in diffusivities 
between the cocrystal components.  The larger the difference between the diffusivities, the lower 
the concentration of the faster diffusing component will be at the surface.    
  The purpose of this work is to provide a mechanistically realistic physical mass transport 
analysis of the dissolution behavior of cocrystals under the combined influence of ionization and 
micellar solubilization.  Mass transport models were developed by applying Fick’s Law of 
diffusion to dissolution with simultaneous chemical reactions in the hydrodynamic boundary layer 
adjacent to the dissolving cocrystal surface24.  To evaluate the predictive power of these models, 
the constant surface area dissolution rates of two model cocrystals with 1:1 stoichiometric ratio, 
carbamazepine-saccharin (CBZ-SAC) and carbamazepine-salicylic acid (CBZ-SLC) were 
determined using a rotating disk dissolution apparatus.  Carbamazepine is non-ionizable, saccharin 
and salicylic acid are monoprotic weak acids with reported pKa values of 1.6 and 3.0, 
respectively13, 17.   
Materials and methods 
Materials   
Anhydrous carbamazepine (CBZ), salicylic acid (SLC) and sodium lauryl sulfate (SLS) 
were purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  
Carbamazepine dihydrate (CBZD) was prepared by slurrying anhydrous CBZ in deionized water 
for 24 hours and solid was obtained through vacuum filtration.  Saccharin (SAC) was purchased 
from Acros Organics (Pittsburgh, PA) and used as received.  Isopropanol, acetonitrile, methanol 
and hydrochloric acid were purchased from Fisher Scientific (Pittsburgh, PA).  Sodium hydroxide 
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pellets were purchased from J.T. Baker (Philipsburg, NJ).  Water used in this study was filtered 
through a double deionized purification system (Milli Q Plus Water System) from Millipore Co. 
(Bedford, MA).   
Cocrystal synthesis   
Cocrystals were prepared by reaction crystallization method26 at room temperature.  CBZ-
SAC was prepared by adding 1:1 molar ratio of CBZ and SAC in isopropanol solution.  CBZ-SLC 
was prepared by adding 1:1 molar ratio of CBZ and SLC in acetonitrile solution containing 0.1 M 
SLC.  Solid phases were characterized by X-ray powder diffraction (XRPD) and differential 
scanning calorimetry (DSC). 
Cocrystal solubility measurements   
Cocrystal solubility was measured by determining the eutectic concentrations of the drug 
and coformer as a function of SLS concentration at pH 1 and 25°C.  A detailed discussion of the 
eutectic point measurement was reported elsewhere27.   Cocrystals (~100 to 150 mg) and CBZD 
(~50 to 100 mg) were suspended in 3 mL of aqueous SLS solution and stirred for 4 days.  Samples 
were collected at 24 hour intervals and centrifuged using Corning Costar Spin-X plastic centrifuge 
tubes with filters to separate the excess solid from solution.  Solution concentrations were 
measured using HPLC and solid phases were analyzed by XRPD.  Cocrystal stoichiometric 
solubility was determined from the measured eutectic concentrations of the cocrystal components 
using the method previously developed27. 
Cocrystal dissolution measurements  
The constant surface area dissolution rates of cocrystals were determined using a rotating 
disk apparatus.  Cocrystal powder (~150 mg) was compressed in a stainless steel rotating disk die 
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with a tablet radius of 0.50 cm at approximately 85 MPa for 2 minutes using a hydraulic press.  
The die containing the compact was mounted onto a stainless steel shaft attached to an overhead, 
variable speed motor.  The disk was exposed to 150 mL of the dissolution medium in a water 
jacketed beaker with temperature controlled at 25°C and a rotation speed of 200 rpm was used.  
Dissolution medium was prepared on the day of the experiment by dissolving SLS in water and 
solution pH was adjusted using HCl or NaOH.  The pH of dissolution media did not change during 
the experiments at pH 1-3 for both cocrystals.  Although the pH decreased for dissolution at pH 4 
and above, the final pH was still within the buffering region.  This means that the change in bulk 
pH during dissolution would not have significant impact on the interfacial pH.  Sink conditions 
were maintained throughout the experiments by ensuring the concentrations at the last time point 
of the dissolution were less than 10% of the cocrystal solubility.  Solution concentrations were 
measured using HPLC and solid phases after dissolution were analyzed by XRPD.   
HPLC   
Waters HPLC equipped with a photodiode array detector was used for all analysis.  The 
mobile phase was composed of 55% methanol and 45% water with 0.1% trifluoroacetic acid and 
the flow rate of 1 mL/min was used.  Separation was achieved using Waters, Atlantis, T3 column 
(5.0 µm, 100 Å) with dimensions of 4.6 x 250 mm.  The sample injection volume was 20 µL.  The 
wavelengths for the analytes were as follows: 284 nm for CBZ, 250 nm for SAC and 303 nm for 
SLC.    
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XRPD   
XRPD diffractograms of solid phases were collected with a benchtop Rigaku Miniflex X-
ray diffractometer using Cu-Kα radiation (λ = 1.54 Å), a tube voltage of 30 kV, and a tube current 
of 15 mA.  Data was collected from 5 to 40° at a continuous scan rate of 2.5°/min. 
DSC   
Crystalline samples were analyzed by DSC using a TA instrument 2910 MDSC system 
equipped with a refrigerated cooling unit.  All experiments were performed by heating the samples 
at a rate of 10 °C/min under a dry nitrogen atmosphere.  Temperature and enthalpy of the 
instrument were calibrated using high purity indium standard.   
Theoretical 
The following mass transport analysis utilizes the classic film theory that postulates the 
presence of a diffusion boundary layer (i.e. stagnant layer) adjacent to the dissolving surface28.  
The dissolution process is determined by the concentration gradient across the diffusion boundary 
layer and influenced by the simultaneous diffusion and chemical reactions occurring at the 
dissolving surface and in the adjacent boundary layer24.  For the dissolution of a 1:1 cocrystal in 
non-reactive media (eg: no ionization or micellar solubilization), the cocrystal would first dissolve 
according to its solubility product to give equal molar concentrations of the drug and coformer.  
Both components would then diffuse across the boundary layer into the bulk solution based on 
their diffusion coefficients and concentration gradients.  Cocrystalline solids have well defined 
stoichiometry so they will dissolve according to their stoichiometric ratios assuming that there is 
no precipitation.   
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At steady state, the dissolution rate of the drug must be the same as the coformer for a 1:1 
cocrystal if there is no solid phase transformation during dissolution (eg: drug precipitation).  As 
mentioned above, diffusion across the boundary layer is influenced by component diffusion 
coefficients and for most cocrystals, the drug molecule is larger than the coformer, so the diffusion 
coefficient of the drug is usually less than the coformer.  The difference in diffusivities between 
the cocrystal components may be magnified if the dissolution is performed in surfactant solution 
where the drug may be highly solubilized by micelles, but the coformer is only slightly solubilized.  
Micellar solubilization typically reduces the diffusion rate of the drug significantly compared to 
the coformer due to the much lower diffusion coefficient of the drug loaded micelles.  With slower 
diffusion, the transport rate of the drug would be less than the coformer.   To maintain 
stoichiometric dissolution of both components of the cocrystal, the difference in diffusivities can 
influence the concentrations of the components at the dissolving surface under steady state 
conditions.   
The mass transport process of cocrystals may be analyzed in two ways described here as 
the interfacial equilibrium and the surface saturation models.  Both of these models were developed 
based on the classic film theory of dissolution28 and the solubility product behavior of cocrystals. 
The major difference between the two models is related to the boundary conditions at the solid-
liquid interface.  For the interfacial equilibrium model, the solubility product of the cocrystal is 
assumed to apply at the dissolving surface at all times t  0.  For the surface saturation model, the 
concentration of the slower diffusing component, typically the drug, is maintained equal to the 
stoichiometric solubility of the cocrystal while the concentration of the faster diffusing component, 
typically the coformer, is depleted due to its more rapid diffusion.  Due to the depletion of the 
coformer at the dissolving surface, the solubility product of the cocrystal is not maintained for the 
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surface saturation model. It is appropriate to point out that the application of rotating disk 
hydrodynamics and the associated hydrodynamic boundary layer are simplifying assumptions 
where simultaneous chemical reactions and micelle solubilization occur.  However, useful 
predictions may be obtained that provide insight into the mechanisms and rate limiting processes 
impacting dissolution.  More detailed descriptions of the two models are provided in the following 
sections. 
Both models are based on the following assumptions: chemical reactions and solute 
solubilization within the diffusion layer occur instantaneously, free solute and micelle are in 
equilibrium throughout the diffusion layer, the ionized form of the coformer is not solubilized by 
surfactant, the solubilization constant of the coformer does not change with surfactant 
concentration, aqueous diffusivity of the ionized and non-ionized forms are the same.  For 
simplification of the interfacial pH prediction, the effective diffusivity of the coformer is assumed 
to be the same as the aqueous diffusivity because it is not significantly solubilized by the surfactant.  
In this study, the effect of surfactant concentration on the viscosity of dissolution media was not 
accounted for the mass transport analysis.  Although the viscosity of the dissolution media may 
approximately double at high surfactant concentration (eg: 300 mM)29, its impact on the 
hydrodynamic boundary layer is small as shown in equation 10.  The viscosity of dissolution media 
is not expected to significantly affect the diffusion of free species as they are assumed to be 
diffusing through the aqueous phase where the surfactant concentration is equal to the critical 
micellar concentration (CMC) and the viscosity is not substantially different from water30. The 
effect of viscosity on the diffusion coefficient of the micelles incorporates the effect of viscosity 
changes.    
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Interfacial equilibrium model  
A schematic representation of the dissolution process for a 1:1 cocrystal with non-ionizable 
components, RA, where R is drug and A is coformer, in non-reactive media, is shown in Figure 
2.1.  The first step of dissolution is the formation of a saturated solution at the solid-liquid interface, 
which represents the equilibrium between the solid cocrystal and solution. This leads to the 
dissociation of RA into its components, R and A, according to the solubility product, Ksp, as 
described by the following equations:  
(𝑅𝐴)𝑠 ⇋ 𝑅𝑎𝑞 + 𝐴𝑎𝑞              (2.1) 
𝐾𝑠𝑝 = [𝑅]𝑎𝑞[𝐴]𝑎𝑞              (2.2) 
where subscript s denotes the solid phase and aq denotes the aqueous phase.  
 
Figure 2.1.  Schematic representation of the dissolution process of RA in non-reactive media using 
the interfacial equilibrium model.  [R]aq,0 and [A]aq,0 represent the concentrations of R and A at the 
dissolving surface; [R]aq,h and [A]aq,h represent the concentrations of R and A in the bulk assuming 
sink conditions; SRA is the solubility of the cocrystal and Ksp is the solubility product of the 
cocrystal.  
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At time = 0, before any component diffusion, the concentration of the drug in the saturated 
layer should be the same as the coformer for 1:1 cocrystals as shown in Figure 2.1.  As diffusion 
occurs, the chemical equilibrium shown in equation 2.1 is disrupted in the saturated layer because 
of the decrease in concentration of A due to its more rapid diffusion.  To re-establish this 
equilibrium in the saturated layer, which means keeping Ksp constant, the concentrations of R and 
A would have to vary.  A boundary condition assumption at the solid-liquid interface for the 
interfacial equilibrium model is that the Ksp relationship is assumed to apply at all times (t  0).  
Because of the different diffusivities between the cocrystal components, the concentrations of R 
and A will differ at the dissolving surface for t > 0 to maintain stoichiometric dissolution.  At 
steady state, the concentration of R at the solid liquid interface would be higher than the 
stoichiometric solubility of the cocrystal due to its lower diffusion coefficient, while the 
concentration of A is consequently smaller to maintain the Ksp. 
If there is no solid phase transformation or precipitation in the boundary layer or at the 
solid surface, the dissolution rate of the drug must be the same as the coformer for a 1:1 cocrystal.  
The dissolution rate of the cocrystal in terms of components can be described by the Nernst-
Brunner equation28, 31 for flux: 
𝐽𝑅 =
𝐷𝑅[𝑅]𝑎𝑞,0
ℎ
= 𝐽𝐴 =
𝐷𝐴[𝐴]𝑎𝑞,0
ℎ
             (2.3) 
where D is diffusivity, [𝑅]𝑎𝑞,0 and [𝐴]𝑎𝑞,0 are total concentrations of the drug and coformer at the 
dissolving surface and h is the thickness of the hydrodynamic boundary layer that reflects the 
hydrodynamic conditions near the dissolving surface and sink conditions are assumed.  Since this 
model is assumed to maintain Ksp, the following relationship is true at all time: 
[𝑅]𝑎𝑞,0 ∗ [𝐴]𝑎𝑞,0 = 𝐾𝑠𝑝                        (2.4) 
 46 
 
The concentration of coformer, [𝐴]𝑎𝑞,0 and drug, [𝑅]𝑎𝑞,0, at the solid liquid interface can 
be solved using equations 2.3 and 2.4 as follows: 
[𝐴]𝑎𝑞,0 = (
𝐷𝑅
𝐷𝐴
)1/2√𝐾𝑠𝑝             (2.5) 
[𝑅]𝑎𝑞,0 = (
𝐷𝐴
𝐷𝑅
) [𝐴]𝑎𝑞,0 = (
𝐷𝐴
𝐷𝑅
) (
𝐷𝑅
𝐷𝐴
)1/2√𝐾𝑠𝑝 = (
𝐷𝐴
𝐷𝑅
)
1
2
√𝐾𝑠𝑝               (2.6) 
The concentrations of both components at the surface are dependent on the solubility and 
differential diffusivity between the components.  A large difference between the component 
diffusivities increases the concentration difference between the drug and coformer at the solid-
liquid interface while maintaining the solubility product. 
Surface saturation model  
The dissolution process of RA in non-reactive media can also be described using the 
surface saturation model, illustrated in Figure 2.2.  It is assumed that a saturated layer adjacent to 
the dissolving surface consists of equal molar concentrations of R and A at the saturated solubility 
of the cocrystal (ie: stoichiometric cocrystal solubility) at time = 0.  Before any component 
diffusion, the concentration product of both components within the saturated layer is equal to the 
solubility product of the cocrystal.  Both components then diffuse across the diffusion layer at 
equal rates in proportion to their respective diffusion coefficients.  As diffusion begins, the 
concentrations of both components would be depleted, but the depletion of A would be greater 
because of its greater diffusivity compared to R.  In response to the depletion, more solid cocrystal 
would dissolve to maintain a saturated solution corresponding to the solubility of the cocrystal in 
the saturated layer.  As the slower diffusing component, the rate of R depletion determines the rate 
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of replenishment.  Therefore, the concentration of R at the dissolving surface is maintained at the 
stoichiometric solubility of the cocrystal: 
[𝑅]𝑎𝑞,0 = √𝐾𝑠𝑝              (2.7) 
while the concentration of A may be lower.  By assuming the dissolution rate of the drug is equal 
to the coformer, the concentration of A at the surface can be solved as follows: 
𝐽𝑅 =
𝐷𝑅√𝐾𝑠𝑝
ℎ
= 𝐽𝐴 =
𝐷𝐴[𝐴]𝑎𝑞,0
ℎ
             (2.8) 
[𝐴]𝑎𝑞,0 =
𝐷𝑅
𝐷𝐴
√𝐾𝑠𝑝              (2.9) 
 
Figure 2.2.  Schematic representation of the dissolution process of RA in non-reactive media using 
the surface saturation model. [R]aq,0 and [A]aq,0 represent the concentrations of R and A at the 
dissolving surface; [R]aq,h and [A]aq,h represent the concentrations of R and A in the bulk assuming 
sink conditions; SRA is the solubility of the cocrystal and Ksp is the solubility product of the 
cocrystal. 
 
The concentration of the drug at the surface is the same as the stoichiometric solubility of 
the cocrystal, but the coformer concentration is dependent on both the cocrystal solubility and 
differential diffusivity between the cocrystal components.  The greater the difference in diffusivity, 
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the lower the concentration of coformer is at the surface.  Because of the lower coformer 
concentration, the solubility product no longer applies beyond the interface at x > 0.    
The assumptions made for both models are based upon the fact that the diffusion 
coefficients of the cocrystal components are different.  Under stoichiometric dissolution for a 1:1 
cocrystal, the dissolution rates of both species are observed to be equal with no solid phase 
transformation.  The difference in diffusion coefficients can result in unequal concentrations of the 
cocrystal components at the dissolving surface and impact the ability of the cocrystal to maintain 
the solubility product, Ksp.  The interfacial equilibrium model is assumed to maintain constant Ksp 
at all time at the dissolving surface during dissolution with the result that the drug concentration 
is higher but a lower coformer concentration.  The surface saturation model assumes that the drug 
concentration remains equal to the stoichiometric solubility of the cocrystal, but with a lower 
coformer concentration to maintain stoichiometric dissolution and without maintaining Ksp 
constant at the dissolving surface.  If the drug and coformer have equal diffusion coefficients, the 
concentrations of both components at the surface will be the same and the two models will merge 
into one. 
Rotating Disk Dissolution Hydrodynamics 
Dissolution experiments may be performed using a variety of experimental systems.  For 
this study, rotating disk dissolution experiments were performed.  Two significant advantages of 
this system include the maintenance of a constant surface area available for dissolution as well as 
defined hydrodynamics that provide an a priori estimate of the hydrodynamic boundary layer 
adjacent to the rotating surface.  According to Levich32, the hydrodynamic boundary layer 
thickness, h, is given by: 
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ℎ = 1.612𝐷
1
3𝑣
1
6𝜔−
1
2            (2.10) 
 where 𝑣 is the kinematic viscosity and 𝜔 is the angular velocity in radians per unit time.  
Both interfacial equilibrium and surface saturation models described above are based on 
the assumption that the diffusion layer is the same for both the drug and coformer.  However, 
according to equation 2.10, the diffusion layer thickness has a dependence on the diffusion 
coefficient.  The diffusion coefficients of the drug and coformer in water can be different due to 
their molecular sizes difference.  The different hydrophobicity between the drug and coformer can 
also magnify the difference in diffusivity in surfactant solution.  The differential diffusivity can 
result in a significant difference between the diffusion layer of the two cocrystal components as h 
is directly proportional to the diffusion coefficient.    
An alternative approach for the two models is to redefine the diffusion layer thicknesses 
for both the drug and coformer as they have different diffusion coefficients and consequently 
different diffusion layer thicknesses according to equation 2.10.  Applying equation 2.10 
separately for the diffusion layer of R (ℎ𝑅 = 1.612𝐷𝑅
1/3
𝑣
1
6𝜔−
1
2) and A (ℎ𝐴 = 1.612𝐷𝐴
1/3
𝑣
1
6𝜔−
1
2) to 
equation 2.3 and applying equation 2.4, the concentrations of R and A at the dissolving surface for 
the interfacial equilibrium model are shown to become a function of the diffusion coefficients: 
[𝐴]𝑎𝑞,0 = (
𝐷𝑅
𝐷𝐴
)1/3√𝐾𝑠𝑝           (2.11) 
[𝑅]𝑎𝑞,0 = (
𝐷𝐴
𝐷𝑅
)1/3√𝐾𝑠𝑝           (2.12) 
And similarly, applying equation 2.10 separately for R and A to equation 2.8, the concentration of 
A at the surface for the surface saturation model becomes: 
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[𝐴]𝑎𝑞,0 = (
𝐷𝑅
𝐷𝐴
)2/3√𝐾𝑠𝑝           (2.13) 
and [𝑅]𝑎𝑞,0 is given by equation 2.7. 
Dissolution in reactive media 
Cocrystals can contain components with different ionization properties (eg: nonionizable 
drug and ionizable coformer) and these components can undergo chemical reactions at the solid 
liquid interface and in the boundary layer with the species from the bulk solution.  These reactions 
can alter the pH and concentrations at the dissolving surface.  A schematic representation of the 
dissolution process for a 1:1 cocrystal with R as the non-ionizable drug and HA as the monoprotic 
acidic coformer is shown in Figure 2.3.  As cocrystal is initially exposed to solution, it dissociates 
into its components, R and HA at the dissolving surface.  Both R and HA diffuse across the 
diffusion layer with a thickness of h, however, HA can simultaneously react with incoming base 
(B-) from the bulk solution to form A- and HB.   
 
Figure 2.3.  Schematic representation of the dissolution process24 for a 1:1 cocrystal with R as the 
non-ionizable drug and HA as the monoprotic acidic coformer in the presence of a reactive medium 
containing base, B-.  A- and HB are the products of the reaction. 
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For the dissolution of RHA in a reactive medium containing hydroxide ion and water as 
the reactive basic species (eg: no additional buffer), the chemical reactions occurring at the surface 
and within the boundary layer include the self-dissociation of the cocrystal into R, HA and 
ionization of HA as it is a weakly acidic coformer.  The chemical equilibria and the equations for 
equilibrium constants for the dissolution of RHA are provided in Appendix A. 
Dissolution in surfactant solution 
Previous studies have shown that surfactants can solubilize the cocrystal components to 
different extents due to the different hydrophobicity of the drug and coformer17, 22, 23.  Typically, 
the drug component is more hydrophobic and it is highly solubilized by surfactants compared to 
the coformer.  The equilibria reflecting the solubilization of drug (R) and the unionized form of 
coformer (HA) are given in Appendix 2A. 
Because of the differential solubilization, the parent drug, which is typically less soluble 
than the cocrystal in the absence of surfactant, can achieve the same solubility as the cocrystal in 
solution containing surfactant concentration at the CSC17, 22, 23.  As surfactant concentration 
exceeds the CSC, the parent drug becomes more soluble, so drug precipitation during dissolution 
of the cocrystal can be prevented.  The two cocrystals studied here have higher solubility than the 
parent drug, so dissolution experiments were performed in media containing surfactant 
concentrations above the CSC to prevent solid phase transformation.  Among the surfactants 
studied in our lab, sodium lauryl sulfate (SLS) solubilizes CBZ to the greatest extent so it was 
chosen to study in this work. 
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Mass transport analysis 
Detailed derivations of the mass transport analysis for the two models applying the above 
considerations are provided in Appendix 2A.  The different boundary conditions of the cocrystal 
components from the two models lead to different mass transport analyses.  These mass transport 
analyses allow for predictions of cocrystal flux as a function of bulk pH and surfactant 
concentration by taking the pH at the surface into consideration.  The comparison of the mass 
transport analyses between the two models are shown in the Results section.   
Results 
Physicochemical properties 
The physicochemical properties of the cocrystal and its components such as solubility 
products, ionization constants, micellar solubilization constants and diffusion coefficients are 
required to predict the interfacial pH and flux of the cocrystal components.  These values can be 
obtained independently.  The solubility products of the model cocrystals, the ionization constants 
of their coformers and the diffusion coefficients in water are summarized in Table 2.1 for 
carbamazepine-saccharin (CBZ-SAC) and carbamazepine-salicylic acid (CBZ-SLC).  The 
solubility product of CBZ-SLC was determined by measuring the eutectic concentrations of the 
components as a function of surfactant concentration.  The solubility product of CBZ-SAC was 
obtained from the literature13.  The diffusion coefficients in water were estimated using the 
approach of Othmer Thaker33.  According to Othmer Thaker’s equation for estimating diffusion in 
dilute water solutions, the aqueous diffusion coefficient is inversely proportional to the molecular 
volume of the substance33.  As a larger molecule, the diffusion coefficient of CBZ in water is 
smaller than both SAC and SLC. 
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Table 2.1.  Physicochemical properties of model cocrystals and their components. 
Cocrystal (R-HA) Ksp (mM2) pKa of HA 
Aqueous diffusion coefficientc (x 10-6 cm2/sec) 
𝑫𝑹𝒂𝒒  𝑫𝑯𝑨𝒂𝒒 
CBZ-SAC 1.00a 1.6a 5.7 7.6 
CBZ-SLC 0.40 3.0b 5.7 7.7 
aFrom reference13.  bFrom reference17.  cEstimated using Othmer Thaker’s equation33.   
 
The micellar solubilization constants of the drug and coformers are summarized in Table 
2.2.  The solubilization power of a surfactant can be influenced by the size and shape of the 
micelles34, 35.  It was reported in the literature that the size and shape of the micelles may change 
as surfactant and additive concentrations change36.  Therefore, it was not surprising to observe that 
SLS solubilizes CBZ to different extents at different concentrations.  The solubilization of 
coformers in SLS is small compared to the drug, and the Ks values were assumed to be independent 
of SLS concentration in the range studied.  The diffusion of CBZ in SLS solution would be smaller 
than the coformers because CBZ is significantly solubilized in the micelles compared to both SAC 
and SLC. 
Table 2.2.  Micellar solubilization constants of CBZ, SAC and SLC in SLS solution. 
Components 
Ks in SLS (mM-1) 
22-44 mM 70 mM 100 mM 150 mM 250 mM 400 mM 
CBZ 0.58a 
0.465b ± 
0.004 
0.45b ± 
0.01 
0.43b ± 
0.01 
0.392b ± 
0.003 
0.35b ± 
0.01 
SAC 0.013a 
SLC 0.060a 
aFrom reference17.  The Ks values for SAC and SLC are assumed to be constant for SLS 
concentrations ranging from 22 to 400 mM. 
bDetermined using 𝑆𝑇 = 𝑆𝑎𝑞(1 + 𝐾𝑠
𝑅[𝑚]), where ST is the total solubility of the drug in SLS 
solution and Saq is the aqueous solubility in water, which is 0.53 mM
17.  The total drug solubility 
in SLS solution is the same as the eutectic concentrations of CBZ shown in Figure 4 because both 
solid drug and cocrystal are in equilibrium with solution at the eutectic point27. 
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Solubility study 
The concentrations of the cocrystal components at the eutectic point are shown in Figure 
2.4 for both cocrystals at pH 1 as a function of SLS concentration.  Since all the experiments were 
performed above the CSC, the eutectic concentrations of the drug were greater than the coformers, 
meaning the solubility of the cocrystal is less than the drug under these conditions.  At the eutectic 
point, the solid phases of both drug and cocrystal are in equilibrium with solution, and thus the 
drug eutectic concentration is at its solubility at the same solution conditions27.  This allows the 
calculations of solubilization constants for the drug shown in Table 2.2.  Using previously 
developed model27, the solubility of CBZ-SAC and CBZ-SLC were determined from the eutectic 
concentrations and plotted in Figure 2.5.  The lowest SLS concentration used was 22 mM, which 
is above the reported CMC of SLS in the literature (6 mM)17.  The formation of micelles in solution 
preferentially solubilizes CBZ and results in solubility enhancement as SLS concentration 
increases.  SLS does not solubilize SAC and SLC to the same extent as CBZ because these 
coformers are more hydrophilic.  The differential solubilization between the drug and coformers 
causes the solubility of the cocrystal to increase nonlinearly as a function of surfactant 
concentration and the slightly nonlinear nature of the curves in Figure 2.5 may be attributed to this.  
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(a)                                                                          (b) 
 
Figure 2.4.  Eutectic measurements for CBZ-SAC (a) and CBZ-SLC (b) at pH 1 as a function of 
SLS concentration. 
 
(a)                         (b) 
 
Figure 2.5.  Solubility of cocrystals, CBZ-SAC (a) and CBZ-SLC (b) at pH 1 as a function of 
surfactant concentration.  Cocrystal solubility was determined using eutectic concentrations from 
Figure 2.4 by 𝑆𝑐𝑐 = √[𝑑𝑟𝑢𝑔]𝑒𝑢𝑡𝑒𝑐𝑡𝑖𝑐[𝑐𝑜𝑓𝑜𝑟𝑚𝑒𝑟]𝑒𝑢𝑡𝑒𝑐𝑡𝑖𝑐
27. 
 
Effect of surfactant on dissolution 
The dissolution profiles of CBZ-SAC and CBZ-SLC at different SLS concentrations at 
constant pH (pH = 1) where the coformers are mostly nonionized are shown in Figure 2.6.  Since 
experiments were conducted above the CSC where the cocrystals were thermodynamically stable, 
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the dissolution behavior of both cocrystals was linear as expected under sink conditions.  Similar 
to solubility, the dissolution rates of both cocrystals increase as SLS concentration increases.  
(a)             (b) 
 
(c)                                                                         (d) 
 
Figure 2.6.  Dissolution profiles for CBZ-SAC in terms of CBZ concentrations (a) and SAC 
concentrations (b); and CBZ-SLC in terms of CBZ concentrations (c) and SLC concentrations (d) 
at different SLS concentrations at pH1.  The solid circles are experimental data points and the solid 
lines are fitted liner regressions.   
 
The effective diffusion coefficients of CBZ can be estimated from the dissolution rates of 
the cocrystals at pH 1 as a function of SLS concentration using equation 2A.49 from Appendix 
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2A.  The micellar diffusivity of CBZ can then be estimated from the effective diffusivity according 
to the following relationship: 
𝐷𝑅𝑒𝑓𝑓 =
𝐷𝑎𝑞+𝐾𝑠𝐷𝑚[𝑚]
1+𝐾𝑠[𝑚]
                 (2.14) 
where 𝐷𝑅𝑒𝑓𝑓is the effective diffusivity of the drug and Dm is the micellar diffusivity
37.  The micellar 
diffusivities of CBZ for the two cocrystals as a function of SLS concentration are plotted in Figure 
2.7.  A power regression can be fitted to describe the relationship between micellar diffusivity and 
SLS concentration.  Micellar diffusivity of CBZ decreases as surfactant concentration increases.  
The same trend was also observed in the literature38-40.  Detailed analysis of this is beyond the 
scope of this study.  However, this behavior may be due to the formation of larger micelles as 
surfactant concentration increases38 and the potential changes in viscosity.  Another possible 
reason could be the increase in electrostatic repulsion as surfactant concentration increases since 
SLS is negatively charged39.  The diffusion of the micelle-drug complexes can be reduced by the 
electronic repulsion between the negatively charged micelles39.  The CBZ micellar diffusivities 
determined from the dissolution of CBZ-SLC are somewhat greater than those determined for 
CBZ-SAC.  The reason for these differences is not known but may be due to the different chemical 
environments surrounding the micelles between the two cocrystals.  Both SAC and SLC are able 
to ionize and form negatively charged ions that can potentially increase the electronic repulsion in 
solution.  CBZ-SAC has a higher Ksp value and SAC is more acidic than SLC, so the degree of 
SAC ionization is higher than SLC at the same pH.  The higher SAC ion concentration in solution 
may cause a greater increase in electronic repulsion for CBZ-SAC than CBZ-SLC.  Consequently, 
the diffusion of micelles may be slower in CBZ-SAC dissolution than in CBZ-SLC dissolution.  
For this study, the micellar diffusivities shown in Figure 2.7 are used to assess the mass transport 
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models described here.  It is also appropriate to point out that equation 2A.49 from Appendix 2A 
does not take into account kinetic processes involving surfactant and micelles that may occur at 
the dissolving surface. 
 
Figure 2.7.  Micellar diffusivities of CBZ determined from the dissolution of CBZ-SAC ( ) 
and CBZ-SLC ( ) at pH 1 as a function of SLS concentration.  The solid circles are 
experimental data points determined from the dissolution shown in Figure 2.6 using equations 
2A.49 from Appendix 2A and 2.14 and solubility shown in Figure 2.5.  The solid lines are the 
fitted power regression.  The power regression line for CBZ-SAC is y = 9.9771E-06x-4.3920E-01 and 
CBZ-SLC is y = 2.1553E-05*x-5.4153E-01. 
 
Effect of pH on dissolution   
The effect of pH on dissolution of cocrystals was studied at constant surfactant 
concentration as a function of pH.  The dissolution experiments were conducted in 400 mM SLS 
solution for CBZ-SAC and 150 mM for CBZ-SLC.  The dissolution profiles of CBZ-SAC and 
CBZ-SLC in terms of cocrystal components as a function of pH are shown in Figure 2.8 and 2.9.  
The linear dissolution behavior of the two cocrystals indicates no solid phase transformation 
occurred during dissolution as the experiments were performed above the CSC.  The dissolution 
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rates of both cocrystals increase as pH increases and then remain relatively constant in the self-
buffering region of the coformers.  Since SAC has a lower pKa than SLC, pH has a greater impact 
on the dissolution rate of CBZ-SAC compared to CBZ-SLC as reflected in the larger range of 
dissolution rates in Figure 2.8 compared to Figure 2.9.   
(a)                                                                         (b) 
 
Figure 2.8.  Dissolution profiles of CBZ-SAC in terms of CBZ (a) and SAC (b) as a function of 
bulk pH at 400 mM SLS.  The symbols are experimental data points and the solid lines are fitted 
liner regressions.  The pH values represent the initial bulk pH of the dissolution media. 
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(a)                                                                          (b) 
 
Figure 2.9.  Dissolution profiles of CBZ-SLC in terms of CBZ (a) and SLC (b) as a function of 
bulk pH at 150 mM SLS.  The symbols are experimental data points and the solid lines are fitted 
liner regressions.  The pH values represent the initial bulk pH of the dissolution media.  
 
Comparison of flux predictions between the mass transport models 
For comparison purposes, only literature reported micellar diffusivities of CBZ in SLS 
solution were used and no parameters were adjusted to fit the experimental data to the theoretical 
equations of the two transport models shown in Table 2.3 and Figure 2.10.  A micellar diffusivity 
of 3.6E-7 cm2/sec at 400 mM SLS was used for CBZ-SAC and for CBZ-SLC, a value of 6.4E-7 
cm2/sec at 150 mM SLS was used40.  The difference in concentrations of the cocrystal components 
at the surface predicted using the two models and how this difference could affect the interfacial 
pH is illustrated in Table 2.3 for the dissolution of CBZ-SAC at 400 mM SLS.  The interfacial pH 
calculated from both models lags behind bulk pH above the pKa value of SAC (pKa=1.6) due to 
the ionization of SAC in the diffusion layer.  The interfacial equilibrium model predicts a lower 
surface pH (approximately 0.3 pH units at pH 6) compared to the surface saturation model.  The 
lower interfacial pH calculated from the interfacial equilibrium model is due to the greater SAC 
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concentration predicted at the dissolving surface to maintain the Ksp of CBZ-SAC.  As shown in 
Table 2.3, the concentrations of both CBZ and SAC at the surface calculated from the interfacial 
equilibrium model are higher than those calculated from the surface saturation model.  Because of 
the depletion of SAC at the surface of the boundary layer due to faster diffusion, the concentration 
product of CBZ and SAC from the surface saturation model is less than the Ksp of CBZ-SAC.  In 
order to re-establish the equilibrium disrupted by diffusion, both CBZ and SAC concentrations 
from the interfacial equilibrium model are predicted to increase at the surface to maintain a 
concentration product equal to the Ksp of CBZ-SAC.  As seen in Table 2.3 and Figure 2.10, both 
models result in qualitatively similar predictions.  Subtle but potentially important differences in 
surface concentrations result in different predicted dissolution rates.  
Table 2.3.  Interfacial pH and concentrations of CBZ and SAC at the surface calculated using the 
surface saturation and interfacial equilibrium models for the dissolution of CBZ-SAC at 400 mM 
SLS as a function of bulk pH. 
Surface saturation model 
Bulk 
pH 
Interfacial 
pHa 
Concentrations at the surface (mM) [CBZ]aq*[SAC]aq 
(mM2) [CBZ]tot
b [CBZ]aq
c [SAC]tot
d [SAC]aq
e 
1.27 1.27 30.4 0.2 4.2 0.6 0.1 
2.16 2.15 36.8 0.3 5.1 0.5 0.1 
3.02 2.84 57.4 0.4 8.0 0.3 0.1 
4.03 3.10 72.7 0.5 10.1 0.3 0.1 
5.97 3.14 75.6 0.5 10.5 0.3 0.1 
7.66 3.14 75.6 0.5 10.5 0.3 0.1 
Interfacial equilibrium model 
1.27 1.27 81.5 0.6 11.3 1.7 1.0 
2.16 2.14 98.3 0.7 13.7 1.4 1.0 
3.02 2.70 137.3 1.0 19.1 1.0 1.0 
4.03 2.85 155.2 1.1 21.6 0.9 1.0 
5.97 2.87 157.9 1.1 22.0 0.9 1.0 
7.66 2.87 157.9 1.1 22.0 0.9 1.0 
aCalculated using equation 2A.45 from Appendix 2A for surface saturation model and equation 
2A.57 from Appendix 2A for interfacial equilibrium model with Ksp, Ka, Ks and 𝐷𝐻𝐴𝑎𝑞  values 
shown in Table 2.1 and 2.2.  𝐷𝐻𝐴𝑒𝑓𝑓  is assumed to be equal to 𝐷𝐻𝐴𝑎𝑞 .  The 𝐷𝑅𝑒𝑓𝑓  value for CBZ-
SAC (3.9E-7 cm2/sec) was calculated from equation 2.14 using the Dm value of 3.6E-7 cm
2/sec 
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from the literature40.  The diffusion coefficients for H+ and OH- are 9.31E-5 and 5.28E-5 cm2/sec, 
respectively41.    
bCalculated using equation 2A.13 from Appendix 2A with the Ks value from Table 2.2 and 
calculated [CBZ]aq from surface saturation and interfacial equilibrium models. 
cCalculated using equations 2A.38 and 2A.51 from Appendix 2A for surface saturation model and 
interfacial equilibrium model, respectively.  Ksp, Ka, Ks values are from Table 2.1 and 2.2 and 
interfacial pH is from a.  𝐷𝑅𝑒𝑓𝑓  is 3.9E-7 cm
2/sec and 𝐷𝐻𝐴𝑒𝑓𝑓  is assumed to be equal to 𝐷𝐻𝐴𝑎𝑞  
shown in Table 2.1. 
dCalculated using equation 2A.14 from Appendix 2A with the Ks and Ka values from Table 2.1 
and 2.2, calculated [SAC]aq from surface saturation and interfacial equilibrium models, and 
interfacial pH from a. 
eCalculated using equations 2A.40 and 2A.52  from Appendix 2A for surface saturation model and 
interfacial equilibrium model, respectively.  Ksp, Ka, Ks values are from Table 2.1 and 2.2 and 
interfacial pH is from a.  𝐷𝑅𝑒𝑓𝑓  is 3.9E-7 cm
2/sec and 𝐷𝐻𝐴𝑒𝑓𝑓  is assumed to be 𝐷𝐻𝐴𝑎𝑞  shown in 
Table 2.1. 
 
The flux of CBZ-SAC at 400 mM SLS and CBZ-SLC at 150 mM SLS as a function of 
bulk pH were predicted using both models and the predicted values were compared with the 
experimental data as shown in Figure 2.10.  The predictions from both models follow the same 
trend as the experimental data.  However, the predictions from both models deviate from the 
experimental data because the effective diffusivities of CBZ used here were estimated from the 
micellar diffusivities of SLS in the literature determined at conditions different from the study 
here.  The surface saturation model slightly under predicted the flux, while the interfacial 
equilibrium model over predicted the flux.  However, the surface saturation model is able to 
provide more accurate prediction of cocrystal flux compared to the interfacial equilibrium model.  
It is difficult to experimentally prove which model more accurately represents the conditions at 
the dissolving surface as it requires concentration measurements at the dissolving surface.  
Analysis of the experimental results and theoretical predictions from the surface saturation model 
indicated somewhat better alignment.  Consequently, the surface saturation model is used to 
perform the mass transport analysis for the two cocrystals studied here.  
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(a)                                                                          (b) 
 
Figure 2.10.  Experimental ( ) and predicted flux comparison of CBZ-SAC at 400 mM SLS (a) 
and CBZ-SLC at 150 mM SLS (b) as a function of bulk pH using the surface saturation model (
) and interfacial equilibrium model ( ).  The flux predictions were calculated using 
equations 2A.49 and 2A.58 from Appendix 2A based on the interfacial pH predicted from 
equations 2A.45 and 2A.57 from Appendix 2A for surface saturation and interfacial equilibrium 
models, respectively.  The Ksp, Ka, Ks and 𝐷𝐻𝐴𝑎𝑞  values are shown in Table 2.1 and 2.2.  𝐷𝑅𝑒𝑓𝑓 
values for CBZ-SAC is 3.9E-7 cm2/sec and CBZ-SLC is 7.2E-7 cm2/sec. 
 
Interfacial pH and CSC predictions from surface saturation model  
Interfacial pH can be predicted using equation 2A.45 derived from the surface saturation 
model shown in Appendix 2A and the physicochemical parameters of the cocrystals and their 
components (eg: solubility products, ionization constants, solubilization constants and effective 
diffusivities).  The effect of bulk pH and surfactant concentration on interfacial pH for CBZ-SAC 
and CBZ-SLC is shown in Figure 2.11 utilizing the surface saturation model.  At constant 
surfactant concentration, for bulk pH < pKa, interfacial pH is approximately equal to bulk pH 
because the hydrogen ion in the bulk solution suppresses the ionization of the coformers24.  As 
bulk pH increases above the pKa value of the coformer, coformer ionization begins to occur.  This, 
in effect, results in a buffer effect at the interface and the interfacial pH no longer continues to 
increase linearly with increasing bulk pH24.  Both cocrystals have the ability to self-buffer the pH 
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microenvironment in the diffusion layer24 and this is demonstrated by the plateau region that 
ranges from bulk pH 4 to 8 in Figure 2.11.  CBZ-SAC is able to self-buffer the interfacial pH to 
around 3.0; while the plateau interfacial pH for CBZ-SLC is around 3.7.  The buffering ability is 
affected by the degree of ionization of the ionizable components at the interface and this is 
determined by the concentration and pKa values of the ionizable components.  With a higher 
solubility product and a lower pKa, CBZ-SAC is able to self-buffer to a lower pH at the interface 
compared to CBZ-SLC.  Surfactant has little or no effect on interfacial pH at bulk pH < pKa values 
of the coformers because the interfacial pH is determined by bulk pH.  As bulk pH increases above 
the pKa of the coformer, the degree of coformer ionization is not affected by SLS significant 
enough to cause any changes in interfacial pH.  For the cocrystals studied here, no significant 
impact on interfacial pH was predicted or observed as a function of surfactant concentration. 
(a)                                                                          (b) 
 
Figure 2.11.  Theoretical predictions of interfacial pH for CBZ-SAC (a) and CBZ-SLC (b) as a 
function of pH and SLS concentration using surface saturation model.  Interfacial pH was 
calculated using equation 2A.45 from Appendix 2A.  The Ksp, Ka, Ks and 𝐷𝐻𝐴𝑎𝑞  values are shown 
in Table 2.1 and 2.2 and 𝐷𝑅𝑒𝑓𝑓 values are from Figure 2.7. 
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The critical stabilization concentration, CSC has a pH dependence for the cocrystals 
studied here, so different surfactant concentrations will be required to stabilize the cocrystals at 
different pH to prevent solid phase transformation.  Based on the predicted interfacial pH, the CSC 
needed at the dissolving cocrystal surface to prevent phase transformation can be estimated using 
the previously developed model17.  The surfactant concentrations that are required to stabilize the 
model cocrystals at different pH are calculated and shown in Table 2.4.   
Table 2.4.  Estimated SLS concentrations for stabilizing cocrystals during dissolution at different 
pH using the surface saturation model. 
CBZ-SAC CBZ-SLC 
pH 
CSCb (mM) 
pH 
CSCb (mM) 
Bulk Interfaciala Bulk Interfaciala 
1.0 1.0 12 1.0 1.0 7 
2.0 2.0 27 2.0 2.0 7 
3.0 2.8 161 3.0 3.0 10 
4.0 3.0 306 4.0 3.6 18 
5.0 3.0 326 5.0 3.7 21 
6.0 3.0 326 6.0 3.7 21 
7.0 3.0 326 7.0 3.7 21 
8.0 3.0 326 8.0 3.7 21 
aFrom Figure 2.11.    
bCalculated from previously developed model17. 
 
The CSC of CBZ-SAC is significantly higher than CBZ-SLC since the solubility of CBZ-
SAC is higher and thus requires higher surfactant concentration to stabilize the cocrystal during 
dissolution.  Because of the self-buffering ability of the cocrystals, the CSC is essentially the same 
in the buffering region regardless of the bulk pH.  
Surface saturation model flux predictions – pH effect   
The flux of the cocrystals were calculated from the dissolution rates and compared to 
theoretical predictions to evaluate the predictive power of the surface saturation model.  The 
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theoretical flux can be calculated using equation 2A.49 from Appendix 2A and the 
physicochemical parameters of the cocrystals and their components.  The experimental and 
theoretical flux comparison is shown in Figure 2.12.  The experimental data confirmed that the 
flux of the cocrystal components are equal as expected because the stoichiometry of both cocrystals 
are 1:1.  Also as expected, the flux of CBZ-SAC and CBZ-SLC plateau in the buffering region 
because there is minimal change in interfacial pH as predicted from the mass transport analysis.  
By modeling the interfacial pH, the theoretical flux shows excellent agreement with the 
experimental data using the physicochemical parameters in Table 2.1 and 2.2 and Figure 2.7.  
Because of the acidity of SAC, the flux of CBZ-SAC is very sensitive to interfacial pH changes 
and this can lead to the large deviations observed in the buffering region.  A 0.2 unit pH change in 
interfacial pH around 3.0 can lead to a roughly 20% change in the flux of CBZ-SAC.  Accurate 
predictions of interfacial pH are clearly very important for predicting the flux of cocrystals with 
ionizable components.   
(a)                                                                           (b) 
 
Figure 2.12.  Flux of CBZ-SAC at 400 mM SLS (a) and CBZ-SLC at 150 mM SLS (b) as a function 
of bulk pH.  Flux predictions were calculated using equation 2A.49 from Appendix 2A based on 
the interfacial pH predicted from Figure 2.11.  The Ksp, Ka, Ks values are shown in Table 2.1 and 
2.2 and 𝐷𝑅𝑒𝑓𝑓 values are from Figure 2.7. 
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Combination effect of pH and surfactant on dissolution  
The combination of pH and surfactant effect on the dissolution of cocrystals was studied 
by performing dissolution experiments at different pH and surfactant concentrations.  The 
dissolution rates were expressed in terms of flux and compared to the predicted values from the 
surface saturation model.  The dependence of flux on pH and surfactant concentration for both 
cocrystals is shown in the three dimensional plots in Figure 2.13.  For both cocrystals, the 
theoretical values showed excellent agreement with the experimental data.  There are fewer 
experimental data points on the CBZ-SAC plot because much of the area in the plot is not 
experimentally accessible due to the potential phase transformation during dissolution.  At the 
buffering region (bulk pH 4 to 8), the surfactant concentration required to stabilize CBZ-SAC 
during dissolution is at least 326 mM (Table 2.4).  Due to the potential conversion of CBZ-SAC 
back to the stable drug form, no dissolution experiments were performed in SLS concentration 
below 400 mM in the bulk pH range of 4 to 8.  The effect of bulk pH on the flux of cocrystal is 
dictated by the interfacial pH.  Any bulk pH changes in the range of 4 to 8 does not have a 
significant impact on the dissolution of the cocrystal because the cocrystal can self-buffer the pH 
microenvironment at the dissolving surface to produce essentially the same interfacial pH.  Flux 
increases as surfactant concentration increases; however, the increase is larger at lower surfactant 
concentration.   
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(a)                                                                        (b) 
 
Figure 2.13.  Influence of pH and surfactant concentration on flux of CBZ-SAC (a) and CBZ-SLC 
(b).  The wireframe mesh represents the theoretical flux predictions and circles represent the 
experimentally measured flux of cocrystals in terms of CBZ.  Flux predictions were calculated 
using equation 2A.49 from Appendix 2A based on the interfacial pH predicted from Figure 2.11.  
The Ksp, Ka, Ks values are shown in Table 2.1 and 2.2 and 𝐷𝑅𝑒𝑓𝑓  values are from Figure 2.7. 
 
The effects of surfactant concentration on solubility and micellar diffusivity are opposite.  
At low surfactant concentrations, the advantage of solubility enhancement on dissolution is greater 
than the disadvantage of decreased micellar diffusivity, so the increase in flux is greater.  As 
surfactant concentration increases, the disadvantage of reduced micellar diffusivity is slowly 
approaching the advantage of solubility enhancement and thus the flux increase is smaller.  When 
the opposite effects of surfactant on micellar diffusivity and solubility essentially cancel each other 
out, the enhancement in flux by surfactant is limited as indicated by the plateau values of CBZ-
SAC at surfactant concentrations range from 300 to 400 mM.   
Discussion 
 This work highlights the importance of interfacial pH on determining the flux of cocrystals 
with ionizable components.  Without the knowledge of interfacial pH, one might assume the pH 
at the dissolving surface is the same as the bulk pH.  Assuming this, the flux of both CBZ-SAC 
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and CBZ-SLC would be expected to increase with increasing bulk pH instead of plateauing at the 
buffering region.  The fifth order equation (equation 2A.45 from Appendix 2A) developed from 
the mass transport analysis of the surface saturation model gives reasonably accurate predictions 
of interfacial pH that are otherwise difficult to measure experimentally.  This allows the model to 
capture the plateaued region in the flux of both cocrystals as a function of bulk pH.  The surfactant 
concentrations required to stabilize the cocrystal during dissolution at different bulk pH can also 
be estimated from the interfacial pH predictions.  The use of surfactant can enhance the dissolution 
of cocrystals, but sometimes the enhancement may not be as large as expected because of the 
counter balancing effect of surfactant on solubility and micellar diffusion coefficients. 
One of the important elements for the mass transport analysis of cocrystal is the 
concentrations of the cocrystal components at the dissolving surface as they determine the rate of 
dissolution.  The surface concentrations of the components may not follow the cocrystal’s 
stoichiometric ratio because they have different diffusion coefficients.  For the cocrystals studied 
here, the drug has a slower diffusion compared to the coformers.  According to the surface 
saturation model, the slower diffusing component (ie: the drug) is able to maintain a surface 
concentration at the stoichiometric cocrystal solubility and acts as the determinant for the 
dissolution of the cocrystal while the faster diffusing component has a lower surface concentration.  
The mass transport analysis here is only applicable for cocrystals that have the same stoichiometry 
and ionization property as CBZ-SAC and CBZ-SLC.  However, the surface saturation model 
developed here can be applied to the mass transport analysis for cocrystals with different 
stoichiometries and ionization properties. 
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Conclusions 
The mechanism of cocrystal dissolution as a function of pH and surfactant concentration 
has been successfully analyzed through the development and evaluation of a physically realistic 
mass transport model.  This mass transport analysis demonstrated the importance of interfacial pH 
in determining the flux of cocrystals with ionizable components.  The ionizable components have 
the ability to self-buffer the pH microenvironment at the interface.  Evaluation of the 
physicochemical properties such as solubility product, ionization constant, solubilization constant 
and diffusion coefficient, are required for accurate prediction of interfacial pH and flux of the 
cocrystal.  The predictive power of the mass transport analysis was evaluated by performing 
dissolution above the CSC to prevent the conversion of highly soluble cocrystal back to the drug 
form.  The model adequately describes the dissolution behavior of cocrystal as a function of pH 
and surfactant concentration.  Bulk pH itself does not adequately explain the dissolution behavior 
of cocrystal because the rate of dissolution is affected by the pH at the interface.  The effect of 
surfactant on dissolution of cocrystal is also an important consideration and can diminish as 
surfactant concentration increases due to the counter balancing effects of surfactant on micellar 
diffusivity and solubility.     
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APPENDIX 2A  
The chemical equilibria and the equations for equilibrium constants during the dissolution of 1:1 
cocrystal, RHA with R as the nonionizable drug and HA as the weak acidic coformer in the 
presence of surfactant can be described as follows: 
(𝑅𝐻𝐴)𝑠𝑜𝑙𝑖𝑑 ⇋ 𝑅𝑎𝑞 + 𝐻𝐴𝑎𝑞          (2A.1) 
𝐾𝑠𝑝 = [𝑅]𝑎𝑞[𝐻𝐴]𝑎𝑞               (2A.2) 
𝑅𝑎𝑞 + 𝑚 ⇋ 𝑅𝑚           (2A.3) 
𝐾𝑠
𝑅 =
[𝑅]𝑚
[𝑅]𝑎𝑞[𝑚]
            (2A.4) 
𝐻𝐴𝑎𝑞 + 𝑚 ⇋ 𝐻𝐴𝑚           (2A.5)  
𝐾𝑠
𝐻𝐴 =
[𝐻𝐴]𝑚
[𝐻𝐴]𝑎𝑞[𝑚]
           (2A.6)  
𝐻2𝑂 + 𝐻𝐴𝑎𝑞 ⇋ 𝐻3𝑂
+ + 𝐴𝑎𝑞
−           (2A.7)  
𝐾𝑎 =
[𝐻3𝑂
+][𝐴−]𝑎𝑞
[𝐻𝐴]𝑎𝑞
           (2A.8) 
𝐻3𝑂
+ + 𝑂𝐻− ⇋ 2𝐻2𝑂          (2A.9)  
𝐾𝑤 = [𝐻3𝑂
+][𝑂𝐻−]                    (2A.10) 
𝐻𝐴𝑎𝑞 + 𝑂𝐻
− ⇋ 𝐻2𝑂 + 𝐴𝑎𝑞
−                    (2A.11) 
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𝐾1 =
[𝐴−]𝑎𝑞
[𝐻𝐴]𝑎𝑞[𝑂𝐻−]
                    (2A.12)  
where 𝐾𝑠
𝑅 is the solubilization constant of R and 𝐾𝑠
𝐻𝐴 is the solubilization constant of HA, m is the 
micellar concentration in the solution and is equal to the total surfactant concentration minus the 
CMC, Ka is the ionization constant of HA, Kw is the dissociation constant of water, K1 is the ratio 
of Ka/Kw.  Subscript aq denotes the aqueous phase and m denotes the micellar phase.   An 
assumption in this analysis is that the ionized coformer is not solubilized by surfactant. 
The total concentrations of the cocrystal components, 𝑅𝑡𝑜𝑡,0 and 𝐴𝑡𝑜𝑡,0 at the dissolving 
surface can be described as: 
𝑅𝑡𝑜𝑡,0 = 𝑅𝑎𝑞,0(1 + 𝐾𝑠
𝑅[𝑚])                   (2A.13) 
𝐴𝑡𝑜𝑡,0 = 𝐻𝐴𝑎𝑞,0(1 +
𝐾𝑎
𝐻0
+ + 𝐾𝑠
𝐻𝐴[𝑚])                  (2A.14) 
When the cocrystal is in equilibrium with solution at the dissolving surface at time = 0 before any 
diffusion, the stoichiometric solubility of RHA is as follow: 
𝑆𝑐𝑐 = 𝑅𝑡𝑜𝑡,0 = 𝐴𝑡𝑜𝑡,0 = √𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(1 +
𝐾𝑎
𝐻0
+ + 𝐾𝑠
𝐻𝐴[𝑚])              (2A.15) 
The flux of all the species across the diffusion layer includes both the diffusion and 
chemical reactions happening during dissolution.  At steady state, the diffusion and simultaneous 
chemical reactions of the individual species within the diffusion layer can be written using Fick’s 
law as follows24: 
𝜕[𝑅]𝑎𝑞
𝜕𝑡
= 𝐷𝑅𝑎𝑞
𝜕2 [𝑅]𝑎𝑞
𝜕𝑥2
+ 𝜙1 = 0                  (2A.16) 
𝜕[𝑅]𝑚
𝜕𝑡
= 𝐷𝑅𝑚
𝜕2 [𝑅]𝑚
𝜕𝑥2
+ 𝜙2 = 0                  (2A.17) 
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𝜕[𝐻𝐴]𝑎𝑞
𝜕𝑡
= 𝐷𝐻𝐴𝑎𝑞
𝜕2 [𝐻𝐴]𝑎𝑞
𝜕𝑥2
+ 𝜙3 = 0                  (2A.18) 
𝜕[𝐴−]𝑎𝑞
𝜕𝑡
= 𝐷𝐴𝑎𝑞−
𝜕2 [𝐴−]𝑎𝑞
𝜕𝑥2
+ 𝜙4 = 0                  (2A.19) 
𝜕[𝐻𝐴]𝑚
𝜕𝑡
= 𝐷𝐻𝐴𝑚
𝜕2 [𝐻𝐴]𝑚
𝜕𝑥2
+ 𝜙5 = 0                  (2A.20) 
𝜕[𝑂𝐻−]
𝜕𝑡
= 𝐷𝑂𝐻−
𝜕2 [𝑂𝐻−]
𝜕𝑥2
+ 𝜙6 = 0                  (2A.21) 
𝜕[𝐻+]
𝜕𝑡
= 𝐷𝐻+
𝜕2 [𝐻+]
𝜕𝑥2
+ 𝜙7 = 0                  (2A.22) 
where ϕ1-7 are the reaction rate functions.  At equilibrium, the reaction rate of the reactant should 
be the opposite of the product.  Based on the chemical equilibria, the followings can be written: 
𝜙1 = −𝜙2                     (2A.23) 
𝜙3 = −𝜙4 − 𝜙5                    (2A.24) 
The reaction rate of A- can be reflected by the reaction rate of H+ and OH-, therefore, 
𝜙4 = 𝜙7 − 𝜙6                     (2A.25) 
Based on equation 2A.25, equation 2A.24 can be written as:  
𝜙3 = 𝜙6 − 𝜙5 − 𝜙7                    (2A.26) 
Based on the equations 2A.23, 2A.24 and 2A.26, the following mass balance equations can be 
written:  
𝐷𝑅𝑎𝑞
𝑑2 [𝑅]𝑎𝑞
𝑑𝑥2
= −𝐷𝑅𝑚
𝑑2 [𝑅]𝑚
𝑑𝑥2
                   (2A.27) 
𝐷𝐻𝐴𝑎𝑞
𝑑2 [𝐻𝐴]𝑎𝑞
𝑑𝑥2
= −𝐷𝐴𝑎𝑞−
𝑑2[𝐴−]𝑎𝑞
𝑑𝑥2
− 𝐷𝐻𝐴𝑚
𝑑2 [𝐻𝐴]𝑚
𝑑𝑥2
                (2A.28) 
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𝐷𝐻𝐴𝑎𝑞
𝑑2 [𝐻𝐴]𝑎𝑞
𝑑𝑥2
= 𝐷𝑂𝐻−
𝑑2 [𝑂𝐻−]
𝑑𝑥2
− 𝐷𝐻+
𝑑2[𝐻+]
𝑑𝑥2
− 𝐷𝐻𝐴𝑚
𝑑2 [𝐻𝐴]𝑚
𝑑𝑥2
              (2A.29) 
Integrating equations 2A.27 to 2A.29 once gives: 
𝐷𝑅𝑎𝑞
𝑑[𝑅]𝑎𝑞
𝑑𝑥
= −𝐷𝑅𝑚
𝑑 [𝑅]𝑚
𝑑𝑥
+ 𝐶1                  (2A.30) 
𝐷𝐻𝐴𝑎𝑞
𝑑 [𝐻𝐴]𝑎𝑞
𝑑𝑥
= −𝐷𝐴𝑎𝑞−
𝑑[𝐴−]𝑎𝑞
𝑑𝑥
− 𝐷𝐻𝐴𝑚
𝑑 [𝐻𝐴]𝑚
𝑑𝑥
+ 𝐶2               (2A.31) 
𝐷𝐻𝐴𝑎𝑞
𝑑 [𝐻𝐴]𝑎𝑞
𝑑𝑥
= 𝐷𝑂𝐻−
𝑑 [𝑂𝐻−]
𝑑𝑥
− 𝐷𝐻+
𝑑[𝐻+]
𝑑𝑥
− 𝐷𝐻𝐴𝑚
𝑑 [𝐻𝐴]𝑚
𝑑𝑥
+ 𝐶3              (2A.32) 
Since 𝐴𝑎𝑞
−  is the product of the reaction between HA and OH-, so its flux can be reflected by both 
OH- and H+: 
−𝐷𝐴𝑎𝑞−
𝑑[𝐴−]𝑎𝑞
𝑑𝑥
= 𝐷𝑂𝐻−
𝑑 [𝑂𝐻−]
𝑑𝑥
− 𝐷𝐻+
𝑑[𝐻+]
𝑑𝑥
                 (2A.33) 
With this mass balance relationship, it can be seen that  
𝐶2 = 𝐶3                     (2A.34) 
Integrating equations 2A.30 to 2A.32 once gives:  
𝐷𝑅𝑎𝑞[𝑅]𝑎𝑞 = −𝐷𝑅𝑚[𝑅]𝑚 + 𝐶1𝑥 + 𝐶4                 (2A.35) 
𝐷𝐻𝐴𝑎𝑞[𝐻𝐴]𝑎𝑞 = −𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚−𝐷𝐴𝑎𝑞− [𝐴
−]𝑎𝑞 + 𝐶2𝑥 + 𝐶5               (2A.36) 
𝐷𝐻𝐴𝑎𝑞[𝐻𝐴]𝑎𝑞 = 𝐷𝑂𝐻−[𝑂𝐻
−] − 𝐷𝐻+[𝐻
+]−𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚 + 𝐶3𝑥 + 𝐶6             (2A.37) 
Interfacial pH and flux of the species can be evaluated by solving these mass balance equations 
with the boundary conditions obtained from the surface saturation and interfacial equilibrium 
models. 
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Surface saturation model 
Given that the concentration of the drug is the same as the solubility of the cocrystal at the 
surface for the surface saturation model, the aqueous concentration of the drug at the surface can 
be solved using equation 2A.13 and 2A.15:  
𝑅𝑎𝑞,0 =
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+𝐾𝑠
𝑅[𝑚]
                  (2A.38) 
Assuming the dissolution of RHA in the presence of surfactant gives equal flux of R and HA:  
𝐽𝑅𝑡𝑜𝑡 =
𝐷𝑅𝑒𝑓𝑓[𝑅]𝑡𝑜𝑡,0
ℎ
= 𝐽𝐴𝑡𝑜𝑡 =
𝐷𝐻𝐴𝑒𝑓𝑓[𝐴]𝑡𝑜𝑡,0
ℎ
                 (2A.39) 
where 𝐷𝑅𝑒𝑓𝑓 and 𝐷𝐻𝐴𝑒𝑓𝑓 are the effective diffusion coefficients of the drug and coformer, which 
are defined in equation 2.14 as the total diffusion of the free and micelle solubilized solute.37  Given 
equations 2A.13-2A.15 above and applying the equation for diffusion layer thickness shown in 
equation 2.10, the aqueous concentration of the coformer at the surface is given by: 
[𝐻𝐴]𝑎𝑞,0 = (
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)2/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚]
                (2A.40) 
Based on equations 2A.38 and 2A.40, the following boundary conditions for each species can be 
written for the surface saturation model: 
At x = 0:        at x = h: 
[𝑅]𝑎𝑞,0 =
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+𝐾𝑠
𝑅[𝑚]
   [𝑅]𝑎𝑞,ℎ = 0 (under sink condition) 
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[𝐻𝐴]𝑎𝑞,0 = (
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)2/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚]
  [𝐻𝐴]𝑎𝑞,ℎ = 0 (under sink condition) 
[𝑅]𝑚,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛      [𝑅]𝑚,ℎ = 0 (under sink condition) 
[𝐻𝐴]𝑚,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛      [𝐻𝐴]𝑚,ℎ = 0 (under sink condition) 
[𝐴−]𝑎𝑞,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛      [𝐴
−]𝑎𝑞,ℎ = 0 (under sink condition) 
[𝐻+] = [𝐻+]0       [𝐻
+] = [𝐻+]ℎ 
[𝑂𝐻−] = [𝑂𝐻−]0      [𝑂𝐻
−] = [𝑂𝐻−]ℎ 
Evaluation of pH at the solid surface   
Applying the above boundary conditions to equations 2A.36 and 2A.37, at x = 0:  
𝐷𝐻𝐴𝑎𝑞(
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)2/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚]
= −𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚,0−𝐷𝐴𝑎𝑞− [𝐴
−]𝑎𝑞,0 + 𝐶5         (2A.41) 
𝐷𝐻𝐴𝑎𝑞(
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)2/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚]
= 𝐷𝑂𝐻−[𝑂𝐻
−]0 − 𝐷𝐻+[𝐻
+]0−𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚,0 + 𝐶6       
                                               (2A.42) 
and at x = h, since sink conditions are assumed, equations 2A.36 and 2A.37 can be written as: 
𝐶2ℎ + 𝐶5 = 0                     (2A.43) 
0 = 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ + 𝐶3ℎ + 𝐶6                 (2A.44) 
Combining equations 2A.41 to 2A.44 and algebraically solving for interfacial pH, [H+]0, yields the 
following equation: 
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𝐴[𝐻+]0
5
+ 𝐵[𝐻+]0
4
+ 𝐶[𝐻+]0
3
+ 𝐷[𝐻+]0
2
+ 𝐸[𝐻+]0 + 𝐹 = 0              (2A.45) 
where 
𝐴 = 𝐷𝐻+
2 (1 + 𝐾𝑠
𝐻𝐴[𝑚]); 
𝐵 = −2𝐷𝐻+(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)(1 + 𝐾𝑠
𝐻𝐴[𝑚]) + 𝐷𝐻+
2 𝐾𝑎; 
𝐶 = −2𝐷𝐻+𝐷𝑂𝐻−𝐾𝑤(1 + 𝐾𝑠
𝐻𝐴[𝑚]) + (1 + 𝐾𝑠
𝐻𝐴[𝑚])(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)
2 −
2𝐷𝐻+(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)𝐾𝑎; 
𝐷 = 2𝐷𝑂𝐻−𝐾𝑤(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)(1 + 𝐾𝑠
𝐻𝐴[𝑚]) − 2𝐷𝐻+𝐷𝑂𝐻−𝐾𝑤𝐾𝑎 +
(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)
2𝐾𝑎; 
𝐸 = (𝐷𝑂𝐻−𝐾𝑤)
2(1 + 𝐾𝑠
𝐻𝐴[𝑚]) + 2𝐷𝑂𝐻−𝐾𝑤(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)𝐾𝑎 −
(𝐷𝐴𝑎𝑞−
1/3
𝐷𝑅𝑒𝑓𝑓
2/3
Ka√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚]))
2; 
𝐹 = 𝐾𝑎(𝐷𝑂𝐻−𝐾𝑤)
2. 
Evaluation of flux of the cocrystal components   
Applying the boundary conditions to equation 2A.35, at x = 0: 
𝐷𝑅𝑎𝑞
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+𝐾𝑠
𝑅[𝑚]
= −𝐷𝑅𝑚𝐾𝑠
𝑅[𝑚]
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+𝐾𝑠
𝑅[𝑚]
+ 𝐶4             (2A.46) 
and at x = h, assuming sink conditions: 
0 = 𝐶1ℎ + 𝐶4                     (2A.47) 
Combining equations 2A.46 and 2A.47 and solving for −𝐶1 for the flux of the cocrystal in terms 
of drug: 
𝐽𝑅 =
𝐷𝑅𝑒𝑓𝑓
ℎ𝑅
√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(1 +
𝐾𝑎
𝐻0
+ + 𝐾𝑠
𝐻𝐴[𝑚])                (2A.48) 
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By substituting equation 2.10 into equation 2A.48, it becomes: 
𝐽𝑅 = 0.62𝐷𝑅𝑒𝑓𝑓
2/3
𝜔1/2𝑣−1/6√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(1 +
𝐾𝑎
𝐻0
+ + 𝐾𝑠
𝐻𝐴[𝑚])              (2A.49) 
The flux of the cocrystal in terms of coformer can be also solved in a similar manner by applying 
the boundary conditions to equation 2A.36: 
𝐽𝐻𝐴 =
𝐷𝐻𝐴𝑒𝑓𝑓
1
3 𝐷𝑅𝑒𝑓𝑓
2
3
ℎ𝐻𝐴
√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(1 +
𝐾𝑎
𝐻0
+ + 𝐾𝑠
𝐻𝐴[𝑚])               (2A.50) 
By substituting equation 2.10 into equation 2A.50, it can be shown to equal equation 2A.49.  This 
is expected since the flux of drug and coformer should be the same for a 1:1 cocrystal even though 
they have different diffusivities.   
Interfacial equilibrium model 
Given equations 2A.2, 2A.13, 2A.14, 2A.15, 2A.39 and applying the equation for diffusion 
layer thickness shown in equation 2.10, the aqueous concentrations of R and HA at the dissolving 
surface required to maintain constant Ksp at all time t ≥ 0 are as follows:  
[𝑅]𝑎𝑞,0 = (
𝐷𝐻𝐴𝑒𝑓𝑓
𝐷𝑅𝑒𝑓𝑓
)1/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+𝐾𝑠
𝑅[𝑚]
                (2A.51) 
[𝐻𝐴]𝑎𝑞,0 = (
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)1/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚]
                 (2A.52) 
Based on equations 2A.51 and 2A.52, the following boundary conditions for each species can be 
written for the interfacial equilibrium model: 
At x = 0:        at x = h: 
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[𝑅]𝑎𝑞,0 = (
𝐷𝐻𝐴𝑒𝑓𝑓
𝐷𝑅𝑒𝑓𝑓
)1/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+𝐾𝑠
𝑅[𝑚]
  [𝑅]𝑎𝑞,ℎ = 0 (under sink condition) 
[𝐻𝐴]𝑎𝑞,0 = (
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)1/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚]
  [𝐻𝐴]𝑎𝑞,ℎ = 0 (under sink condition) 
[𝑅]𝑚,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛      [𝑅]𝑚,ℎ = 0 (under sink condition) 
[𝐻𝐴]𝑚,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛      [𝐻𝐴]𝑚,ℎ = 0 (under sink condition) 
[𝐴−]𝑎𝑞,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛      [𝐴
−]𝑎𝑞,ℎ = 0 (under sink condition) 
[𝐻+] = [𝐻+]0       [𝐻
+] = [𝐻+]ℎ 
[𝑂𝐻−] = [𝑂𝐻−]0      [𝑂𝐻
−] = [𝑂𝐻−]ℎ 
Evaluation of pH at the solid surface   
Applying the above boundary conditions to equations 2A.36 and 2A.37, at x = 0:  
𝐷𝐻𝐴𝑎𝑞(
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)1/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚]
= −𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚,0−𝐷𝐴𝑎𝑞− [𝐴
−]𝑎𝑞,0 + 𝐶5        (2A.53) 
𝐷𝐻𝐴𝑎𝑞(
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)1/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚]
= 𝐷𝑂𝐻−[𝑂𝐻
−]0 − 𝐷𝐻+[𝐻
+]0−𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚,0 + 𝐶6 
                       (2A.54) 
and at x = h: 
𝐶2ℎ + 𝐶5 = 0                     (2A.55) 
0 = 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ + 𝐶3ℎ + 𝐶6                 (2A.56) 
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Combining equations 2A.53 to 2A.56 and algebraically solving for interfacial pH yields the 
following equation: 
𝐴[𝐻+]0
5
+ 𝐵[𝐻+]0
4
+ 𝐶[𝐻+]0
3
+ 𝐷[𝐻+]0
2
+ 𝐸[𝐻+]0 + 𝐹 = 0              (2A.57) 
where,  
𝐴 = 𝐷𝐻+
2 (1 + 𝐾𝑠
𝐻𝐴[𝑚]); 
𝐵 = −2𝐷𝐻+(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)(1 + 𝐾𝑠
𝐻𝐴[𝑚]) + 𝐷𝐻+
2 𝐾𝑎; 
𝐶 = −2𝐷𝐻+𝐷𝑂𝐻−𝐾𝑤(1 + 𝐾𝑠
𝐻𝐴[𝑚]) + (1 + 𝐾𝑠
𝐻𝐴[𝑚])(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)
2 −
2𝐷𝐻+(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)𝐾𝑎; 
𝐷 = 2𝐷𝑂𝐻−𝐾𝑤(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)(1 + 𝐾𝑠
𝐻𝐴[𝑚]) − 2𝐷𝐻+𝐷𝑂𝐻−𝐾𝑤𝐾𝑎 +
(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)
2𝐾𝑎; 
𝐸 = (𝐷𝑂𝐻−𝐾𝑤)
2(1 + 𝐾𝑠
𝐻𝐴[𝑚]) + 2𝐷𝑂𝐻−𝐾𝑤(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)𝐾𝑎 −
(𝐷𝐴𝑎𝑞−
2/3
𝐷𝑅𝑒𝑓𝑓
1/3
Ka√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚]))
2; 
𝐹 = 𝐾𝑎(𝐷𝑂𝐻−𝐾𝑤)
2. 
This equation is very similar to the one obtained from the surface saturation model.  The only 
difference is the coefficient E in the equation because of the different boundary layer conditions.   
Evaluation of flux of the cocrystal components   
Applying the new boundary conditions to mass balance equations 2A.35 and 2A.36, the flux of 
the cocrystal in terms of components can be re-evaluated as: 
𝐽𝑅 = 𝐽𝐻𝐴 = 0.62(𝐷𝑅𝑒𝑓𝑓𝐷𝐻𝐴𝑒𝑓𝑓)
1/3𝜔1/2𝑣−1/6√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(1 +
𝐾𝑎
𝐻0
+ + 𝐾𝑠
𝐻𝐴[𝑚])          (2A.58) 
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Unlike the surface saturation model, the flux of the cocrystal is not only dependent on the effective 
diffusivity of the drug, but also the coformer.   
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CHAPTER 3  
MECHANISTIC BASIS OF COCRYSTAL DISSOLUTION ADVANTAGE 
Abstract 
The current interest in cocrystal development resides in the advantages that the cocrystal 
may have in solubility and dissolution compared to the parent drug.  The mechanism of cocrystal 
solubility advantage has been studied in detail, however, limited research has been carried out on 
the dissolution of cocrystals. The purpose of this work is to provide a mechanistic analysis and 
comparison of the dissolution behavior of carbamazepine (CBZ) and its two cocrystals, 
carbamazepine-saccharin (CBZ-SAC) and carbamazepine-salicylic acid (CBZ-SLC) under the 
influence of pH and micellar solubilization.  A simple mathematical equation is derived based on 
the mass transport analyses of both the drug and cocrystal to describe the dissolution advantage of 
cocrystal, which is defined as the ratio of the cocrystal flux over the drug flux.  The dissolution 
advantage of cocrystal has a dependence on both the solubility and diffusivity advantages.  In this 
work, the effective diffusivity of CBZ in the presence of surfactant is determined to be different 
from those of the cocrystals.  The higher effective diffusivities of the cocrystals can impart 
dissolution advantages to cocrystals with lower solubility than the parent drugs while still 
maintaining thermodynamic stability.  Dissolution conditions where cocrystals display both 
thermodynamic stability and dissolution advantage can be obtained from the mass transport 
models and this information is useful for both cocrystal selection and formulation development.   
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Introduction 
Cocrystallization is one of the powerful strategies used in pharmaceutical development to 
improve the aqueous solubility of inherently insoluble drugs1-6.  Cocrystallization usually involves 
the formation of cocrystal through hydrogen bonding between the hydrophobic drug and 
hydrophilic coformer7, 8.  As a new and different solid form, the physicochemical properties of 
cocrystal need to be fully evaluated in order to develop a feasible formulation.  Among these 
properties, solubility and dissolution are of particular interests due to their importance in 
determining the oral absorption of drugs9.  A thorough understanding of the solubility and 
dissolution mechanisms of cocrystals not only aids the formulation development, but also provides 
an improved perspective on the oral absorption of drugs from the cocrystalline solids. 
One of the motivations for cocrystal development is the solubility advantages that these 
cocrystalline materials can generate1-6.  However, these solubility advantages are not constant and 
they can vanish under certain solution conditions, such as pH and the presence of solubilizing 
additive10-15.  Cocrystals can exhibit higher, equal or lower solubility compared to the parent drugs 
depending on the solution conditions.  Important transition points, such as pHmax and critical 
stabilization concentration (CSC), have been identified to access the solubility behavior of 
cocrystals10, 11, 15.  Cocrystal is thermodynamically unstable below the CSC, but it is 
thermodynamically stable above the CSC10, 12, 13.  CSC can be achieved using any additives that 
preferentially solubilize the drug compared to the coformer10, 12, 13.  Without knowing these 
important concepts, cocrystals could lose their solubility advantages compared to the parent drugs 
if the concentrations of solubilizing agents used are above the CSC.  Consequently, a thorough 
understanding of the transition point is essential for fine-tuning the formulations of cocrystals to 
achieve desired solubility advantages.     
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Another question of interest for cocrystal development is whether cocrystal could exhibit 
higher dissolution rate compared to the parent drug.  Knowing the dissolution behavior of 
cocrystals adds another level of confidence in formulation development.  The dissolution 
mechanism of cocrystals under the influence of pH and surfactant has been evaluated through the 
development of mass transport models16.  The mass transport analyses indicate that the 
physicochemical properties of cocrystals and their components, such as solubility products, 
ionization constants, solubilization constants and diffusion coefficients, are important parameters 
for determining the rates of cocrystal dissolution16.    Dissolution rate is directly proportional to 
the solubility of the cocrystal.  This relationship leads to an important question to be addressed in 
this study, which is whether a cocrystal solubility advantage is necessary to obtain higher cocrystal 
dissolution rate compared to the parent drug.  
Here, a simple mathematical model is presented to determine the dissolution advantages of 
cocrystals compared to the parent drugs.  This model is evaluated using a model drug, 
carbamazepine (CBZ) and its two cocrystals with 1:1 stoichiometry, carbamazepine saccharin 
(CBZ-SAC) and carbamazepine salicylic acid (CBZ-SLC).  CBZ is non-ionizable and both SAC 
and SLC are acidic coformers with pKa values of 1.6 and 3.0
1, 10, respectively.  The stable form of 
CBZ in solution is its dihydrated form.  To eliminate the complication of conversion, CBZ 
dihydrate (CBZD) was used for this study.  Constant surface area dissolution of both CBZD and 
its two cocrystals was determined using rotating disk apparatus.  Both CBZ-SAC and CBZ-SLC 
have higher solubility than CBZD, so dissolution studies were performed in solution containing 
sodium lauryl sulfate (SLS) concentration at or above the CSC to prevent solid phase 
transformation during dissolution.  Effect of pH and surfactant concentration on the dissolution of 
CBZD and two CBZ cocrystals was evaluated and compared in this study. 
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Materials and methods 
Materials  
Anhydrous carbamazepine (CBZ), salicylic acid (SLC) and sodium lauryl sulfate (SLS) 
were purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  
Carbamazepine dihydrate (CBZD) was prepared by slurrying anhydrous CBZ in deionized water 
for 24 hours and solid was obtained through vacuum filtration.  Saccharin (SAC) was purchased 
from Acros Organics (Pittsburgh, PA) and used as received.  Isopropanol, acetonitrile, methanol 
and hydrochloric acid were purchased from Fisher Scientific (Pittsburgh, PA).  Sodium hydroxide 
pellets were purchased from J.T. Baker (Philipsburg, NJ).  Water used in this study was filtered 
through a double deionized purification system (Milli Q Plus Water System) from Millipore Co. 
(Bedford, MA).   
Cocrystal synthesis   
Cocrystals were prepared by reaction crystallization method17 at room temperature.  CBZ-
SAC was prepared by adding 1:1 molar ratio of CBZ and SAC in isopropanol solution.  CBZ-SLC 
was prepared by adding 1:1 molar ratio of CBZ and SLC in acetonitrile solution containing 0.1 M 
SLC.  Solid phases were characterized by X-ray powder diffraction (XRPD) and differential 
scanning calorimetry (DSC).   
Cocrystal solubility  
Cocrystal solubility was measured by determining the eutectic concentrations of the drug 
and coformer as a function of SLS concentration at pH 1 and 25°C.  A detailed discussion of the 
eutectic point measurement was reported elsewhere18.  Cocrystals (100 – 150 mg) and CBZD (50 
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– 100 mg) were suspended in 3 mL of aqueous SLS solution and stirred for 4 days.  Samples were 
collected at 24 hour intervals and centrifuged using Corning Costar Spin-X plastic centrifuge tubes 
with filters to separate the excess solid from solution.  Solution concentrations were measured 
using HPLC and solid phases were analyzed by XRPD.  Cocrystal stoichiometric solubility was 
determined from the measured eutectic concentrations of the components using previously 
developed method18. 
Dissolution experiments   
The constant surface area dissolution rates of cocrystals and CBZD were determined using 
a rotating disk apparatus.  Cocrystal or CBZD powder (~150 mg) was compressed in a stainless 
steel rotating disk die with a tablet radius of 0.50 cm at 85 MPa for 2 minutes using a Carver 
hydraulic press.  The die containing the compact was mounted onto a stainless steel shaft attached 
to an overhead, variable speed motor.  The disk was exposed to 150 mL of the dissolution medium 
in a water jacketed beaker with temperature controlled at 25°C and a rotation speed of 200 rpm 
was used.  Dissolution medium was prepared on the day of the experiment by dissolving SLS in 
water and solution pH was adjusted using HCl or NaOH.  Sink conditions were maintained 
throughout the experiments by ensuring the concentrations at the last time point of dissolution 
were less than 10% of the cocrystal solubility.  Solution concentrations were measured using 
HPLC and solid phases after dissolutions were analyzed by XRPD.   
HPLC   
Waters HPLC equipped with a photodiode array detector was used for all analysis.  The 
mobile phase was composed of 55% methanol and 45% water with 0.1% trifluoroacetic acid and 
the flow rate was 1 mL/min was used.  Separation was achieved using Waters, Atlantis, T3 column 
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(5.0 µm, 100 Å) with dimensions of 4.6 x 250 mm.  The sample injection volume was 20 µL.  The 
wavelengths for the analytes were as follows: 284 nm for CBZ, 250 nm for SAC and 303 nm for 
SLC.    
XRPD   
XRPD diffractograms of solid phases were collected with a benchtop Rigaku Miniflex X-
ray diffractometer using Cu-Kα radiation (λ = 1.54 Å), a tube voltage of 30 kV, and a tube current 
of 15 mA.  Data was collected from 5 to 40° at a continuous scan rate of 2.5°/min. 
DSC 
Crystalline samples were analyzed by DSC using a TA instrument 2910 MDSC system 
equipped with a refrigerated cooling unit.  All experiments were performed by heating the samples 
at a rate of 10 °C/min under a dry nitrogen atmosphere.  Temperature and enthalpy of the 
instrument were calibrated using high purity indium standard.   
Theoretical  
The solubility of non-ionizable drug in surfactant solution can be described as: 
𝑆𝑑𝑟𝑢𝑔 = 𝑆0(1 + 𝐾𝑠
𝑅[𝑚])             (3.1) 
where 𝑆0 is the intrinsic solubility of the drug, 𝐾𝑠
𝑅 is the solubilization constant of the drug in 
surfactant solution and [m] is the concentration of the micelle10.   
The solubility of a 1:1 cocrystal with non-ionizable drug and acidic coformer in surfactant 
solution can be described as: 
𝑆𝑐𝑐 = √𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(1 + 𝐾𝑠𝐻𝐴[𝑚] +
𝐾𝑎
𝐻+
)          (3.2) 
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where 𝐾𝑠𝑝 is the solubility product of the cocrystal, 𝐾𝑠
𝐻𝐴 is the solubilization constant of the 
coformer in surfactant solution and 𝐾𝑎 is the ionization constant of the coformer
10.  Here, the 
solubilization of the ionized form of the coformer in surfactant solution is assumed to be negligible.     
For rotating disk dissolution, the flux of both drug and cocrystal in surfactant solution can 
be described as follows: 
𝐽𝑅 = 0.62𝐷𝑅𝑒𝑓𝑓,𝑑𝑟𝑢𝑔
2/3
𝜔1/2𝑣−1/6𝑆0(1 + 𝐾𝑠
𝑅[𝑚])          (3.3) 
𝐽𝑐𝑐 = 0.62𝐷𝑅𝑒𝑓𝑓,𝑐𝑐
2/3
𝜔1/2𝑣−1/6√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(1 +
𝐾𝑎
𝐻0
+ + 𝐾𝑠
𝐻𝐴[𝑚])       (3.4) 
where 𝐷𝑅𝑒𝑓𝑓,𝑑𝑟𝑢𝑔  and 𝐷𝑅𝑒𝑓𝑓,𝑐𝑐 are the effective diffusivities of the drug determined from the 
dissolution of drug and cocrystal respectively, 𝜔 is the rotation speed during dissolution and 𝑣 is 
the viscosity of the dissolution media16, 19.  The effective diffusivity in surfactant solution can be 
described as:  
𝐷𝑅𝑒𝑓𝑓 =
𝐷𝑎𝑞+𝐾𝑠𝐷𝑚[𝑚]
1+𝐾𝑠[𝑚]
              (3.5) 
where 𝐷𝑎𝑞 is the aqueous diffusivity and 𝐷𝑚 is the micellar diffusivity
20.  
The dissolution advantage of cocrystal, ∅, is defined as the ratio of the cocrystal flux over 
the drug flux, which is given by: 
∅ =
𝐽𝑐𝑐
𝐽𝑅
= (
𝐷𝑅𝑒𝑓𝑓,𝑐𝑐
𝐷𝑅𝑒𝑓𝑓,𝑑𝑟𝑢𝑔
)2/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
𝑆0(1+𝐾𝑠
𝑅[𝑚])
         (3.6) 
A ∅ value greater than 1 indicates the cocrystal has higher dissolution rate than the drug; whereas 
the dissolution rate of cocrystal is less than the drug with ∅ value below 1.  Equation 3.6 is specific 
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for determining the cocrystal dissolution advantage under surfactant conditions.  However, a 
simplified equation can be derived to apply for dissolution under different solution conditions: 
∅ = (
𝐷𝑅,𝑐𝑐
𝐷𝑅,𝑑𝑟𝑢𝑔
)2/3
𝑆𝑐𝑐
𝑆𝑑𝑟𝑢𝑔
              (3.7) 
where 
𝐷𝑅,𝑐𝑐
𝐷𝑅,𝑑𝑟𝑢𝑔
 is the diffusivity advantage and 
𝑆𝑐𝑐
𝑆𝑑𝑟𝑢𝑔
 is the solubility advantage of the cocrystal.  By 
knowing the cocrystal diffusivity and solubility advantage, the dissolution advantage of cocrystal 
can be predicted under the different solution conditions.  The dissolution advantage of cocrystal 
would only depend on the solubility advantage if the diffusion coefficients are the same for the 
drug and cocrystal.  This is usually true under aqueous conditions with no surfactant.  However, 
under surfactant conditions, the effective diffusion coefficient of the drug maybe different from 
the cocrystal due to the different solubility dependence on surfactant concentration.  Therefore, 
besides the solubility advantage, the effective diffusion coefficients of both drug and cocrystal 
have to be taken into consideration as well for determining the dissolution advantage of cocrystal 
under surfactant conditions.  Due to the differential diffusion coefficients, dissolution advantages 
can be imparted to cocrystals with lower solubility than the parent drugs, as long as the diffusion 
coefficients of the cocrystals are large enough to compensate for the disadvantages in solubility.   
Results and discussion 
Solubility study 
The equilibrium solubility of both cocrystals as a function of surfactant concentration at 
pH 1 was determined using the eutectic point measurement.  At the eutectic point, the solid phases 
of both the drug and cocrystal are in equilibrium with solution and the concentrations of both 
cocrystal components can be measured18.  The relative solubility of the cocrystal to the parent drug 
 94 
 
can be accessed by the eutectic constant, Keu, which is a ratio of the coformer eutectic 
concentration over the drug eutectic concentration18, 21.  Cocrystal is more soluble than the parent 
drug when Keu > 1; but it is less soluble than the parent drug when Keu < 1
18, 21.  The eutectic 
concentrations of the cocrystal components16 and Keu as a function of SLS at pH 1 are shown in 
Figure 3.1 and 3.2.  The concentrations of both components increase with surfactant concentration 
increases, however, the drug concentrations are higher than the coformer concentrations at all 
surfactant concentrations.  This is expected because all the solubility studies were performed at 
surfactant concentrations above the CSC, where the cocrystals are less soluble.  The eutectic 
constants shown in Figure 3.1 and 3.2 further confirm the thermodynamic stability of the cocrystals 
under these conditions.  Keu values decrease as SLS concentration increases because the surfactant 
concentration is further away from the CSC. 
(a)                                                                                (b) 
 
Figure 3.1.  (a) Eutectic concentrations of CBZ ( ) and SAC ( ) measured at the eutectic point 
for CBZ-SAC at pH 1 as a function of SLS concentration16.  (b) Keu values calculated from the 
eutectic concentrations. 
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(a)                                                                                 (b) 
 
Figure 3.2.  (a) Eutectic concentrations of CBZ ( ) and SLC ( ) measured at the eutectic point 
for CBZ-SLC at pH 1 as a function of SLS concentration16.  (b) Keu values calculated from the 
eutectic concentrations.  
 
The equilibrium solubility of cocrystals can be calculated from the eutectic concentrations 
of the cocrystal components using the following equation18: 
𝑆𝑐𝑐 = √[𝑑𝑟𝑢𝑔]𝑒𝑢𝑡𝑒𝑐𝑡𝑖𝑐[𝑐𝑜𝑓𝑜𝑟𝑚𝑒𝑟]𝑒𝑢𝑡𝑒𝑐𝑡𝑖𝑐           (3.8) 
The solubility of CBZD is the same as the eutectic concentration because the solid phase of CBZD 
is in equilibrium with solution.  Previous studies have shown that the solubilization of CBZD by 
SLS is not affected by the presence of coformer10, 12, 13.  The solubility of CBZ-SAC and CBZ-
SLC was determined and compared to CBZD in Figure 3.3 and 3.4, respectively.  Solubility of 
both drug and cocrystals increases as surfactant concentration increases, however, the drug has a 
greater rate of increase compared to both of the cocrystals.  As shown in equations 3.1 and 3.2, the 
solubility of drug has a linear dependence on surfactant concentration, while the cocrystal has a 
square root dependence.  This explains why the drug has a higher increase in solubility as a 
function of surfactant concentration compared to the cocrystals.  The square root dependence of 
cocrystal solubility on surfactant concentration is a result of the preferential solubilization of the 
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drug compared to the coformers by surfactant10.  Since the solubility studies were performed above 
the CSC, both cocrystals exhibited no solubility advantage over the parent drug, as indicated in 
Figure 3.3 and 3.4 with the ratios of Scc/Sdrug less than 1.  The Scc/Sdrug ratios of both cocrystals 
decrease as SLS concentration increases because the difference in solubility between the drug and 
cocrystals increases as the concentration of SLS moves further away from the CSC.   
(a)                                                                                (b) 
 
Figure 3.3.  (a) Solubility of CBZD ( ) and CBZ-SAC ( ) at pH 1 as a function of SLS 
concentration16.  (b) Solubility advantage of CBZ-SAC, Scc/Sdrug, calculated from the solubility 
data.   
 
(a)                                                                                (b) 
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Figure 3.4.  (a) Solubility of CBZD ( ) and CBZ-SLC ( ) at pH 1 as a function of SLS 
concentration16.  (b) Solubility advantage of CBZ-SLC, Scc/Sdrug, calculated from the solubility 
data.   
 
Effect of surfactant on dissolution of CBZD and CBZ cocrystals 
Dissolution studies of CBZD, CBZ-SAC and CBZ-SLC were performed at pH 1 as a 
function of SLS concentration.  The flux values of CBZD are compared to CBZ-SAC in Figure 
3.5 and CBZ-SLC in Figure 3.6.  Flux of both drug and cocrystals increases as SLS concentration 
increases, however, there is a greater increase for the drug compared to the two cocrystals because 
it has a greater solubility dependence on surfactant concentration.  Dissolution advantages were 
determined by comparing the cocrystal flux to CBZD flux.  Both cocrystals have no dissolution 
advantages over the parent drug under these dissolution conditions as indicated by ∅ < 1 shown in 
Figure 3.5 and 3.6.  Under these conditions, the solubility of the drug is higher than both of the 
cocrystals, so the flux of both CBZ-SAC and CBZ-SLC is smaller than CBZD.  As shown in 
equation 3.7, ∅ is proportional to Scc/Sdrug, so it follows the same trend as the solubility advantage, 
in which the dissolution advantage decreases with increasing SLS concentration. 
(a)                                                                                (b) 
 
Figure 3.5.  (a) Flux of CBZD ( ) and CBZ-SAC16 ( ) at pH 1 as a function of SLS concentration.  
(b) Dissolution advantage (∅) of CBZ-SAC calculated from the experimental flux. 
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(a)                                                                                 (b) 
 
Figure 3.6.  (a) Flux of CBZD ( ) and CBZ-SLC16 ( ) at pH 1 as a function of SLS concentration.  
(b) Dissolution advantage (∅) of CBZ-SLC calculated from the experimental flux. 
 
Micellar diffusion coefficients 
Micellar diffusion coefficients of CBZ as a function of SLS concentration have been 
determined from the dissolution of CBZ-SAC and CBZ-SLC in previous study16.  Micellar 
diffusion coefficients determined from the two cocrystals are different from each other and this 
difference may be due to the different chemical environment surrounding the micelles during 
dissolution16.  Using equations 3.3, 3.4 and 3.5, micellar diffusion coefficients of CBZ can be 
determined from the dissolution of CBZD as a function of SLS concentration at pH 1.  These 
micellar diffusivities are compared to those determined from the dissolution of CBZ-SAC and 
CBZ-SLC in Figure 3.7.  The micellar diffusivities of CBZ determined from the dissolution of 
CBZD follow the same trend as the ones determined from the cocrystals.  As shown in Figure 3.7, 
micellar diffusivities of all three solid forms decrease with increasing surfactant concentration and 
these relationships can be fitted into power regressions.  The decrease in micellar diffusivities is 
possibly due to the increase in micellar size and electric repulsion as SLS concentration increases, 
and detailed explanation was provided elsewhere16.  Among the three sets of micellar diffusion 
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coefficients, the ones determined from the dissolution of CBZD are the lowest.  Detailed analysis 
of this is beyond the scope of this study.  However, the difference in solubility dependence on 
surfactant concentration between the drug and cocrystal could be the potential reason for the 
difference in micellar diffusion coefficients.  The solubility of CBZD has a stronger dependence 
on surfactant concentration compared to the cocrystals as indicated by the linear dependence 
shown in equation 3.1.  It is possible that more drug molecules are solubilized into the micelles 
during the dissolution of CBZD compared to the dissolution of the cocrystals and thus results in 
slower micellar diffusion compared to the cocrystals.   
 
Figure 3.7.  Micellar diffusivities of CBZ determined from the dissolution of CBZD ( ), CBZ-
SAC16 ( ) and CBZ-SLC16 ( ) at pH 1 as a function of SLS.  The circles are the experimental 
data and the solid lines are the power regressions. 
 
Solubility and dissolution enhancements by SLS 
Due to micellar solubilization, the solubility and dissolution of CBZD and the two 
cocrystals can be enhanced in the presence of surfactant.  The solubility and dissolution 
enhancements by SLS for CBZD, CBZ-SAC and CBZ-SLC were determined by normalizing the 
solubility and dissolution data at all surfactant concentrations to those at 22 mM SLS.  As shown 
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in Figure 3.8, both solubility and dissolution enhancements increase as surfactant concentration 
increases, however, the enhancement for solubility is greater than that for dissolution and this 
difference increases as surfactant concentration increases.  According to equations 3.3 and 3.4, the 
flux of the drug and cocrystal is proportional to solubility, so the dissolution enhancement should 
theoretically be proportional to the solubility enhancement.  However, the presence of surfactant 
increases the solubility of a compound by solubilizing it into the micelles, but at the same time, it 
decreases the diffusivity of the solubilized compound.  The counter effect of surfactant on 
solubility and micellar diffusivity results in lower dissolution enhancement compared to the 
solubility enhancement.  This counter effect increases as surfactant concentration increases and 
results in greater difference between the solubility and dissolution enhancements.  As expected, 
both solubility and dissolution enhancements of CBZD are higher than those of CBZ-SAC and 
CBZ-SLC because of the higher solubility dependence on surfactant. 
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                           (a) 
 
(b)            (c) 
 
Figure 3.8.  Solubility ( ) and dissolution ( ) enhancements of CBZD (a), CBZ-SAC (b) and 
CBZ-SLC (c) at pH 1 as a function of SLS.  Both solubility and dissolution enhancements were 
determined by normalizing the data to 22 mM SLS.    
 
Cocrystal solubility and dissolution advantage comparison 
The solubility and dissolution advantages of both cocrystals at pH 1 as a function of SLS 
concentration were compared and shown in Figure 3.9.  Both solubility and dissolution advantages 
decrease with increasing SLS concentration because the surfactant concentration is moving away 
from the CSC.  However, the dissolution advantages of both cocrystals are higher than the 
solubility advantages at all surfactant concentrations.  According to equation 3.6, dissolution 
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advantage depends on both the solubility and diffusivity advantages.  As discussed earlier, the 
micellar diffusivities of CBZ determined from the dissolution of CBZD are smaller than those 
determined from both of the cocrystals.  Therefore, the dissolution advantages of both cocrystals 
are enhanced by the higher micellar diffusions compared to the parent drug.  The enhancement in 
dissolution advantage of CBZ-SLC is greater than CBZ-SAC because there is larger difference in 
micellar diffusivity between CBZD and CBZ-SLC.  
(a)                    (b) 
 
Figure 3.9.  Solubility ( ) and dissolution ( ) advantages of CBZ-SAC (a) and CBZ-SLC (b) at 
pH 1 as a function of SLS.     
 
Effect of pH on dissolution of CBZD and CBZ cocrystals 
By cocrystallizing with acidic coformers, SAC and SLC, the nonionizable drug, CBZD, is 
able to possess pH dependent dissolution.  The effect of pH on the dissolution of CBZ-SAC and 
CBZ-SLC was evaluated at constant surfactant concentration as a function of bulk pH and 
compared to the parent drug in Figure 3.10 and 3.11, respectively.  The flux of CBZD is predicted 
to be constant as a function of bulk pH due to its nonionizable property.  Since pH has no effect 
on the dissolution of CBZD, dissolution experiments were conducted in SLS solutions with no pH 
adjustment.  The flux of both CBZ-SAC and CBZ-SLC increases as bulk pH increases because of 
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the acidity of the coformers.  However, both flux plateau at bulk pH ranges from 4 to 8, where the 
coformers are self-buffering the pH microenvironment at the dissolving surface.   Interfacial pH is 
relatively constant in this region, so no significant change in flux is observed in this region.  The 
dissolution advantages, ∅, of both cocrystals were determined by comparing the experimental 
cocrystal flux to CBZD flux, and these values are shown in Figure 3.10 for CBZ-SAC and Figure 
3.11 for CBZ-SLC.  As shown in these figures, there exists a transition pH where the flux of the 
drug is the same as the cocrystal flux.  Below this transition pH, the drug flux is higher, however, 
above it, the cocrystal flux becomes higher.  Theoretically, both cocrystals should not display any 
dissolution advantages under these conditions since the dissolution studies were performed above 
the CSC to prevent the solid phase transformation of the cocrystals back to the stable drug form.  
Under these dissolution conditions, both cocrystals have no solubility advantage over the parent 
drug as indicated by the ratios of Scc/Sdrug less than 1 shown in Table 3.1 and 3.2.  Despite the 
lower solubility, CBZ-SAC and CBZ-SLC can still display higher dissolution rates compared to 
CBZD above the transition pH.  According to equation 3.6, the cocrystal dissolution advantage is 
dependent on not only the solubility advantage, but also the diffusivity advantage.  As shown in 
Figure 3.7 above, the effective diffusivities of CBZ determined from the dissolution of CBZ-SAC 
and CBZ-SLC are higher than those of CBZD.  The effective diffusion coefficient of CBZ-SAC 
at 400 mM SLS and CBZ-SLC at 150 mM SLS is about 1.7x and 2.1x higher than that of CBZD, 
respectively.  These differences in effective diffusion coefficients are not large enough to impart 
dissolution advantages to both cocrystals below the transition pH because the solubility advantages 
are too low under these conditions as shown in Table 3.1 and 3.2.  As the solubility advantages of 
both cocrystals become higher above the transition pH, the higher effective diffusivities of both 
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cocrystals is able to compensate for the disadvantages in solubility and impart dissolution 
advantages.     
(a)                                                                              (b) 
 
Figure 3.10.  (a) Flux of CBZD and CBZ-SAC at 400 mM SLS as a function of bulk pH.  (b) 
Dissolution advantages, ∅, of CBZ-SAC calculated from the experimental flux.  The flux of CBZD 
( ) are predicted using equation 3.3 and the flux of CBZ-SAC ( ) are predicted using 
equation 3.4.  CBZD experimental flux: ; CBZ-SAC experimental flux: . 
 
 
(a)                                                                              (b) 
 
Figure 3.11.  (a) Flux of CBZD and CBZ-SLC at 44 mM SLS as a function of bulk pH.  (b) 
Dissolution advantages, ∅, of CBZ-SLC calculated from the experimental flux.  The flux of CBZD 
( ) are predicted using equation 3.3 and the flux of CBZ-SLC ( ) are predicted using 
equation 3.4.  CBZD experimental flux: ; CBZ-SAC experimental flux: . 
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By knowing the solubility and diffusivity advantages, the dissolution advantages of 
cocrystals can be predicted using equation 3.6.  The predicted dissolution advantages of CBZ-SAC 
and CBZ-SLC are shown in Table 3.1 and 3.2, respectively.  These predicted values agree well 
with the experimental values shown in Figure 3.10 and 3.11.  The higher effective diffusivity of 
the cocrystals is able to compensate for the disadvantage in solubility and results in dissolution 
advantage for both cocrystals without having to deal with the solid phase transformation of the 
cocrystals during dissolution. 
Table 3.1.  Theoretical predictions of dissolution advantages for CBZ-SAC at 400 mM SLS as a 
function of pH. 
pH Solubilityb (mM) 
Scc/Sdrug 
Deff,R (x 10-7 cm2/sec) Predicted 
∅d Bulk Interfaciala CBZD CBZ-SAC CBZD CBZ-SACc 
1.27 1.27 
74.2 
30.4 0.41 
4.16±0.02 7.2±0.3 
0.59 
2.16 2.15 36.8 0.50 0.72 
3.02 2.78 54.6 0.74 1.07 
4.03 3.00 66.2 0.89 1.28 
5.97 3.03 68.0 0.92 1.33 
7.66 3.03 68.0 0.92 1.33 
a) From reference 16.  
b) Predicted from equation 3.1 for CBZD and equation 3.2 for CBZ-SAC. 
c) From reference 16. 
d) Predicted from equation 3.6. 
 
Table 3.2.  Theoretical predictions of dissolution advantages for CBZ-SLC at 44 mM SLS as a 
function of pH. 
pH Solubilityb (mM) 
Scc/Sdrug 
Deff,R (x 10-6 cm2/sec) Predicted 
∅d Bulk Interfaciala CBZD CBZ-SLC CBZD CBZ-SLCc 
1.15 1.15 
12.2 
6.53 0.54 
1.41±0.04 2.98±0.04 
0.88 
3.08 2.97 6.27 0.51 0.84 
5.05 3.65 8.49 0.70 1.15 
5.99 3.66 8.55 0.70 1.15 
7.49 3.66 8.55 0.70 1.15 
a) From reference 16. 
b) Predicted from equation 3.1 for CBZD and equation 3.2 for CBZ-SAC. 
c) From reference 16. 
d) Predicted from equation 3.6. 
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Dissolution conditions for maintaining cocrystal dissolution advantage 
Solid phase transformation is one of the challenges for developing cocrystals because it 
can lead to minimal or no dissolution advantage compared to the parent drug.  The enhanced 
dissolution rate through cocrystallization can potentially increase the bioavailability of the parent 
drug.  Therefore, it would be beneficial to formulate a cocrystal that can display higher dissolution 
rate than the parent drug without having to deal with solid phase transformation during dissolution.  
It is possible to develop such formulations because the effective diffusivity of the cocrystal in the 
presence of surfactant is found to be larger than the drug and this allows the cocrystal to achieve 
dissolution advantage even it has lower solubility than the parent drug.  Knowledge of the 
dissolution behavior of cocrystals would help to develop feasible formulations.  To evaluate the 
dissolution conditions in which the cocrystals can maintain both dissolution advantage and 
thermodynamic stability for formulation development, the combination effect of pH and surfactant 
concentration on the dissolution of CBZD is compared to CBZ-SAC and CB-SLC in Figure 3.12.  
Because of the nonionizable property, the dissolution rate of CBZD is only affected by the 
surfactant concentration, whereas the cocrystals are affected by both surfactant and pH because of 
the acidity of the coformers.  As shown in Figure 3.12, CBZ-SAC is able to achieve dissolution 
advantages from bulk pH 3 to 8 at SLS concentrations range from 22 to 400 mM.  However, this 
does not mean that the cocrystal is thermodynamically stable under all these conditions.  The CSC 
for CBZ-SAC at bulk pH 3 is 161 mM SLS and from bulk pH 4 to 8 is 306 mM.  This suggests 
that CBZ-SAC would be able to maintain dissolution advantage without solid phase transformation 
at bulk pH 3 with SLS concentration of 161 mM and above; and from bulk pH 4 to 8 with SLS 
concentration of 306 mM and above.  These surfactant concentrations maybe too high for oral 
formulation.  However, the CSC for CBZ-SLC at bulk pH up to 8 is only 21 mM SLS.  This means 
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that the cocrystal is thermodynamically stable and less soluble than the parent drug under all the 
dissolution conditions shown in Figure 3.12.  Although it is less soluble than CBZD, CBZ-SLC is 
able to maintain dissolution advantages at SLS concentrations range from 22 to 70 mM and bulk 
pH ranges from 4 to 8 because of the higher effective diffusivities.   
(a)                                                                          (b) 
 
Figure 3.12.  (a) Theoretical flux comparison of CBZD (yellow) to CBZ-SAC (blue), and (b) 
CBZD (yellow) to CBZ-SLC (purple) as a function of pH and SLS concentration.  Flux predictions 
of CBZD were determined using equation 3.3 and cocrystals were from reference16. 
 
Conclusions 
This work has compared the effect of pH and surfactant on the dissolution of CBZD to its 
two cocrystals, CBZ-SAC and CBZ-SLC.  Solubility and dissolution pH dependence are imparted 
to CBZ through the cocrystallization with acidic coformers.  Because of the preferential 
solubilization of the drug over the coformers by surfactant, the solubility dependence on surfactant 
of the drug is different from the cocrystals.  There is a linear dependence for the solubility of the 
drug, whereas cocrystal solubility has a square root dependence.  Because of this different 
dependence, the enhancements in solubility and dissolution by surfactant for the drug are higher 
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than for both of the cocrystals.  Cocrystal dissolution advantage can be determined by comparing 
the cocrystal flux to the drug flux.  Based on the mass transport analyses, cocrystal dissolution 
advantage is proportional to both the solubility and diffusivity advantages.  In this study, the 
micellar diffusivity of CBZ determined from the dissolution of CBZD is found to be smaller than 
those of the cocrystals because the drug has a higher solubility dependence on surfactant.  Because 
of the higher diffusivities, cocrystals with lower solubility than the parent drug do not necessarily 
have slower dissolution rates.  The diffusivity advantages allow cocrystals to compensate for their 
lower solubility above the CSC and result in higher dissolution rates compared to the parent drug.  
Dissolution conditions where the cocrystal can obtain both thermodynamic stability and 
dissolution advantage are useful information for cocrystal formulation development and these 
conditions can be evaluated through the simple mass transport models provided in this work.       
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CHAPTER 4  
COMMON COFORMER EFFECT ON THE DISSOLUTION RATE OF COCRYSTAL 
Abstract 
The presence of excess coformer in solution is known to decrease the solubility of 
cocrystals because of the solubility product behavior.  However, its effect on dissolution rates has 
not been addressed.  The purpose of this work is to develop mass transport models to evaluate the 
common coformer effect on the dissolution rates of cocrystals.  These mass transport analyses not 
only provide useful insights for the oral absorption of cocrystals with drug membrane permeation 
higher than the coformer, but also validate the surface saturation model that was developed 
previously to describe the dissolution process of cocrystals.  Rotating disk dissolution experiments 
of the model cocrystal, carbamazepine salicylic acid (CBZ-SLC) show that the dissolution rates 
decrease with increasing coformer concentration.  The common coformer effect decreases the 
ability of CBZ-SLC in lowering the pH at the dissolving surface due to the lower degree of 
coformer ionization and results in higher interfacial pH.  The higher interfacial pH subsequently 
reduces the common coformer effect on the dissolution rate of CBZ-SLC because of the acidity of 
salicylic acid. 
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Introduction 
Cocrystals have gained tremendous interest in pharmaceutical industry in recent years due 
to their potential of increasing bioavailability of poorly water soluble drugs1-5.  The solubility and 
dissolution behavior of cocrystals have been widely studied1, 3, 4, 6-8 in order to gain a better 
understanding on the oral absorption of these cocrystalline materials.  The solubility mechanism 
of cocrystals have been well studied by Rodriguez, et al.9-12 and the dissolution mechanism has 
been proposed by a recent study13.  Detailed mass transport models have been developed to predict 
the pH at the dissolving surface (i.e. interfacial pH) and the flux of cocrystals13.  These mass 
transport analyses emphasize the importance of physicochemical properties of the cocrystal 
components on the rate of dissolution. 
Cocrystals usually contain components with different physicochemical properties, such as 
hydrophobicity, micellar solubilization, diffusion coefficient and permeability.  The more 
lipophilic drug usually has a faster membrane permeation compared to the less lipophilic coformer.  
The faster permeation of the drug through the intestinal membrane can result in excess coformer 
concentration in the intestinal lumen.  This excess coformer concentration can impact the 
dissolution rate of the cocrystal if it is not fully dissolved.   
Cocrystals behave similarly to pharmaceutical salts in a way that the solubility is also 
described by the solubility product of the components.  The presence of excess counter ion can 
suppress the degree of salt dissociation because of the solubility product behavior and this 
phenomenon is known as the common ion effect14-17.  The solubility of hydrochloride salts have 
been shown to decrease in dilute hydrochloric solutions and similar behavior was also observed 
for other pharmaceutical salts in solutions containing their counter ions14-17.  Because of the 
common ion effect, the dissolution rates of pharmaceutical salts are also suppressed by the 
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presence of counter ions14-17.  With similar solubility product behavior, the solubility of cocrystals 
also decrease in solutions containing excess coformer9, 18.  The solubility of carbamazepine-
nicotinamide cocrystal has been shown to decrease with increasing nicotinamide concentration in 
solution18.  While the effect of excess coformer on the solubility of cocrystals has been addressed, 
its effect on the dissolution rates has not been explored.  Using pharmaceutical salts as an analogy, 
the effect of excess coformer on the solubility and dissolution of cocrystals is defined as the 
common coformer effect.  Herein, mechanism based models were developed to evaluate the 
common coformer effect on the dissolution behavior of cocrystals. 
  Surface saturation model has been proposed previously to describe the dissolution 
mechanism of cocrystals13.  It is difficult to validate this model experimentally because it would 
require the measurements of surface concentrations of the cocrystal components.  Another purpose 
of this work is to validate the surface saturation model by varying the coformer concentration at 
the dissolving surface by the addition of coformer in the bulk solution.  To evaluate the common 
coformer effect and validate the surface saturation model, rotating disk dissolution experiments of 
carbamazepine salicylic acid (CBZ-SLC) cocrystal were performed in dissolution media 
containing different salicylic acid concentrations.   
Materials and methods 
Materials   
Anhydrous carbamazepine (CBZ), salicylic acid (SLC) and sodium lauryl sulfate (SLS) 
were purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  
Acetonitrile, methanol and hydrochloric acid were purchased from Fisher Scientific (Pittsburgh, 
PA).  Sodium hydroxide pellets were purchased from J.T. Baker (Philipsburg, NJ).  Water used in 
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this study was filtered through a double deionized purification system (Milli Q Plus Water System) 
from Millipore Co. (Bedford, MA).  
Cocrystal synthesis   
Cocrystals were prepared by reaction crystallization method19 at room temperature.  CBZ-
SLC was prepared by adding 1:1 molar ratio of CBZ and SLC in acetonitrile solution containing 
0.1 M SLC.  Solid phases were characterized by X-ray powder diffraction (XRPD) and differential 
scanning calorimetry (DSC). 
Dissolution experiments   
Constant surface area dissolution rates of CBZ-SLC were determined using a rotating disk 
apparatus.  Cocrystal powder (~150 mg) was compressed in a stainless steel rotating disk die with 
a tablet radius of 0.50 cm at approximately 85 MPa for 2 minutes using a hydraulic press.  The die 
containing the compact was mounted onto a stainless steel shaft attached to an overhead, variable 
speed motor.  The disk was exposed to 150 mL of dissolution medium in a water jacketed beaker 
with temperature controlled at 25°C and a rotation speed of 200 rpm was used.  Dissolution 
medium was prepared on the day of the experiment by dissolving SLC in 150 mM SLS solution 
and solution pH was adjusted using HCl or NaOH.  Sink conditions were maintained throughout 
the experiments by ensuring the concentrations at the last time point of the dissolution were less 
than 10% of the cocrystal solubility.  Bulk solution pH was maintained at constant throughout the 
dissolution using HCl or NaOH.  Solution concentrations were measured using HPLC and solid 
phases after dissolution were analyzed by XRPD.   
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HPLC   
Waters HPLC equipped with a photodiode array detector was used for all analysis.  The 
mobile phase was composed of 55% methanol and 45% water with 0.1% trifluoroacetic acid and 
the flow rate was 1 mL/min was used.  Separation was achieved using Waters, Atlantis, T3 column 
(5.0 µm, 100 Å) with dimensions of 4.6 x 250 mm.  The sample injection volume was 20 µL.  The 
wavelengths for the analytes were as follows: 284 nm for CBZ and 303 nm for SLC.    
XRPD 
XRPD diffractograms of solid phases were collected with a benchtop Rigaku Miniflex X-
ray diffractometer using Cu-Kα radiation (λ = 1.54 Å), a tube voltage of 30 kV, and a tube current 
of 15 mA.  Data was collected from 5 to 40° at a continuous scan rate of 2.5°/min. 
DSC 
Crystalline samples were analyzed by DSC using a TA instrument 2910 MDSC system 
equipped with a refrigerated cooling unit.  All experiments were performed by heating the samples 
at a rate of 10 °C/min under a dry nitrogen atmosphere.  Temperature and enthalpy of the 
instrument were calibrated using high purity indium standard.  
Theoretical  
Surface saturation model was previously developed to describe the dissolution mechanism 
of cocrystals13.  Because of the different diffusivities between the drug and coformer, the 
concentrations of the cocrystal components are different at the dissolving surface in order to 
maintain stoichiometric dissolution13.  Due to faster diffusion, the coformer concentration is lower 
than that of the drug at the dissolving surface, whereas the drug is able to maintain the same 
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concentration as the solubility of the cocrystal13.  The depletion in concentration of the faster 
diffusing component at the dissolving surface is not easy to demonstrate experimentally because 
of the difficulty in measuring the surface concentrations.  Alternative approaches to validate this 
model are to vary the coformer concentrations at the dissolving surface by the addition of coformer 
in the bulk solution.  Approach 1 is to achieve a coformer concentration that is the same as the 
drug at the dissolving surface by adding equivalent amount of coformer that would be depleted 
due to rapid diffusion in the dissolution medium.  Approach 2 is to achieve a coformer 
concentration that is higher than the drug at the dissolving surface by adding larger amount of 
coformer than the depleted amount in the dissolution medium.  By adding coformer in the 
dissolution medium, the depleted coformer concentration at the dissolving surface due to faster 
diffusion can be replenished to the same or even higher concentration than the drug.  Knowing the 
solubility product behavior of cocrystals, the presence of excess coformer in the dissolution 
medium can influence the solubility and consequently, the dissolution of cocrystals.  Therefore, 
besides validation, these approaches can also be used to demonstrate the common coformer effect 
on the dissolution of cocrystals. 
Approach 1: [𝑅]𝑎𝑞,0 = [𝐴]𝑎𝑞,0 
A schematic representation of approach 1 for a 1:1 cocrystal with nonionizable 
components, RA is illustrated in Figure 4.1.  At time = 0, the cocrystal would first dissociate into 
its components to give equal molar concentrations of R and A at the dissolving surface according 
to its solubility.  However, with the excess coformer added in the bulk solution, the coformer 
concentration would be higher than the drug concentration at the dissolving surface before any 
diffusion happens.  As both drug and coformer diffuse away from the dissolving surface, the 
coformer concentration would be depleted due to faster diffusion.  However, the coformer 
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concentration added in the bulk solution is the same as the depleted concentration, so the coformer 
would be able to maintain the same surface concentration as the drug at steady state.   
 
Figure 4.1.  Schematic representation of approach 1 for the dissolution of RA with R and A as the 
nonionizable components.  The concentration of coformer added in the bulk solution is the same 
as the depleted coformer concentration due to faster diffusion.  [R]aq,0 and [A]aq,0 represent the 
concentrations of R and A at the surface; [R]aq,h and [A]aq,h represent the concentrations of R and 
A in the bulk solution; SRA is the solubility of the cocrystal and Cexc is the concentration of 
coformer added in the dissolution medium. 
 
Approach 2: [𝑅]𝑎𝑞,0 < [𝐴]𝑎𝑞,0 
The schematic representation of approach 2 is shown in Figure 4.2.  Similar to approach 1, 
the coformer concentration at the dissolving surface is higher than that of the drug before any 
diffusion happens.  However, for this approach, the coformer would be able to maintain a surface 
concentration that is higher than the drug concentration at steady state because the coformer 
concentration added in the dissolution medium is higher than the depleted concentration due to 
faster diffusion.   
 118 
 
 
Figure 4.2.  Schematic representation of approach 2 for the dissolution of RA with R and A as the 
nonionizable components.  The concentration of coformer added in the bulk solution is higher than 
the depleted coformer concentration.  [R]aq,0 and [A]aq,0 represent the concentrations of R and A at 
the surface; [R]aq,h and [A]aq,h represent the concentrations of R and A in the bulk; SRA is the 
solubility of the cocrystal and Cexc is the concentration of coformer added in the dissolution 
medium. 
 
Chemical equilibria within diffusion layer 
Carbamazepine salicylic acid (CBZ-SLC) is chosen as the model cocrystal because it has 
a low solubility product, so it does not require much coformer to achieve the two approaches.  
CBZ-SLC has higher solubility than the parent drug, so solid phase transformation can happen 
during dissolution.  Previous studies have shown that the cocrystal can be stabilized during 
dissolution in 150 mM SLS at bulk pH up to 7.513.  To avoid the complication of conversion, all 
dissolution studies were performed in 150 mM SLS.  Chemical equilibria involved for the 
dissolution of CBZ-SLC in the presence of SLS can be written as follows with R representing the 
non-ionizable drug, CBZ and HA as the acidy coformer, SLC: 
(𝑅𝐻𝐴)𝑠𝑜𝑙𝑖𝑑 ⇋ 𝑅𝑎𝑞 + 𝐻𝐴𝑎𝑞             (4.1) 
𝐾𝑠𝑝 = [𝑅]𝑎𝑞[𝐻𝐴]𝑎𝑞              (4.2) 
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𝐻2𝑂 + 𝐻𝐴𝑎𝑞 ⇋ 𝐻3𝑂
+ + 𝐴𝑎𝑞
−              (4.3) 
𝐾𝑎 =
[𝐻3𝑂
+][𝐴−]𝑎𝑞
[𝐻𝐴]𝑎𝑞
              (4.4) 
𝐻3𝑂
+ + 𝑂𝐻− ⇋ 2𝐻2𝑂             (4.5) 
𝐾𝑤 = [𝐻3𝑂
+][𝑂𝐻−]              (4.6) 
𝐻𝐴𝑎𝑞 + 𝑂𝐻
− ⇋ 𝐻2𝑂 + 𝐴𝑎𝑞
−              (4.7) 
𝐾1 =
[𝐴−]𝑎𝑞
[𝐻𝐴]𝑎𝑞[𝑂𝐻−]
              (4.8) 
𝑅𝑎𝑞 + 𝑚 ⇋ 𝑅𝑚              (4.9) 
𝐾𝑠
𝑅 =
[𝑅]𝑚
[𝑅]𝑎𝑞[𝑚]
             (4.10) 
𝐻𝐴𝑎𝑞 + 𝑚 ⇋ 𝐻𝐴𝑚            (4.11) 
𝐾𝑠
𝐻𝐴 =
[𝐻𝐴]𝑚
[𝐻𝐴]𝑎𝑞[𝑚]
            (4.12) 
where Ksp is the solubility product of the cocrystal, Ka is the ionization constant of HA, Kw is the 
dissociation constant of water, K1 is the ratio of Ka / Kw, 𝐾𝑠
𝑅 is the solubilization constant of R and 
𝐾𝑠
𝐻𝐴 is the solubilization constant of HA, m is the micellar concentration in solution and it is equal 
to the total surfactant concentration minus the critical micellar concentration (CMC).  Subscript 
aq denotes the aqueous phase and m denotes the micellar phase.   
Common coformer effect on solubility 
As shown in equation 4.2, the solubility product, Ksp, is a chemical equilibrium constant 
describing the solubility of the cocrystal.  In the presence of excess coformer, the solubility of 
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cocrystal would decrease in order to maintain a constant Ksp value.   This behavior is very similar 
to the common ion effect of pharmaceutical salts and it is defined as the common coformer effect.  
In the presence of excess coformer, the solubility of CBZ-SLC in surfactant solution can be 
described as follow18: 
𝑆𝑐𝑐 =
− 𝐶𝑒𝑥𝑐+√𝐶𝑒𝑥𝑐
2+4𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻+
+𝐾𝑠
𝐻𝐴[𝑚])
2
        (4.13) 
where 𝐶𝑒𝑥𝑐 is the concentration of excess coformer in the dissolution medium.   
According to the surface saturation model, the total concentrations of the cocrystal 
components at the dissolving surface can be written as follows13: 
[𝑅]𝑇 = [𝑅]𝑎𝑞 + [𝑅]𝑚 = 𝑆𝑐𝑐           (4.14) 
[𝐻𝐴]𝑇 = [𝐻𝐴]𝑎𝑞 + [𝐻𝐴]𝑚 + [𝐴
−]𝑎𝑞 = (
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)2/3𝑆𝑐𝑐       (4.15) 
where 𝐷𝑅𝑒𝑓𝑓 and 𝐷𝐻𝐴𝑒𝑓𝑓 are the effective diffusion coefficients of R and HA, Scc is the solubility 
of cocrystal and subscript T denotes the total concentration.  For approach 1, excess coformer 
would be added to the dissolution medium so that the coformer concentration at the dissolving 
surface would be the same as the drug concertation and this can be described by the following: 
[𝑅]𝑇 = [𝐻𝐴]𝑇 + 𝐶𝑒𝑥𝑐            (4.16) 
Substituting equations 4.13, 4.14 and 4.15 into 4.16, the concentration of coformer required to 
achieve approach 1 can be described as follow: 
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𝐶𝑒𝑥𝑐 =
√
4𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻+
+𝐾𝑠
𝐻𝐴[𝑚])
[
2
1−(
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)
2
3
+1]2−1
          (4.17) 
By knowing the equilibrium constants and the effective diffusion coefficients, the concentration 
of coformer required in the bulk solution to achieve equivalent concentrations of cocrystal 
components at the surface can be calculated as a function of pH and surfactant concentration.   
Detailed mass transport analyses for the two approaches are shown in Appendix 4A.  These 
analyses allow the validation of the surface saturation model and the evaluation of the common 
coformer effect on interfacial pH and flux of the cocrystals.  Both approaches are based on the 
following assumptions: all chemical reactions and solute solubilization within the diffusion layer 
occur instantaneously, free solute and micelle are in equilibrium throughout the diffusion layer, 
the ionized form of the coformer is not solubilized by surfactant, aqueous diffusivity of the ionized 
and non-ionized forms are the same.  For simplification of the interfacial pH prediction, the 
effective diffusivity of the coformer is assumed to be the same as the aqueous diffusivity because 
it is not significantly solubilized by the surfactant.  In this study, the effect of surfactant 
concentration on the viscosity of dissolution medium was not accounted for the mass transport 
analyses.  Although the viscosity of the dissolution medium may approximately double at high 
surfactant concentration (eg: 300 mM)20, its impact on the hydrodynamic boundary layer is small.  
The viscosity of dissolution medium is not expected to significantly affect the diffusion of free 
species as they are assumed to be diffusing through the aqueous phase where the surfactant 
concentration is equal to the critical micellar concentration (CMC) and the viscosity is not 
substantially different from water21.  The effect of viscosity on the diffusion coefficient of the 
micelles incorporates the effect of viscosity changes.      
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Results and discussion 
 Physicochemical properties of CBZ-SLC and its components such as solubility product, 
ionization constant, micellar solubilization constant and diffusion coefficient are required to 
perform the mass transport analyses for the dissolution of cocrystal in the presence of excess 
coformer in the dissolution medium.  These properties can be obtained from the literature and they 
are summarized in Table 4.1.  All dissolution experiments in this study were performed in 150 mM 
SLS to prevent solid phase transformation of the cocrystal back to the stable drug form.  Therefore, 
the solubilization constants of CBZ and SLC and effective diffusion coefficient of CBZ in Table 
4.1 are obtained from 150 mM SLS.  The effective diffusivity of SLC is not listed in Table 4.1 
because it has a pH dependence due to the ionization properties of SLC.  By knowing the micellar 
diffusivity (Dm), the effective diffusivity of SLC at a given pH can be estimated using the following 
equation: 
𝐷𝐻𝐴𝑒𝑓𝑓 =
𝐷𝑎𝑞(1+
𝐾𝑎
𝐻+
)+𝐾𝑠
𝐻𝐴𝐷𝑚[𝑚]
1+
𝐾𝑎
𝐻+
+𝐾𝑠
𝐻𝐴[𝑚]
          (4.18) 
Table 4.1.  Physicochemical properties of CBZ-SLC and its components. 
Cocrystal 
Ksp 
(mM2)a 
pKa of 
SLCa 
Ks in 150 mM SLS 
(mM-1)a 
Diffusion coefficient 
(x 10-6 cm2/sec)a 
CBZ SLC 𝑫𝑹𝒂𝒒  𝑫𝑹𝒆𝒇𝒇 𝑫𝑯𝑨𝒂𝒒 
CBZ-SLC 0.40 3.0 0.43 0.060 5.7 1.5 7.7 
a) From Reference 13. 
Evaluation of approach 1 
The concentrations of coformer required to establish approach 1 were calculated using 
equation 4.17 as a function of bulk pH, and these are summarized in Table 4.2.  As pH increases, 
the solubility of CBZ-SLC increases due to the acidity of SLC, consequently, it requires higher 
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SLC concentration in the dissolution medium to compensate for the depletion of SLC at the 
dissolving surface due to faster diffusion.  The concentrations of SLC are the same at the self-
buffering region of CBZ-SLC because there is only minimal change in interfacial pH at bulk pH 
from 5.0 to 7.5. 
Table 4.2.  Concentrations of SLC required to establish approach 1 as a function of bulk pH. 
pH SLC 
(mM)b Bulk Interfaciala 
1.0 1.0 2.87 
2.0 2.0 3.05 
3.0 3.0 4.45 
5.0 3.8 8.50 
6.0 3.8 8.56 
7.5 3.8 8.57 
a) Calculated using equation 4A.27 from Appendix 4A; 
b) Calculated using equation 4.17. 
 
The solubility of cocrystal decreases in the presence of coformer in excess to the 
stoichiometric concentration because of the solubility product behavior.  The decrease in cocrystal 
solubility lowers the degree of coformer ionization at the dissolving surface and thus influences 
the pH at the interface.  The common coformer effect on interfacial pH and solubility of CBZ-SLC 
as a function of bulk pH for approach 1 is summarized in Table 4.3.  Interfacial pH is not affected 
by the common coformer effect at bulk pH ≤ pKa of SLC (3.0) because the pH microenvironment 
is dominated by the bulk pH.  As bulk pH increases above the pKa value, the ability in lowering 
interfacial pH is smaller in the presence of excess coformer.  The common coformer effect 
decreases the solubility of CBZ-SLC and lowers the degree of SLC ionization at the interface, and 
thus results in slightly higher interfacial pH.  As shown in Table 4.3, solubility of CBZ-SLC 
decreases in the presence of SLC at all pH.  As the SLC concentrations required to achieve 
approach 1 are very small at pH 1 and 2, there is no significant decrease in solubility of CBZ-SLC 
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under these conditions.  The common coformer effect on the dissolution rates of CBZ-SLC under 
these conditions may not be very significant.  Therefore, dissolution studies of CBZ-SLC at bulk 
pH 3, 5 and 7.5 were performed to evaluate the mass transport model for approach 1.   
Table 4.3.  Common coformer effect on interfacial pH and solubility of CBZ-SLC as a function of 
bulk pH.   
pH SLC 
(mM)b 
Scc (mM)c 
Bulk Interfaciala 
1.0 
1.0 0 15.6 
1.0 2.87 14.2 
2.0 
2.0 0 15.7 
2.0 3.05 14.2 
3.0 
3.0 0 16.4 
3.0 4.45 14.3 
5.0 
3.7 0 19.3 
3.8 8.50 16.3 
6.0 
3.7 0 19.4 
3.8 8.56 16.4 
7.5 
3.7 0 19.4 
3.8 8.57 16.4 
a) Absence of SLC is from reference 13 and presence of SLC is from Table 4.1; 
b) From Table 4.2;  
c) Calculated using equation 4.13. 
 
Dissolution studies of CBZ-SLC at bulk pH 3, 5 and 7.5 were performed in 150 mM SLS 
containing SLC concentrations shown in Table 4.2 to maintain equal component concentrations at 
the dissolving surface.  The rotating disk dissolution concentration profiles are shown in Figure 
4.3.  The linear dissolution behavior indicated that no solid phase transformation happened during 
dissolution under these conditions.   
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Figure 4.3.  Dissolution concentration profiles of CBZ-SLC in 150 mM SLS at pH 3.06, 4.5 mM 
SLC ( ); pH 5.03, 8.2 mM SLC ( ) and pH 7.50, 8.3 mM SLC ( ).  
 
To evaluate the predictive power of the mass transport model for approach 1, the 
experimental flux of CBZ-SLC were calculated from the dissolution concentration profiles shown 
in Figure 4.3 and compared to the theoretical predictions.  Table 4.4 summarizes the interfacial 
pH, concentrations of the cocrystal components at the surface, the theoretical and experimental 
flux of CBZ-SLC in the absence and presence of excess SLC.  With no excess SLC in the 
dissolution medium, the concentration of SLC at the dissolving surface is smaller than that of CBZ 
because it is depleted due to faster diffusion.  By adding the depleted amount of SLC in the 
dissolution medium, the SLC concentration at the dissolving surface is able to maintain the same 
concentration as that of the drug.  The presence of excess SLC decreases the solubility of CBZ-
SLC due to the common coformer effect and thus lowers the concentration of CBZ at the dissolving 
surface compared to that without excess coformer.  The common coformer effect is also reflected 
in the dissolution of CBZ-SLC by the lower flux in the presence of excess SLC compared to those 
in the absence of excess SLC.  As shown in Table 4.4, the theoretical flux predictions have 
excellent agreement with the experimental values.  The developed mass transport model with 
consideration of interfacial pH for approach 1 is able to accurately predict the flux of CBZ-SLC.   
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Table 4.4.  Interfacial pH, concentrations of CBZ and SLC at the dissolving surface, predicted and 
experimental flux of CBZ-SLC in the absence and presence of excess SLC. 
pH 
SLC (mM) 
Conc. at the 
surface (mM) 
Flux  
(x 10-4 mmole/cm2 min) 
% 
difference 
Bulk  Interfacial CBZa SLCb Predicted Experimental 
3.11 ± 0.02 3.0 0 16.4 5.5 8.0c 7.9 ± 0.2c 2.1 
3.06 ± 0.01 3.0 4.47 ± 0.01 14.4 14.4 7.0d 7.5 ± 0.1 7.0 
4.96  ± 0.03 3.7 0 19.3 6.5 9.4c 9.8 ± 0.4c 4.4 
5.03 ± 0.03 3.8 8.2 ± 0.5 16.3 16.3 7.9d 8.5 ± 0.1 7.2 
7.5  ± 0.1 3.7 0 19.4 6.5 9.4c 9.69 ± 0.01c 2.9 
7.5 ± 0.1 3.8 8.3 ± 0.5 16.4 16.4 8.0d 8.1 ± 0.2 1.1 
a) Calculated using equation 4.14; 
b) Calculated using equation 4.15; 
c) From reference 13; 
d) Calculated using equation 4A.33 from Appendix 4A. 
 
Evaluation of approach 2 
Approach 2 is to establish a higher coformer concentration than the drug concentration at 
the dissolving surface by adding coformer in the dissolution medium that is higher than the 
required concentration for approach 1.  The interfacial pH and surface concentrations of the 
cocrystal components at bulk pH 3 as a function of SLC are summarized in Table 4.5.  Because 
the bulk pH is at the pKa value of SLC, there is not much deviation in interfacial pH from the bulk 
pH as a function of SLC.  With no SLC in the dissolution medium, surface concentration of SLC 
is less than CBZ due to its rapid diffusion.  In 4.47 mM SLC solution, the concentrations of the 
cocrystal components at the dissolving surface are the same because this SLC concentration is the 
required concentration for approach 1 (Table 4.2).  By further increasing the SLC concentration in 
the dissolution medium, the SLC concentration at the dissolving surface becomes higher than that 
of CBZ.  By varying the SLC concentration in the dissolution medium, the surface concentration 
of SLC can be the same as or higher than the drug concentration.  
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Table 4.5.  Interfacial pH and surface concentrations of CBZ and SLC at bulk pH 3 in 150 mM 
SLS as a function of SLC. 
pH 
SLC (mM) 
Surface concentration 
(mM) 
Bulk  Interfaciala CBZb SLCc 
3.11 ± 0.02 3.0 0 16.4 5.5 
3.06 ± 0.01 3.0 4.47 ± 0.01 14.4 14.4 
3.04 ± 0.02 3.0 6.64 ± 0.01 13.4 15.8 
3.03 ± 0.01 3.0 25.01 ± 0.01 8.1 30.5 
2.98 ± 0.02 3.0 45.02 ± 0.01 5.3 48.6 
a) Calculated using equation 4A.28 from Appendix 4A; 
b) Calculated using equation 4.14; 
c) Calculated using equation 4.15.  
 
 The common coformer effect on the interfacial pH of CBZ-SLC at bulk pH 5 is shown in 
Figure 4.4.  This bulk pH value is above the pKa of SLC, so the cocrystal has the ability to lower 
the interfacial pH due to the ionization of the coformer.  However, this ability decreases as the 
concentration of SLC increases in the bulk solution.  As shown in Figure 4.4, interfacial pH 
increases with increasing SLC concentration in the dissolution medium.  The presence of SLC in 
the bulk solution decreases the solubility of the cocrystal and thus lowers the ionization of the 
coformer at the interface.  The higher interfacial pH can have implications in reducing the common 
coformer effect on dissolution rates of cocrystals.    
 
Figure 4.4.  Interfacial pH of CBZ-SLC in 150 mM SLS at bulk pH 5 as a function of SLC.  
Interfacial pH was predicted using equation 4A.28 from Appendix 4A with physicochemical 
parameters shown in Table 4.1. 
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Approach 2 was evaluated by performing dissolution experiments for CBZ-SLC at bulk 
pH 3 and 5 as a function of excess SLC in 150 mM SLS dissolution media.  The dissolution 
concentration profiles of CBZ-SLC at bulk pH 3 and 5 as a function of SLC are shown in Figure 
4.5.  Solid phase transformation did not occur during dissolution as indicated by the linear 
dissolution behavior.  Dissolution rates of CBZ-SLC decrease with increasing SLC concentration 
due to the common coformer effect.  The impact of common coformer effect on the dissolution of 
CBZ-SLC at bulk pH 3 is greater than at bulk pH 5 as indicated by the larger decrease in dissolution 
rates at bulk pH 3 as a function of SLC concentration. 
(a)                                                                             (b) 
  
Figure 4.5.  Dissolution concentration profiles of CBZ-SLC in 150 mM SLS at bulk pH 3.0 (a) 
and bulk pH 5 (b) as a function of SLC concentration.   
 
Flux of CBZ-SLC at bulk pH 3 and 5 as a function of SLC was calculated from the 
dissolution rates and compared to the theoretical predictions as shown in Figure 4.6.  The flux of 
CBZ-SLC at both pH decreases as SLC concentration increases.  The common coformer effect on 
the flux of CBZ-SLC is greater at bulk pH 3 than pH 5 as indicated by the steeper curve shown in 
Figure 4.6 for pH 3.  The common coformer effect is dampened at bulk pH 5 because of the 
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increase in interfacial pH as a function of SLC concentration shown in Figure 4.4.  The increased 
interfacial pH can help to reduce the common coformer effect on the solubility and dissolution of 
CBZ-SLC because of the acidity of SLC.  The mass transport model is able to capture the common 
coformer effect on the dissolution of CBZ-SLC as indicated by the excellent agreement between 
the theoretical and experimental flux as a function of SLC concentration.  However, there are some 
deviations in the flux predictions at bulk pH 5 from the experimental values.  The largest deviation 
is at 45 mM SLC, but the flux prediction is still within a factor of two compared to the experimental 
value.  These deviations may be due to the pH sensitivity of CBZ-SLC flux because the interfacial 
pH at bulk pH 5 is predicted to be above the pKa value of SLC.  A 0.5 unit pH change in interfacial 
pH at 45 mM SLC can lead to a roughly 70% change in flux prediction of CBZ-SLC.  Obviously, 
accurate interfacial pH prediction is essential for predicting the flux of cocrystal with ionizable 
components.  
(a)                                                                          (b) 
 
Figure 4.6.  The experimental (orange circle) and theoretical (blue line) flux comparison of CBZ-
SLC in 150 mM SLS at bulk pH 3 (a) and 5 (b) as a function of SLC.  Flux predictions were 
calculated using equation 4A.33 from Appendix 4A with physicochemical properties shown in 
Table 4.1. 
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Conclusions 
This chapter has demonstrated the influence of common coformer effect on the interfacial 
pH and flux of cocrystals.  The establishment of the two approaches in this study adds another 
level of confidence to the surface saturation model developed previously for the dissolution of 
cocrystals.  The mass transport analyses based on the surface saturation model for the two 
approaches are able to evaluate the impact of coformer in the bulk solution on interfacial pH and 
flux of cocrystals.  The presence of excess coformer can decrease the cocrystal solubility and lower 
the degree of coformer ionization at the dissolving surface, and consequently, the interfacial pH 
would be higher compared to the absence of excess coformer.  It is essential to understand the 
influence of common coformer effect on interfacial pH because it is required for accurate flux 
predictions.  The flux of cocrystal is predicted to decrease with increasing coformer concentration 
because of the solubility product behavior of cocrystal.  In the case of oral absorption, the lower 
membrane permeation of the coformer can potentially result in excess coformer in the intestinal 
lumen that can influence the dissolution of the continually dissolving cocrystal due to the common 
coformer effect.  These mass transport models can provide useful insights on how the differential 
permeability between the cocrystal components can influence the oral absorption of the drug from 
the cocrystalline materials.   
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APPENDIX 4A  
The flux of all the species across the diffusion layer include both the diffusion and chemical 
reactions happening during dissolution.  At steady state, the diffusion and simultaneous chemical 
reactions of the individual species within the diffusion layer can be written using Fick’s law as 
follows: 
𝜕[𝑅]𝑎𝑞
𝜕𝑡
= 𝐷𝑅𝑎𝑞
𝜕2 [𝑅]𝑎𝑞
𝜕𝑥2
+ 𝜙1 = 0         (4A.1) 
𝜕[𝑅]𝑚
𝜕𝑡
= 𝐷𝑅𝑚
𝜕2 [𝑅]𝑚
𝜕𝑥2
+ 𝜙2 = 0         (4A.2) 
𝜕[𝐻𝐴]𝑎𝑞
𝜕𝑡
= 𝐷𝐻𝐴𝑎𝑞
𝜕2 [𝐻𝐴]𝑎𝑞
𝜕𝑥2
+ 𝜙3 = 0         (4A.3) 
𝜕[𝐴−]𝑎𝑞
𝜕𝑡
= 𝐷𝐴𝑎𝑞−
𝜕2 [𝐴−]𝑎𝑞
𝜕𝑥2
+ 𝜙4 = 0         (4A.4) 
𝜕[𝐻𝐴]𝑚
𝜕𝑡
= 𝐷𝐻𝐴𝑚
𝜕2 [𝐻𝐴]𝑚
𝜕𝑥2
+ 𝜙5 = 0         (4A.5) 
𝜕[𝑂𝐻−]
𝜕𝑡
= 𝐷𝑂𝐻−
𝜕2 [𝑂𝐻−]
𝜕𝑥2
+ 𝜙6 = 0         (4A.6) 
𝜕[𝐻+]
𝜕𝑡
= 𝐷𝐻+
𝜕2 [𝐻+]
𝜕𝑥2
+ 𝜙7 = 0         (4A.7) 
where ϕ1-7 are the reaction rate functions.  At equilibrium, the reaction rate of the reactant should 
be the opposite of the product.  Based on the chemical equilibria, the following can be written: 
𝜙1 = −𝜙2            (4A.8) 
𝜙3 = −𝜙4 − 𝜙5               (4A.9) 
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The reaction rate of A- can be reflected by the reaction rate of H+ and OH-, therefore,  
𝜙4 = 𝜙7 − 𝜙6                        (4A.10) 
Based on equation 4A.10, equation 4A.9 can be written as: 
𝜙3 = 𝜙6 − 𝜙5 − 𝜙7                        (4A.11) 
Based on the equations 4A.8, 4A.9 and 4A.11, the following mass balance equations can be 
written:  
𝐷𝑅𝑎𝑞
𝑑2 [𝑅]𝑎𝑞
𝑑𝑥2
= −𝐷𝑅𝑚
𝑑2 [𝑅]𝑚
𝑑𝑥2
                   (4A.12) 
𝐷𝐻𝐴𝑎𝑞
𝑑2 [𝐻𝐴]𝑎𝑞
𝑑𝑥2
= −𝐷𝐴𝑎𝑞−
𝑑2[𝐴−]𝑎𝑞
𝑑𝑥2
− 𝐷𝐻𝐴𝑚
𝑑2 [𝐻𝐴]𝑚
𝑑𝑥2
                (4A.13) 
𝐷𝐻𝐴𝑎𝑞
𝑑2 [𝐻𝐴]𝑎𝑞
𝑑𝑥2
= 𝐷𝑂𝐻−
𝑑2 [𝑂𝐻−]
𝑑𝑥2
− 𝐷𝐻+
𝑑2[𝐻+]
𝑑𝑥2
− 𝐷𝐻𝐴𝑚
𝑑2 [𝐻𝐴]𝑚
𝑑𝑥2
              (4A.14) 
Integrating equations 4A.12 to 4A.14 once gives: 
𝐷𝑅𝑎𝑞
𝑑[𝑅]𝑎𝑞
𝑑𝑥
= −𝐷𝑅𝑚
𝑑 [𝑅]𝑚
𝑑𝑥
+ 𝐶1                             (4A.15) 
𝐷𝐻𝐴𝑎𝑞
𝑑 [𝐻𝐴]𝑎𝑞
𝑑𝑥
= −𝐷𝐴𝑎𝑞−
𝑑[𝐴−]𝑎𝑞
𝑑𝑥
− 𝐷𝐻𝐴𝑚
𝑑 [𝐻𝐴]𝑚
𝑑𝑥
+ 𝐶2               (4A.16) 
𝐷𝐻𝐴𝑎𝑞
𝑑 [𝐻𝐴]𝑎𝑞
𝑑𝑥
= 𝐷𝑂𝐻−
𝑑 [𝑂𝐻−]
𝑑𝑥
− 𝐷𝐻+
𝑑[𝐻+]
𝑑𝑥
− 𝐷𝐻𝐴𝑚
𝑑 [𝐻𝐴]𝑚
𝑑𝑥
+ 𝐶3              (4A.17) 
Since 𝐴𝑎𝑞
−  is the product of the reaction between HA and OH-, so its flux can be reflected by both 
OH- and H+: 
−𝐷𝐴𝑎𝑞−
𝑑[𝐴−]𝑎𝑞
𝑑𝑥
= 𝐷𝑂𝐻−
𝑑 [𝑂𝐻−]
𝑑𝑥
− 𝐷𝐻+
𝑑[𝐻+]
𝑑𝑥
                 (4A.18) 
With this mass balance relationship, it can be seen that  
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𝐶2 = 𝐶3                     (4A.19) 
Integrating equations 4A.15 to 4A.17 gives:  
𝐷𝑅𝑎𝑞[𝑅]𝑎𝑞 = −𝐷𝑅𝑚[𝑅]𝑚 + 𝐶1𝑥 + 𝐶4                 (4A.20) 
𝐷𝐻𝐴𝑎𝑞[𝐻𝐴]𝑎𝑞 = −𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚−𝐷𝐴𝑎𝑞− [𝐴
−]𝑎𝑞 + 𝐶2𝑥 + 𝐶5                  (4A.21) 
𝐷𝐻𝐴𝑎𝑞[𝐻𝐴]𝑎𝑞 = 𝐷𝑂𝐻−[𝑂𝐻
−] − 𝐷𝐻+[𝐻
+]−𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚 + 𝐶3𝑥 + 𝐶6                       (4A.22) 
Interfacial pH and flux of the species can be evaluated by solving these mass balance equations 
with the following boundary conditions. 
Boundary conditions:   
At x = 0:         at x = h: 
[𝑅]𝑎𝑞,0 =
− 𝐶𝑒𝑥𝑐+√𝐶𝑒𝑥𝑐
2+4𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻+
+𝐾𝑠
𝐻𝐴[𝑚])
2(1+𝐾𝑠
𝑅[𝑚])
   [𝑅]𝑎𝑞,ℎ = 0 (sink conditions) 
[𝐻𝐴]𝑎𝑞,0 = (
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)2/3
− 𝐶𝑒𝑥𝑐+√𝐶𝑒𝑥𝑐
2+4𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻+
+𝐾𝑠
𝐻𝐴[𝑚])
2(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
+ [𝐻𝐴]𝑎𝑞,ℎ [𝐻𝐴]𝑎𝑞,ℎ = [𝐻𝐴]𝑎𝑞,ℎ 
[𝑅]𝑚,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝑅]𝑚,ℎ = 0 (sink conditions) 
[𝐻𝐴]𝑚,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝐻𝐴]𝑚 = [𝐻𝐴]𝑚,ℎ 
[𝐴−]𝑎𝑞,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝐴
−]𝑎𝑞 = [𝐴
−]𝑎𝑞,ℎ 
[𝐻+] = [𝐻+]0        [𝐻
+] = [𝐻+]ℎ 
[𝑂𝐻−] = [𝑂𝐻−]0       [𝑂𝐻
−] = [𝑂𝐻−]ℎ 
Evaluation of pH at the interface   
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Applying the above boundary conditions to equations 4A.21 and 4A.22, at x = 0:  
𝐷𝐻𝐴𝑎𝑞(
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)2/3
− 𝐶𝑒𝑥𝑐+√𝐶𝑒𝑥𝑐
2+4𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻+
+𝐾𝑠
𝐻𝐴[𝑚])
2(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
+ [𝐻𝐴]𝑎𝑞,ℎ =
−𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚,0−𝐷𝐴𝑎𝑞− [𝐴
−]𝑎𝑞,0 + 𝐶5                       (4A.23) 
𝐷𝐻𝐴𝑎𝑞(
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)2/3
− 𝐶𝑒𝑥𝑐+√𝐶𝑒𝑥𝑐
2+4𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻+
+𝐾𝑠
𝐻𝐴[𝑚])
2(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
+ [𝐻𝐴]𝑎𝑞,ℎ = 𝐷𝑂𝐻−[𝑂𝐻
−]0 −
𝐷𝐻+[𝐻
+]0−𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚,0 + 𝐶6                  (4A.24) 
and at x = h: 
𝐷𝐻𝐴𝑎𝑞[𝐻𝐴]𝑎𝑞,ℎ = −𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚,ℎ−𝐷𝐴𝑎𝑞− [𝐴
−]𝑎𝑞,ℎ + 𝐶2ℎ + 𝐶5              (4A.25) 
𝐷𝐻𝐴𝑎𝑞[𝐻𝐴]𝑎𝑞,ℎ = 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ−𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚,ℎ + 𝐶3ℎ + 𝐶6             (4A.26)  
For approach 1, a fifth order equation can be obtained by combining equations 4A.23 to 4A.26 and 
substitute equation 4.17 for Cexc to calculate the interfacial pH: 
𝐴[𝐻+]0
5
+ 𝐵[𝐻+]0
4
+ 𝐶[𝐻+]0
3
+ 𝐷[𝐻+]0
2
+ 𝐸[𝐻+]0 + 𝐹 = 0              (4A.27) 
where,  
𝐴 = 𝐷𝐻+
2 (1 + 𝐾𝑠
𝐻𝐴[𝑚]); 
𝐵 = −2𝐷𝐻+(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)(1 + 𝐾𝑠
𝐻𝐴[𝑚]) + 𝐷𝐻+
2 𝐾𝑎; 
𝐶 = −2𝐷𝐻+𝐷𝑂𝐻−𝐾𝑤(1 + 𝐾𝑠
𝐻𝐴[𝑚]) + (1 + 𝐾𝑠
𝐻𝐴[𝑚])(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)
2 −
2𝐷𝐻+(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)𝐾𝑎; 
𝐷 = 2𝐷𝑂𝐻−𝐾𝑤(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)(1 + 𝐾𝑠
𝐻𝐴[𝑚]) − 2𝐷𝐻+𝐷𝑂𝐻−𝐾𝑤𝐾𝑎 +
(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)
2𝐾𝑎; 
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𝐸 = (𝐷𝑂𝐻−𝐾𝑤)
2(1 + 𝐾𝑠
𝐻𝐴[𝑚]) + 2𝐷𝑂𝐻−𝐾𝑤(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)𝐾𝑎 −
(𝐷𝐴𝑎𝑞−
1
3 𝐷𝑅𝑒𝑓𝑓
2
3 Ka√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(√
1
𝑔
+ 1 −
1
√𝑔
))2; 
𝐹 = 𝐾𝑎(𝐷𝑂𝐻−𝐾𝑤)
2; 
and 𝑔 = [
2
1−(
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)
2
3
+ 1]2 − 1. 
 
For approach 2, a sixth order equation is obtained by combining equations 4A.23 to 4A.26 for 
calculating the interfacial pH: 
𝐴[𝐻+]0
6
+ 𝐵[𝐻+]0
5
+ 𝐶[𝐻+]0
4
+ 𝐷[𝐻+]0
3
+ 𝐸[𝐻+]0
2
+ 𝐹[𝐻+]0 + 𝐺 = 0            (4A.28) 
where,  
𝐴 = 𝐷𝐻+
2 (1 + 𝐾𝑠
𝐻𝐴[𝑚])2;  
𝐵 = −2𝐷𝐻+(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)(1 + 𝐾𝑠
𝐻𝐴[𝑚])2 + 2𝐷𝐻+
2 𝐾𝑎(1 + 𝐾𝑠
𝐻𝐴[𝑚]); 
𝐶 = −2𝐷𝐻+𝐷𝑂𝐻−𝐾𝑤(1 + 𝐾𝑠
𝐻𝐴[𝑚])2 + (1 + 𝐾𝑠
𝐻𝐴[𝑚])2(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)
2 −
4𝐷𝐻+𝐾𝑎(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)(1 + 𝐾𝑠
𝐻𝐴[𝑚]) + (𝐷𝐻+𝐾𝑎)
2 + 𝐷𝐻+𝐷𝐴𝑎𝑞−
1
3 𝐷𝑅𝑒𝑓𝑓
2
3 𝐾𝑎𝐶𝑒𝑥𝑐(1 +
𝐾𝑠
𝐻𝐴[𝑚]); 
𝐷 = 2𝐷𝑂𝐻−𝐾𝑤(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)(1 + 𝐾𝑠
𝐻𝐴[𝑚])2 − 4𝐷𝐻+𝐷𝑂𝐻−𝐾𝑤𝐾𝑎(1 +
𝐾𝑠
𝐻𝐴[𝑚]) + 2 ∗ (1 + 𝐾𝑠
𝐻𝐴[𝑚])(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)
2𝐾𝑎 − 2𝐷𝐻+(𝐷𝐻+[𝐻
+]ℎ −
𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)𝐾𝑎
2 − 𝐷𝐴𝑎𝑞−
1
3 𝐷𝑅𝑒𝑓𝑓
2
3 𝐾𝑎𝐶𝑒𝑥𝑐(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)(1 + 𝐾𝑠
𝐻𝐴[𝑚]) +
𝐷𝐴𝑎𝑞−
1
3 𝐷𝑅𝑒𝑓𝑓
2
3 𝐷𝐻+𝐾𝑎
2𝐶𝑒𝑥𝑐; 
𝐸 = (𝐷𝑂𝐻−𝐾𝑤)
2(1 + 𝐾𝑠
𝐻𝐴[𝑚])2 + 4𝐷𝑂𝐻−𝐾𝑤𝐾𝑎(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)(1 + 𝐾𝑠
𝐻𝐴[𝑚]) −
2𝐷𝐻+𝐷𝑂𝐻−𝐾𝑤𝐾𝑎
2 + 𝐾𝑎
2(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)
2 − 𝐷𝐴𝑎𝑞−
1
3 𝐷𝑅𝑒𝑓𝑓
2
3 𝐷𝑂𝐻−𝐾𝑤𝐾𝑎𝐶𝑒𝑥𝑐(1 +
𝐾𝑠
𝐻𝐴[𝑚]) − 𝐷𝐴𝑎𝑞−
1
3 𝐷𝑅𝑒𝑓𝑓
2
3 𝐾𝑎
2𝐶𝑒𝑥𝑐(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ) − 𝐾𝑠𝑝(𝐷𝐴𝑎𝑞−
1
3 𝐷𝑅𝑒𝑓𝑓
2
3 𝐾𝑎)
2(1 +
𝐾𝑠
𝑅[𝑚])(1 + 𝐾𝑠
𝐻𝐴[𝑚]); 
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𝐹 = 2𝐾𝑎(1 + 𝐾𝑠
𝐻𝐴[𝑚])(𝐷𝑂𝐻−𝐾𝑤)
2 + 2𝐷𝑂𝐻−𝐾𝑤𝐾𝑎
2(𝐷𝐻+[𝐻
+]ℎ − 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ) −
𝐷𝐴𝑎𝑞−
1
3 𝐷𝑅𝑒𝑓𝑓
2
3 𝐷𝑂𝐻−𝐾𝑤𝐾𝑎
2𝐶𝑒𝑥𝑐 − 𝐾𝑠𝑝𝐾𝑎(𝐷𝐴𝑎𝑞−
1
3 𝐷𝑅𝑒𝑓𝑓
2
3 𝐾𝑎)
2(1 + 𝐾𝑠
𝑅[𝑚]); 
𝐺 = (𝐾𝑎𝐷𝑂𝐻−𝐾𝑤)
2. 
 
Evaluation of flux of the cocrystal components   
Applying the boundary conditions to equation 4A.20, at x = 0: 
𝐷𝑅𝑎𝑞
− 𝐶𝑒𝑥𝑐+√𝐶𝑒𝑥𝑐
2+4𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻+
+𝐾𝑠
𝐻𝐴[𝑚])
2(1+𝐾𝑠
𝑅[𝑚])
=
−𝐷𝑅𝑚𝐾𝑠
𝑅[𝑚]
− 𝐶𝑒𝑥𝑐+√𝐶𝑒𝑥𝑐
2+4𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻+
+𝐾𝑠
𝐻𝐴[𝑚])
2(1+𝐾𝑠
𝑅[𝑚])
+ 𝐶4                                       (4A.29) 
and at x = h: 
0 = 𝐶1ℎ + 𝐶4                     (4A.30) 
Combining equations 4A.29 and 4A.30 and solve for −𝐶1 for the flux of the cocrystal in terms of 
drug: 
𝐽𝑅 =
𝐷𝑅𝑒𝑓𝑓
ℎ
∗
1
2
[− 𝐶𝑒𝑥𝑐 + √𝐶𝑒𝑥𝑐
2 + 4𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚]) (1 +
𝐾𝑎
𝐻+
+ 𝐾𝑠𝐻𝐴[𝑚])]            (4A.31) 
For rotating disk, the thickness of the hydrodynamic boundary layer can be defined according to 
Levich22: 
ℎ = 1.612𝐷
1
3𝑣
1
6𝜔−
1
2                    (4A.32) 
 where 𝑣 is the kinematic viscosity and 𝜔 is the angular velocity in radians per unit time.  
Substituting equation 4A.32 into 4A.31, the flux of cocrystal in terms of drug can be written as: 
 139 
 
𝐽𝑅 = 0.62𝐷𝑅𝑒𝑓𝑓
2/3
𝜔1/2𝑣−1/6
− 𝐶𝑒𝑥𝑐+√𝐶𝑒𝑥𝑐
2+4𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻+
+𝐾𝑠
𝐻𝐴[𝑚])
2
                 (4A.33) 
This equation is applicable for both approaches to calculate the flux of the cocrystal in terms of 
drug concentration.  Since the coformer concentration is not measuring, so the flux of the cocrystal 
in terms of coformer is not derived.  
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CHAPTER 5  
MECHANISTIC ANALYSIS OF COCRYSTAL DISSOLUTION AS A GUIDE FOR 
RATIONAL SELECTION 
Abstract 
The dissolution behavior of a dibasic drug, ketoconazole (KTZ) under the influence of pH 
has been evaluated and compared to its three 1:1 cocrystals with diacidic coformers, fumaric acid 
(FUM), succinic acid (SUC), and adipic acid (ADP).  Mass transport models were developed by 
applying Fick’s Law of diffusion to dissolution with simultaneous chemical reactions in the 
hydrodynamic boundary layer adjacent to the dissolving surface to predict the interfacial pH and 
flux of the parent drug and cocrystals.  All three cocrystals have the ability to modulate the 
interfacial pH to different extents compared to the parent drug due to the acidity of the coformers.  
The pH effect on the dissolution of KTZ is significantly reduced by the cocrystallization with 
acidic coformers.  Due to the different dissolution pH dependence, there exists a transition pH 
where the flux of the cocrystal is the same as the parent drug.  Below this transition pH, the KTZ 
flux would be higher, but above it, the cocrystal flux would be higher.  The development of mass 
transport models not only provides a mechanistic understanding of the dissolution behavior, but 
also helps to rationalize the selection process of cocrystals.  
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Introduction 
 Cocrystals are multicomponent solids containing two or more different molecular 
components in the same crystal lattice with well-defined stoichiometry and they have emerged as 
a promising solid state modification strategy to enhance the solubility, dissolution and 
bioavailability of poorly water soluble compounds1-5.  One of the advantages that cocrystals have 
to offer is the large diversity in formation, however, this can complicate the process of selecting 
the proper form for development since each cocrystal form can have very distinct physicochemical 
properties6-8.  Among these properties, solubility and dissolution are important criteria for the 
selection process because they play significant roles in determining the oral absorption9.  
Consequently, mechanistic understanding of the solubility and dissolution processes would be 
beneficial for finding the cocrystal form with optimal physicochemical properties.  
 Unlike the well-established solubility mechanism, the dissolution mechanism of cocrystals 
is still under development.  A recent study has presented the dissolution mechanism for 1:1 
cocrystals with nonionizable drug and monoacidic coformers under the influence of both pH and 
surfactant10.  Due to the different diffusion coefficients between the cocrystal components, the 
concentrations of the components at the dissolving surface have to be different in order to maintain 
stoichiometric dissolution10.  Based on the solubility product behavior of cocrystals, two models 
have been developed to describe the dissolution process10.  The interfacial equilibrium model is 
able to maintain constant solubility product at all time during dissolution, while the surface 
saturation model is only able to maintain the drug concentration at the stoichiometric solubility of 
the cocrystal10.  The theoretical comparison between the two models has demonstrated the mass 
transport analysis based on the surface saturation model provides flux predictions that are more 
align with the experimental data10.  In order to increase the applicability, the surface saturation 
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model is used in this study to perform mass transport analyses for cocrystals containing diverse 
ionization properties, specifically for cocrystals with dibasic drugs and diacidic coformers.  
 The model drug studied here is ketoconazole (KTZ), an antifungal drug used primarily for 
fungal infections11-13.  It is a weakly dibasic drug with poor intrinsic solubility, pH dependent 
dissolution and variable oral absorption11-13.  The dissolution of KTZ below pH 3 is rapid, but the 
rate is significantly reduced above pH 513, 14.  Many studies have demonstrated that the oral 
absorption of KTZ is impaired for patients with reduced gastric acid production15-17.  Therefore, 
the prerequisite for adequate KTZ dissolution and oral absorption is the sufficient gastric acidity.  
There are studies showing the oral absorption of KTZ can be improved by co-administering with 
stomach acid stimulant or acidic beverage11, 13, 17.  Knowing KTZ performs better under acidic 
conditions, it is interesting to figure out whether the cocrystallization with acidic coformers would 
help to improve its performance.  The purpose of this study is to evaluate and compare the pH 
dependent dissolution of KTZ to its three cocrystals discovered by Martin, et al.18, ketoconazole 
fumaric acid (KTZ-FUM), ketoconazole succinic acid (KTZ-SUC), and ketoconazole adipic acid 
(KTZ-ADP) cocrystals. 
Materials and methods 
Materials   
Ketoconazole (KTZ) was purchased from Bosche Scientific (New Brunswick, NJ) and 
used as received.  Adipic acid (ADP), succinic acid (SUC), fumaric acid (FUM), were purchased 
from Sigma-Aldrich (St. Louis, MO) and used as received.  Methanol, 2-propanol and hydrochloric 
acid were purchased from Fisher Scientific (Pittsburgh, PA).  Acetone was purchased from Acros 
Organics (NJ).  Sodium hydroxide pellets were purchased from J.T. Baker (Philipsburg, NJ).  
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Trifluoroacetic acid was purchased from Aldrich Company (Milwaukee, WI).  Water used in this 
study was filtered through a double deionized purification system (Milli Q Plus Water System) 
from Millipore Co. (Bedford, MA).   
Cocrystal synthesis  
Cocrystals were prepared by reaction crystallization method19 at room temperature.  KTZ-
SUC and KTZ-FUM were prepared by adding 1:1 molar ratio of KTZ and coformers in acetone 
solution.  KTZ-ADP was prepared by adding 1:1 molar ratio of KTZ and ADP in 2-propanol 
solution.  Solid phases were characterized by X-ray powder diffraction (XRPD) and differential 
scanning calorimetry (DSC). 
Cocrystal dissolution measurements  
Constant surface area dissolution rates of KTZ and its cocrystals were determined using a 
rotating disk apparatus.  Drug or cocrystal powder (~150 mg) was compressed in a stainless steel 
rotating disk die with a tablet radius of 0.50 cm at approximately 85 MPa for 2 minutes using a 
hydraulic press.  The die containing the compact was mounted onto a stainless steel shaft attached 
to an overhead, variable speed motor.  The disk was exposed to 150 mL of dissolution medium in 
a water jacketed beaker with temperature controlled at 25°C and a rotation speed of 200 rpm was 
used.  All dissolution experiments were performed in water with pH adjusted using HCl or NaOH.  
The bulk pH during dissolution was maintained constant by adding HCl or NaOH as necessary.  
Sink conditions were maintained throughout the experiments by ensuring the concentrations at the 
last time point of the dissolution were less than 10% of the solubility.  Solution concentrations 
were measured using HPLC and solid phases after dissolution were analyzed by XRPD.   
 144 
 
HPLC   
Waters HPLC equipped with a photodiode array detector was used for all analysis.  The 
mobile phase was composed of 60% methanol and 40% water with 0.1% trifluoroacetic acid and 
the flow rate of 1 mL/min was used.  Separation was achieved using Waters, Atlantis, T3 column 
(5.0 µm, 100 Å) with dimensions of 4.6 x 250 mm.  The sample injection volume was 20 µL.  
However, it was increased to 100 µL for the dissolution of KTZ at pH 5 and 6 due to the low 
concentration.  The wavelengths for the analytes were as follows: 230 nm for KTZ, 220 nm for 
FUM and 210 nm for both SUC and ADP.    
XRPD   
XRPD diffractograms of solid phases were collected with a benchtop Rigaku Miniflex X-
ray diffractometer using Cu-Kα radiation (λ = 1.54 Å), a tube voltage of 30 kV, and a tube current 
of 15 mA.  Data was collected from 5 to 40° at a continuous scan rate of 2.5°/min. 
DSC 
Crystalline samples were analyzed by DSC using a TA instrument 2910 MDSC system 
equipped with a refrigerated cooling unit.  All experiments were performed by heating the samples 
at a rate of 10 °C/min under a dry nitrogen atmosphere.  Temperature and enthalpy of the 
instrument were calibrated using high purity indium standard.   
Theoretical 
 The mass transport models presented in this study describe the dissolution mechanisms of 
a dibasic drug and its three 1:1 cocrystals with diacidic coformers in solutions containing hydrogen 
ion, hydroxide ion and water as the reactive species.  The mass transport analyses are based on the 
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classic film theory that postulates the existence of a diffusion boundary layer adjacent to the 
dissolving surface20.  Due to the ionization properties, both drug and coformers can undergo 
chemical reactions with the reactive species from the bulk solution that can alter the pH at the 
dissolving surface.  The dissolution process is determined by the concentration gradient across the 
diffusion boundary layer and influenced by the simultaneous diffusion and chemical reactions 
occurring at the dissolving surface and in the adjacent boundary layer20, 21.   
 The chemical equilibria and equations for chemical equilibrium constants for the 
dissolution of the diabasic drug, B are as follows: 
𝐻2𝑂 + 𝐵𝐻2
2+ ⇋ 𝐻3𝑂
+ + 𝐵𝐻+            (5.1) 
𝐾𝑎1
𝐵 =
[𝐻3𝑂
+][𝐵𝐻+]
[𝐵𝐻2
2+]
                (5.2)  
𝐻2𝑂 + 𝐵𝐻
+ ⇋ 𝐻3𝑂
+ + 𝐵             (5.3)  
𝐾𝑎2
𝐵 =
[𝐻3𝑂
+][𝐵]
[𝐵𝐻+]
               (5.4) 
𝐻3𝑂
+ + 𝑂𝐻− ⇋ 2𝐻2𝑂             (5.5) 
𝐾𝑤 = [𝐻3𝑂
+][𝑂𝐻−]                     (5.6) 
𝑂𝐻− + 𝐵𝐻2
2+ ⇋ 𝐻2𝑂 + 𝐵𝐻
+              (5.7) 
𝐾1 =
[𝐵𝐻+]
[𝐵𝐻2
2+][𝑂𝐻−]
                    (5.8) 
𝑂𝐻− + 𝐵𝐻+ ⇋ 𝐻2𝑂 + 𝐵             (5.9) 
𝐾2 =
[𝐵]
[𝐵𝐻+][𝑂𝐻−]
               (5.10) 
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where 𝐾𝑎1
𝐵  and 𝐾𝑎2
𝐵  are the ionization constants for the dibasic drug.  Under aqueous conditions, 
the solubility of the dibasic drug as a function of pH can be described as follow: 
𝑆𝐵 = [𝐵]0(1 +
𝐻+
𝐾𝑎2
𝐵 +
(𝐻+)
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )                  (5.11) 
where [𝐵]0 is the intrinsic solubility of the drug.  
The chemical equilibria and equations for chemical equilibrium constants for the 
dissolution of a 1:1 cocrystal with dibasic drug, B and diacidic coformer, H2A are as follows: 
(𝐵𝐻2𝐴)𝑠𝑜𝑙𝑖𝑑 ⇋ 𝐵 + 𝐻2𝐴           (5.12) 
𝐾𝑠𝑝 = [𝐵][𝐻2𝐴]                 (5.13) 
𝐻2𝑂 + 𝐵𝐻2
2+ ⇋ 𝐻3𝑂
+ + 𝐵𝐻+          (5.14) 
𝐾𝑎1
𝐵 =
[𝐻3𝑂
+][𝐵𝐻+]
[𝐵𝐻2
2+]
               (5.15) 
𝐻2𝑂 + 𝐵𝐻
+ ⇋ 𝐻3𝑂
+ + 𝐵           (5.16) 
𝐾𝑎2
𝐵 =
[𝐻3𝑂
+][𝐵]
[𝐵𝐻+]
               (5.17) 
𝐻2𝑂 + 𝐻2𝐴 ⇋ 𝐻3𝑂
+ + 𝐻𝐴−           (5.18) 
𝐾𝑎1
𝐻2𝐴 =
[𝐻3𝑂
+][𝐻𝐴−]
[𝐻2𝐴]
                (5.19) 
𝐻2𝑂 + 𝐻𝐴
− ⇋ 𝐻3𝑂
+ + 𝐴2−           (5.20) 
𝐾𝑎2
𝐻2𝐴 =
[𝐻3𝑂
+][𝐴2−]
[𝐻𝐴−]
                (5.21) 
𝐻3𝑂
+ + 𝑂𝐻− ⇋ 2𝐻2𝑂           (5.22) 
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𝐾𝑤 = [𝐻3𝑂
+][𝑂𝐻−]                     (5.23) 
𝑂𝐻− + 𝐵𝐻2
2+ ⇋ 𝐻2𝑂 + 𝐵𝐻
+              (5.24) 
𝐾1 =
[𝐵𝐻+]
[𝐵𝐻2
2+][𝑂𝐻−]
                   (5.25) 
𝑂𝐻− + 𝐵𝐻+ ⇋ 𝐻2𝑂 + 𝐵             (5.26) 
𝐾2 =
[𝐵]
[𝐵𝐻+][𝑂𝐻−]
                    (5.27) 
𝐻2𝐴 + 𝑂𝐻
− ⇋ 𝐻2𝑂 + 𝐻𝐴
−                (5.28) 
𝐾3 =
[𝐻𝐴−]
[𝐻2𝐴][𝑂𝐻−]
                    (5.29) 
𝑂𝐻− + 𝐻𝐴− ⇋ 𝐻2𝑂 + 𝐴
2−           (5.30) 
𝐾4 =
[𝐴2−]
[𝐻𝐴−][𝑂𝐻−]
                 (5.31) 
where Ksp is the solubility product of the cocrystal, 𝐾𝑎1
𝐻2𝐴 and 𝐾𝑎2
𝐻2𝐴 are the ionization constants of 
the coformer.  Under aqueous conditions, the stoichiometric solubility of the cocrystal as a function 
of pH can be described as: 
𝑆𝑐𝑐 = √𝐾𝑠𝑝(1 +
𝐾𝑎1
𝐻2𝐴
[𝐻+]
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]2
)(1 +
[𝐻+]
𝐾𝑎2
𝐵 +
[𝐻+]2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )       (5.32) 
 Previously developed mass transport models for cocrystal dissolution have demonstrated 
that the concentrations of the cocrystal components at the dissolving surface can be different if 
they have different diffusion coefficients10.  The model drug, KTZ, is a bigger molecule compared 
to the carboxylic acid coformers, and thus has smaller diffusion coefficient compared to the 
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coformers.  According to the surface saturation model, the concentration of the slower diffusing 
component at the dissolving surface is maintained at the solubility of the cocrystal, while the 
concentration of the faster diffusing component is lower10.  For the dissolution of 1:1 cocrystals 
with dibasic drugs and diacidic coformers, the concentrations of the components at the dissolving 
surface can be written as:  
[𝐵]𝑇,0 = [𝐵] + [𝐵𝐻
+] + [𝐵𝐻2
2+] = 𝑆𝑐𝑐         (5.33) 
[𝐻2𝐴]𝑇,0 = [𝐻2𝐴] + [𝐻𝐴
−] + [𝐴2−] = (
𝐷𝐵
𝐷𝐻2𝐴
)2/3𝑆𝑐𝑐       (5.34) 
where DB and DH2A are the diffusion coefficients of the drug and coformer, respectively, and 
subscript T,0 denotes the total concentration of the ionized and nonionized forms at dissolving 
surface. 
The mass transport analyses for both drug and cocrystals are based on the assumptions that 
all chemical reactions within the diffusion layer happen instantaneously and the aqueous 
diffusivities of the ionized and non-ionized forms are the same.  Detailed derivations of the mass 
transport models for the drug and cocrystals using the surface saturation model are provided in 
Appendix 5A.  The mass transport analyses for cocrystal dissolution using the interfacial 
equilibrium model are also provided in Appendix 5B.  In this Appendix, a comparison in cocrystal 
flux predictions between the surface saturation and interfacial equilibrium models is also included.  
Results  
Physicochemical properties 
 Accurate flux predictions for cocrystals require knowledge about the physicochemical 
properties of the cocrystals and their components, such as solubility product, ionization constant, 
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and diffusion coefficient and these can be obtained independently from the dissolution studies.  
The physicochemical properties of the model cocrystals are summarized in Table 5.1.  The 
diffusion coefficient of KTZ is about 2x times smaller compared to the three coformers because 
of the bigger molecular size.  These differential diffusion coefficients would result in different 
concentrations for the cocrystal components at the dissolving surface as predicted by the surface 
saturation model10.  Because of the diprotic property, the drug and the three coformers have two 
pKa values.  The pKa values of the parent drug are basic, while those of the coformers are acidic.  
Due to its basicity, the solubility of the drug decreases with increasing pH and reaches constant 
value at the pH region where the drug is completely un-ionized.  By cocrystallizing with acidic 
coformers, the solubility pH dependence of the cocrystals is different from that of the parent drug.  
At low pH, where the basicity of the drug is dominated, the solubility of the cocrystals decreases 
with increasing pH.  However, the rate of decrease is much lower compared to the parent drug 
because of the acidity of the coformers.  As pH increases above the pKa values of the coformers, 
the solubility of the cocrystals starts to increase because the acidity of the coformers is dominating 
the solubility pH effect.  The basicity of the drug and acidity of the coformers result in U shape 
solubility curves for the three cocrystals as a function of pH22 as shown in Figure 5.1.  Because of 
the different solubility pH dependence between the drug and cocrystal, there exists a transition 
point on the solubility phase diagram where the solubility of the drug is the same as the cocrystal22-
24.  The pH at this transition point is known as the pHmax.  The model cocrystals are 
thermodynamically stable below pHmax, but thermodynamically unstable above it and they have 
the tendency to transform back to the stable drug form.  This transition point allows the true 
intrinsic dissolution measurements for the cocrystals at pH below the pHmax.  Among the three 
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cocrystals, KTZ-FUM has the highest pHmax value because it has the lowest Ksp, so it requires a 
higher pH to reach the same solubility as the parent drug
22.   
Table 5.1.  Physicochemical properties of model cocrystals and their components. 
Cocrystal 
(B-H2A) 
Ksp (x 10-2 mM2)a 
pKa values 
Diffusion coefficient 
(x 10-6 cm2/sec)d 
Bb H2Ac 𝑫𝑩𝒂𝒒  𝑫𝑯𝑨𝒂𝒒 
KTZ-FUM 0.15 
2.94, 
6.51 
3.03, 4.38 
3.56 
8.67 
KTZ-SUC 2.4 4.2, 5.6 8.38 
KTZ-ADP 3.4 4.44, 5.44 7.07 
a) From reference 22;  
b) From reference 12;  
c) From reference 18;  
d) Determined using Othmer Thaker’s equation25. 
 
 
Figure 5.1.  Solubility pH dependence of KTZ ( ), KTZ-ADP ( ), KTZ-SUC ( ) and KTZ-
FUM ( ).  pHmax value for KTZ-ADP is 3.6; KTZ-SUC is 3.6; and KTZ-FUM is 3.8.  Solid lines 
represent the theoretical predictions and the symbols are the experimental data22. 
 
Interfacial pH predictions 
 With the knowledge of physicochemical properties, interfacial pH of KTZ and its three 
cocrystals can be predicted using equations 5A.20 and 5A.52 respectively from Appendix 5A.  The 
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ability of KTZ in altering the pH microenvironment at the dissolving surface is compared to that 
of the three cocrystals in Figure 5.2.  At low bulk pH, the interfacial pH of KTZ is higher than the 
bulk solution pH because KTZ is mostly ionized under these conditions and thus increases the pH 
at the dissolving surface.  As bulk pH increases above the pKa values, the ability of KTZ in 
increasing interfacial pH is limited by its lower degree of ionization at the dissolving surface.  
Therefore, interfacial pH is approximately the same as the bulk pH.  By cocrystallizing with acidic 
coformers, all three cocrystals still have the ability to increase the interfacial pH at low bulk pH.  
However, the increase is much smaller compared to the drug because the ionization of KTZ is 
being suppressed by the acidic coformers.  As bulk pH increases above the pKa values of the 
coformers, interfacial pH of the cocrystals is dominated by the acidity of the coformers.  The 
ionization of the coformers lowers the interfacial pH and results in a buffer effect at the dissolving 
surface, in which the interfacial pH does not change with bulk pH.  The interfacial pH at the 
buffering region for KTZ-FUM is 4.1, KTZ-SUC is 4.7 and KTZ-ADP is 4.8.  Even KTZ-FUM 
has the lowest Ksp among three cocrystals, it is still able to buffer the interfacial pH to the lowest 
because FUM is the most acidic among the three coformers.  The interfacial pH at the buffering 
regions of the three cocrystals is above their pHmax values.  This means that the cocrystals are 
thermodynamically unstable in these regions and have the tendency to transform back to the stable 
drug form during dissolution.  
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Figure 5.2.  Interfacial pH of KTZ ( ), KTZ-ADP ( ), KTZ-SUC ( ) and KTZ-FUM (
) as a function of bulk pH.  Interfacial pH of both drug and cocrystals were calculated using 
equations 5A.20 and 5A.52 from Appendix 5A, respectively, with the physicochemical parameters 
shown in Table 5.1. 
 
Drug crystallization may happen during the dissolution of highly soluble cocrystals and the 
crystallization process has a dependence on the degree of supersaturation generated in solution 
with respect to the parent drug.  Knowing the interfacial pH, the degree of supersaturation at the 
dissolving cocrystal surface during dissolution can be determined from the solubility advantage of 
the cocrystal, which is a ratio of the cocrystal solubility over that of the drug.  The solubility 
advantages of the three cocrystals as a function of bulk pH were calculated based on the interfacial 
pH predictions and these are shown in Figure 5.3.  At bulk pH ≤ 3, all cocrystals do not exhibit 
solubility advantage as indicated by the ratios of Scc/Sdrug below 1.  Under these bulk pH conditions, 
the interfacial pH of all cocrystals is below their pHmax values, so the drug is more soluble 
compared to the cocrystals.  This means that the cocrystals are the stable forms and the 
precipitation of solid drug during dissolution should not occur at bulk pH ≤ 3.  Above bulk pH 3, 
the Scc/Sdrug ratios of all three cocrystals are greater than 1, meaning that the cocrystals are more 
soluble than the parent drug because the interfacial pH is above their pHmax values.  Under these 
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bulk pH conditions, all three cocrystals can generate supersaturation with respect to the parent 
drug in solution and provide the driving force for drug crystallization at the dissolving surface 
during dissolution.  The rate of nucleation is inversely proportional to supersaturation26, so the 
probability of drug precipitation during dissolution would increase as the degree of supersaturation 
increases.  Among the three cocrystals, KTZ-ADP has the highest solubility advantage and this 
can translate into the highest tendency for drug precipitation during dissolution.  Drug precipitation 
at the dissolving surface can impede the dissolution of cocrystal and this can lead to disagreement 
with the theoretical flux predictions since the mass transport models have not considered the 
transformation kinetic.  The solubility advantage of KTZ-FUM is about 2 at the buffering region, 
so it may be able to sustain supersaturation during the 30 minute dissolution. 
 
Figure 5.3.  Solubility advantage for KTZ-FUM ( ), KTZ-SUC ( ) and KTZ-ADP ( ) as a 
function of bulk pH.  The solubility of the drug and cocrystals were calculated based on the 
interfacial pH predicted from Figure 5.2 using equation 5.11 and 5.32 respectively.   
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Effect of pH on KTZ dissolution 
 The effect of pH on the dissolution of KTZ was evaluated by performing rotating disk 
dissolution as a function of bulk pH.  The dissolution concentration profiles of KTZ as a function 
of bulk pH are shown in Figure 5.4.  Because of the basicity, the dissolution rates of KTZ decrease 
with increasing pH.  KTZ is a poorly water soluble compound with an intrinsic solubility of 4.7 x 
10-6 M22, so the dissolution rate is very low when it is at minimal ionization.  At bulk pH 4 and 5, 
the KTZ concentration was not detectable by HPLC until 5 and 10 minutes after dissolution started, 
respectively.  At bulk pH 6, KTZ is almost completely unionized and its concentration could not 
be detected until 30 minutes after dissolution started.  Therefore, the dissolution at bulk pH 6 had 
to extend to 60 minutes in order to get enough data points to determine the dissolution rate.  The 
large error bars for the dissolution at bulk pH 6 is possibly associated with the low concentration 
of KTZ. 
(a)                                                                            (b) 
 
Figure 5.4.  Dissolution concentration profiles of KTZ at bulk pH 2 to 5 (a) and bulk pH 6 (b). 
 
The flux of KTZ as a function of bulk pH were calculated from the dissolution rates and 
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have much ability to self-buffer the pH at the dissolving surface.  Consequently, the flux of KTZ 
can vary drastically as a function of bulk pH.  There is almost 2000x difference between the flux 
of KTZ at pH 2 and 6.  The large pH effect on the dissolution rate of KTZ may be responsible for 
its variability in oral absorption observed in patients.   
Although there are some deviations in flux predictions for KTZ at low bulk pH, the 
theoretical values follow the same trend as the experimental data.  The large deviations in flux 
predictions at low bulk pH could be possibly due to the assumption that the diffusion coefficients 
of the unionized and ionized forms are the same.  In multicomponent electrolyte mass transport 
system, the diffusion of the charged species can be significantly different from the neutral species 
due to the electrostatic interactions between the diffusing species in order to maintain charge 
neutrality27-29.  In general, the fast diffusing ion is coupled with a sluggish ion of opposite charge 
to counteract the charge separation between the ions27-29.  In other words, the diffusion of the 
charged species can be accelerated or retarded by the electrostatic interactions27-29.  At pH 2 and 
3, KTZ is mostly in its ionized form.  It is possible that the positively charged KTZ is coupled with 
the highly mobile hydroxide ion to maintain charge neutrality at the dissolving surface and thus 
results in faster diffusion compared to the neutral form of KTZ.  The diffusion of KTZ under low 
bulk pH conditions may have been underestimated based on the assumption that the diffusion 
coefficient of the ionized form is the same as the nonionized form.  The underestimation in 
diffusion coefficient of the ionized form of KTZ could result in deviations of flux predictions under 
low bulk pH conditions.  Since the purpose of this paper is to provide a mechanistic understanding 
of the dissolution behavior of KTZ under the influence of pH, the diffusion coefficient of the 
ionized form was not evaluated for accurate flux predictions.  
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Figure 5.5.  Theoretical ( ) and experimental ( ) flux comparison of KTZ as a function of 
bulk pH.  The flux of KTZ were calculated using equation 5A.23 from Appendix 5A based on the 
interfacial pH predicted in Figure 5.2 and the physicochemical properties shown in Table 5.1.  
 
Effect of pH on the dissolution of KTZ cocrystals 
 The pH effect on the dissolution of the three model KTZ cocrystals was also evaluated and 
the dissolution concentration profiles as a function of bulk pH are shown in Figure 5.6, 5.7 and 5.8 
for KTZ-FUM, KTZ-SUC and KTZ-ADP, respectively.  It is important to measure the 
concentration of the coformer during dissolution because it can serve as an indicator for solid phase 
transformation.  If higher coformer concentration is observed for the dissolution of a 1:1 cocrystal, 
it is likely that the drug is precipitating at the dissolving surface because of its inability in 
sustaining supersaturation.  Without knowing the coformer concentration, it could be difficult to 
confirm the stability of the cocrystal during dissolution when solid phase analysis, such as XRPD 
is not sensitive enough to detect the solid phase transformation.  Among the three cocrystals, the 
measurements of both drug and coformer concentrations during dissolution were only possible for 
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concentrations match those of the drug at all bulk pH conditions studied here, which indicates no 
solid phase transformation occurred during the dissolution of KTZ-FUM.  It seems like KTZ-SUC 
is also stable at all bulk pH conditions studied here as indicated by the linear dissolution behavior 
and the pure cocrystal structure from XRPD analysis after dissolution.  KTZ-ADP was stable 
during dissolution at bulk pH 2 and 3 because the interfacial pH at these conditions was below the 
pHmax.  Although the XRPD analyses after the dissolution of KTZ-ADP at bulk pH 4 to7 showed 
pure cocrystal phase, the nonlinear dissolution behavior under these conditions is a sign of solid 
phase transformation.  An example of nonlinear dissolution behavior at bulk pH 6 for KTZ-ADP 
is demonstrated in Figure 5.7 (b). 
(a)                                                                         (b) 
  
Figure 5.6.  Dissolution concentration profiles of KTZ-FUM in terms of KTZ (a) and FUM (b) 
concentrations as a function of bulk pH. 
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Figure 5.7.  Dissolution concentration profiles of KTZ-SUC in terms of KTZ concentrations as a 
function of bulk pH. 
 
(a)                                                                              (b) 
 
Figure 5.8.  Dissolution concentration profiles of KTZ-ADP in terms of KTZ concentrations as a 
function of bulk pH (a) and the nonlinear dissolution behavior at bulk pH 6 (b). 
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the acidic coformers, the flux of cocrystals still decreases with pH at low bulk pH because the pH 
effect on dissolution is dominated by the basic drug.  The coformers take over the pH effect on the 
dissolution of cocrystals at bulk pH above the acidic pKa values because the coformers start to 
ionize, while the drug ionization is suppressed.  The acidity of the coformers dampens the pH 
effect on the dissolution of the cocrystals compared to the parent drug.  There is about 5x difference 
in the flux of KTZ-FUM between pH 2 and 6, 11x for KTZ-SUC and 15x for KTZ-ADP.  These 
differences are significantly smaller compared to the almost 2000x difference for KTZ.  This 
significant reduction in flux variation due to pH can potentially mitigate the pH effect on oral 
absorption of KTZ.   
By modeling interfacial pH, the mass transport model adequately describes the dissolution 
behavior of cocrystals under the influence of pH.  There is an excellent agreement between the 
theoretical flux predictions and experimental data.  As discussed earlier, the cocrystal flux can be 
over predicted if drug crystallization happened during dissolution.  The driving force for solid 
phase transformation is the highest for KTZ-ADP (Scc/Sdrug = 11) as shown in Figure 5.3 and it 
was confirmed that drug precipitation occurred during dissolution at bulk pH 4 to 7.  The solid 
phase transformation of the cocrystal results in deviations of theoretical flux predictions from the 
experimental data for KTZ-ADP.      
                                        
 
 
 
 
 
 
 
 
 
 
 160 
 
                                      (a) 
 
   (b)                                                                        (c) 
 
Figure 5.9.  Theoretical (solid line) and experimental (solid circle) flux comparison of (a) KTZ-
FUM, (b) KTZ-SUC and (c) KTZ-ADP.  The theoretical flux of cocrystals were calculated using 
equation 5A.54 from Appendix 5A based on the interfacial pH predicted in Figure 5.2 and the 
physicochemical properties shown in Table 5.1. 
 
Comparison of dissolution behavior 
 The pH effect on the flux of KTZ is compared with KTZ-FUM in Figure 5.10, KTZ-SUC 
in Figure 5.11 and KTZ-ADP in Figure 5.12.  These Figures demonstrate that the dissolution pH 
dependence of KTZ is significantly reduced by cocrystallizing with acidic coformers.  Due to the 
different pH dependence, there exists a transition pH where the flux of the drug is the same as the 
cocrystal for each of the three cocrystals.  Below this transition pH, interfacial pH is below the 
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pHmax, so the KTZ flux is higher than those of the cocrystals.  Above the transition pH, interfacial 
pH is above the pHmax and resulting in higher cocrystal flux compared to KTZ.  This transition pH 
is different from the pHmax in a way that it is determined from the kinetic process.  Consequently, 
it cannot be used to evaluate the thermodynamic stability of the cocrystals.  However, it is still 
important because it provides the solution conditions at which the cocrystals would display 
dissolution advantages.  The dissolution advantage of cocrystal is defined as the ratio of the 
cocrystal flux over that of the drug (Jcc/Jdrug).  Cocrystal has no dissolution advantage if Jcc/Jdrug ≤ 
1, but it would display dissolution advantage if Jcc/Jdrug > 1.  The dissolution advantages of the 
three cocrystals were evaluated from the experimental data and shown in Figure 5.10 to 5.12 for 
the three cocrystals.  At bulk pH 2, the dissolution advantages of all three cocrystals are below one 
because the pH is below the transition pH.  At bulk pH 3, near the transition pH, all three cocrystals 
exhibit nearly the same flux as the drug.  Above bulk pH 3, all cocrystals display dissolution 
advantages and these advantages increase with increasing pH because the flux of KTZ decrease 
with pH.  Among the three cocrystals, KTZ-FUM has the highest dissolution advantage, follows 
by KTZ-SUC and KTZ-ADP.   
(a)                                                                            (b) 
 
1.0E-07
2.5E-06
6.3E-05
1.6E-03
3.9E-02
9.8E-01
0 2 4 6 8
F
lu
x
 (
m
m
o
le
/c
m
2
m
in
)
Bulk pH 
0.55 1.2 6.7
53
194
0
50
100
150
200
250
2 3 4 5 6
D
is
s
o
lu
ti
o
n
 a
d
v
a
n
ta
g
e
 (
J
c
c
/J
d
ru
g
)
Bulk pH
 162 
 
Figure 5.10.  (a) Flux comparison between KTZ-FUM ( ) and KTZ ( ) as a function of 
bulk pH.  (b) Dissolution advantages of KTZ-FUM determined from the experimental flux values.  
The solid lines represent the theoretical flux predictions and the symbols represent the 
experimental flux for KTZ-FUM ( ) and KTZ ( ).   
 
(a)                                                                           (b) 
 
Figure 5.11.  (a) Flux comparison between KTZ-SUC ( ) and KTZ ( ) as a function of bulk 
pH.  (b) Dissolution advantages of KTZ-SUC determined from the experimental flux values.  The 
solid lines represent the theoretical flux predictions and the symbols represent the experimental 
flux for KTZ-SUC ( ) and KTZ ( ).   
 
(a)                                                                          (b) 
 
Figure 5.12.  (a) Flux comparison between KTZ-ADP ( ) and KTZ ( ) as a function of bulk 
pH.  (b) Dissolution advantage of KTZ-ADP determined from the experimental flux values.  The 
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solid lines represent the theoretical flux predictions and the symbols represent the experimental 
flux for KTZ-ADP ( ) and KTZ ( ).   
 
Discussion 
The selection of a solid form with optimal physicochemical properties that can lead to 
desired bioperformance is essential for successful oral drug product development.  Solubility and 
dissolution are important parameters for determining the bioavailability of drugs that are given 
orally9.  Hence, the solubility and dissolution advantages of cocrystals are important parameters to 
be considered during the cocrystal selection process.  The advantage in diverse formation of 
cocrystals can become a challenge when it comes to the selection process.  Depending on the 
properties of the coformers and solution conditions, cocrystals can behave very different in 
solution30.  Cocrystals can generate solubility that are orders of magnitude different from that of 
the parent drug30.  One of the important questions needs to be addressed during the selection 
process is what the most desired cocrystal solubility should be.  Usually, higher cocrystal solubility 
would not necessarily lead to better performance because it is more prone for conversion during 
dissolution.  The ideal candidate would be a cocrystal with a solubility advantage that allows 
supersaturation to be sustained in solution.  Understanding the solution behavior of cocrystals 
would help to rationalize the selection process. 
The three cocrystals studied in this work demonstrated different ability in modulating the 
dissolution behavior of the parent drug and this ability is dependent on the properties of the 
coformers and cocrystals.  The ionization properties of the coformers allow the cocrystals to alter 
the interfacial pH to different extents compared to the parent drug.  The ability of modeling 
interfacial pH allows the evaluation of cocrystal solubility advantage at the dissolving surface, 
which provides useful information regarding the thermodynamic stability of the cocrystals during 
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dissolution.  Among the three cocrystals, KTZ-FUM is the most stable because the solubility 
advantage at the buffering region is 2, while KTZ-SUC is 9 and KTZ-ADP is 11.  Although KTZ-
FUM has the smallest solubility advantage, it is able to achieve the highest dissolution advantage.  
With high dissolution advantage and low risk of conversion, it is no doubt that KTZ-FUM is the 
favor cocrystal for further development at this stage.  This work has mainly considered the pH 
effect on the dissolution of cocrystals, however, other factors, such as solubilizing agents should 
also be considered for the selection process.   
Conclusions 
The dissolution mechanism for 1:1 cocrystals with dibasic drug (KTZ) and diacidic 
coformers (FUM, SUC, ADP) under the influence of pH has been analyzed and compared to the 
parent drug through the development and evaluation of physically realistic mass transport models.  
The mass transport analyses for the dissolution of cocrystals are based on the previously developed 
surface saturation model.  The mass transport models show that the pH at the dissolving cocrystal 
surface is different from that of the parent drug because of the ability of the coformers in lowering 
the interfacial pH.  The dissolution behavior of both drug and cocrystals has been theoretically and 
experimentally demonstrated to be dependent on interfacial pH instead of bulk pH.  This highlights 
the importance of modeling the almost experimentally inaccessible interfacial pH.  The dissolution 
of KTZ has been shown to exhibit large pH effect, however, this pH effect is significantly reduced 
by cocrystallizing with acidic coformers.  Because of the different pH dependence, there exists a 
transition pH that can serve as a turning point for the cocrystal dissolution advantage.  Cocrystals 
can modulate the dissolution behavior of the parent drug by altering both interfacial pH and 
solubility.  Having a thorough understanding on the thermodynamic and kinetic behavior of 
cocrystals can help to select the most suitable cocrystal for further development.  
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APPENDIX 5A  
Mass transport analysis for drug 
The flux of all the species across the diffusion layer include both the diffusion and chemical 
reactions happening during dissolution.  At steady state, the diffusion and simultaneous chemical 
reactions of the individual species within the diffusion layer can be written using Fick’s law as 
follows: 
𝜕[𝐵]
𝜕𝑡
= 𝐷𝐵
𝜕2 [𝐵]
𝜕𝑥2
+ 𝜙1 = 0          (5A.1) 
𝜕[𝐵𝐻+]
𝜕𝑡
= 𝐷𝐵
𝜕2 [𝐵𝐻+]
𝜕𝑥2
+ 𝜙2 = 0                    (5A.2) 
𝜕[𝐵𝐻2
2+]
𝜕𝑡
= 𝐷𝐵
𝜕2 [𝐵𝐻2
2+]
𝜕𝑥2
+ 𝜙3 = 0         (5A.3) 
𝜕[𝑂𝐻−]
𝜕𝑡
= 𝐷𝑂𝐻−
𝜕2 [𝑂𝐻−]
𝜕𝑥2
+ 𝜙4 = 0         (5A.4) 
𝜕[𝐻+]
𝜕𝑡
= 𝐷𝐻+
𝜕2 [𝐻+]
𝜕𝑥2
+ 𝜙5 = 0         (5A.5) 
where ϕ1-5 are the reaction rate functions.  At equilibrium, the reaction rate of the reactant should 
be the opposite of the product: 
𝜙3 = −𝜙1 − 𝜙2           (5A.6) 
The reaction rate of the acid and the base should be the same: 
𝜙3 + 𝜙5 = 𝜙1 + 𝜙4           (5A.7) 
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Based on equations 5A.6 and 5A.7, the following mass balance equations can be written: 
𝐷𝐵
𝑑2[𝐵]
𝑑𝑥2
+ 𝐷𝐵
𝑑2[𝐵𝐻+]
𝑑𝑥2
+ 𝐷𝐵
𝑑2[𝐵𝐻2
2+]
𝑑𝑥2
= 0        (5A.8) 
𝐷𝑂𝐻−
𝑑2[𝑂𝐻−]
𝑑𝑥2
+ 𝐷𝐵
𝑑2[𝐵]
𝑑𝑥2
= 𝐷𝐻+
𝑑2[𝐻+]
𝑑𝑥2
+ 𝐷𝐵
𝑑2[𝐵𝐻2
2+]
𝑑𝑥2
            (5A.9) 
Integrating equations 5A.8 and 5A.9 once, gives: 
𝐷𝐵
𝑑[𝐵]
𝑑𝑥
+ 𝐷𝐵
𝑑[𝐵𝐻+]
𝑑𝑥
+ 𝐷𝐵
𝑑[𝐵𝐻2
2+]
𝑑𝑥
= 𝐶1                   (5A.10) 
𝐷𝑂𝐻−
𝑑[𝑂𝐻−]
𝑑𝑥
+ 𝐷𝐵
𝑑[𝐵]
𝑑𝑥
= 𝐷𝐻+
𝑑[𝐻+]
𝑑𝑥
+ 𝐷𝐵
𝑑[𝐵𝐻2
2+]
𝑑𝑥
+ 𝐶2                    (5A.11) 
By charge neutrality:  
𝐷𝑂𝐻−
𝑑[𝑂𝐻−]
𝑑𝑥
= 𝐷𝐻+
𝑑[𝐻+]
𝑑𝑥
+ 𝐷𝐵
𝑑[𝐵𝐻+]
𝑑𝑥
+ 2𝐷𝐵
𝑑[𝐵𝐻2
2+]
𝑑𝑥
                   (5A.12) 
By combining equation 5A.10, 5A.11 and 5A.12, it can be shown that:  
𝐶1 = −𝐶2                     (5A.13) 
Integrating equations 5A.10 and 5A.11,  
𝐷𝐵[𝐵] + 𝐷𝐵[𝐵𝐻
+] + 𝐷𝐵[ 𝐵𝐻2
2+] = 𝐶1𝑥 + 𝐶3                       (5A.14) 
𝐷𝑂𝐻−[𝑂𝐻
−] + 𝐷𝐵[𝐵] = 𝐷𝐻+[𝐻
+] + 𝐷𝐵[ 𝐵𝐻2
2+] + 𝐶2𝑥 + 𝐶4              (5A.15) 
Boundary conditions: 
At x = 0:        At x = h: 
[𝐵] = [𝐵]0 (intrinsic solubility of the drug)    [𝐵] = 0 (sink condition) 
[𝐵𝐻+] = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝐵𝐻+] = 0 (sink condition) 
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[ 𝐵𝐻2
2+] = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [ 𝐵𝐻2
2+] = 0 (sink condition) 
[𝐻+] = [𝐻+]0        [𝐻
+] = [𝐻+]ℎ 
[𝑂𝐻−] = [𝑂𝐻−]0       [𝑂𝐻
−] = [𝑂𝐻−]ℎ 
Evaluation of interfacial pH 
Applying the above boundary conditions to equations 5A.14 and 5A.15, at x = 0: 
𝐷𝐵[𝐵]0 + 𝐷𝐵[𝐵𝐻
+] + 𝐷𝐵[ 𝐵𝐻2
2+] = 𝐶3                         (5A.16) 
𝐷𝑂𝐻−[𝑂𝐻
−]0 + 𝐷𝐵[𝐵]0 = 𝐷𝐻+[𝐻
+]0 + 𝐷𝐵[ 𝐵𝐻2
2+] + 𝐶4               (5A.17) 
and at x = h, assuming sink conditions, equations 5A.14 and 5A.15 can be written as: 
0 = 𝐶1ℎ + 𝐶3                     (5A.18) 
𝐷𝑂𝐻−[𝑂𝐻
−]ℎ = 𝐷𝐻+[𝐻
+]ℎ + 𝐶2ℎ + 𝐶4                 (5A.19) 
Combining equations 5A.16 to 5A.19 and algebraically solving for interfacial pH, [H+]0, yields the 
following equation: 
2𝐷𝐵
[𝐵]0
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 [𝐻
+]0
3
+ (𝐷𝐻+ + 𝐷𝐵
[𝐵]0
𝐾𝑎2
𝐵 ) [𝐻
+]0
2
+ (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)[𝐻
+]0 −
𝐷𝑂𝐻−𝐾𝑤 = 0                                                (5A.20) 
Evaluation of flux 
Combine equations 5A.16 and 5A.18, and solve for −𝐶1 for the total flux of the drug species across 
the diffusion layer: 
𝐽𝐵 =
𝐷𝐵
ℎ
[𝐵]0 (1 +
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )                  (5A.21) 
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For rotating disk, the thickness of the hydrodynamic boundary layer can be defined according to 
Levich model21: 
ℎ = 1.612𝐷
1
3𝑣
1
6𝜔−
1
2                    (5A.22) 
 where 𝑣 is the kinematic viscosity and 𝜔 is the angular velocity in radians per unit time.  Substitute 
equation 5A.22 into 5A.21, the flux of the drug becomes: 
𝐽𝐵 = 0.62𝐷𝐵
2/3
𝜔1/2𝑣−1/6[𝐵]0 (1 +
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )                  (5A.23) 
Mass transport analysis for cocrystal 
The flux of all the species across the diffusion layer include both the diffusion and chemical 
reactions happening during dissolution.  At steady state, the diffusion and simultaneous chemical 
reactions of the individual species within the diffusion layer can be written using Fick’s law as 
follows: 
𝜕[𝐵]
𝜕𝑡
= 𝐷𝐵
𝜕2 [𝐵]
𝜕𝑥2
+ 𝜙1 = 0                   (5A.24) 
𝜕[𝐵𝐻+]
𝜕𝑡
= 𝐷𝐵
𝜕2 [𝐵𝐻+]
𝜕𝑥2
+ 𝜙2 = 0                  (5A.25) 
𝜕[𝐵𝐻2
2+]
𝜕𝑡
= 𝐷𝐵
𝜕2 [𝐵𝐻2
2+]
𝜕𝑥2
+ 𝜙3 = 0                  (5A.26) 
𝜕[𝑂𝐻−]
𝜕𝑡
= 𝐷𝑂𝐻−
𝜕2 [𝑂𝐻−]
𝜕𝑥2
+ 𝜙4 = 0                  (5A.27) 
𝜕[𝐻+]
𝜕𝑡
= 𝐷𝐻+
𝜕2 [𝐻+]
𝜕𝑥2
+ 𝜙5 = 0                  (5A.28) 
𝜕[𝐻2𝐴]
𝜕𝑡
= 𝐷𝐻2𝐴
𝜕2 [𝐻2𝐴]
𝜕𝑥2
+ 𝜙6 = 0                  (5A.29) 
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𝜕[𝐻𝐴−]
𝜕𝑡
= 𝐷𝐻2𝐴
𝜕2 [𝐻𝐴−]
𝜕𝑥2
+ 𝜙7 = 0                  (5A.30) 
𝜕[𝐴2−]
𝜕𝑡
= 𝐷𝐻2𝐴
𝜕2 [𝐴2−]
𝜕𝑥2
+ 𝜙8 = 0                  (5A.31) 
At equilibrium, the reaction rate of the reactant should be the opposite of the product.  Based on 
the chemical equilibria, the followings can be written: 
𝜙3 = −𝜙1 − 𝜙2                    (5A.32) 
𝜙6 = −𝜙7 − 𝜙8                    (5A.33) 
The reaction rate of the acid and the base should be the same: 
𝜙3 + 𝜙5 + 𝜙6 = 𝜙1 + 𝜙4 + 𝜙8                  (5A.34) 
Based on equations 5A.32, 5A.33 and 5A.34, the following mass balance equations can be written:  
𝐷𝐵
𝑑2[𝐵]
𝑑𝑥2
+ 𝐷𝐵
𝑑2[𝐵𝐻+]
𝑑𝑥2
+ 𝐷𝐵
𝑑2[𝐵𝐻2
2+]
𝑑𝑥2
= 0                 (5A.35) 
𝐷𝐻2𝐴
𝑑2[𝐻2𝐴]
𝑑𝑥2
+ 𝐷𝐻2𝐴
𝑑2[𝐻𝐴−]
𝑑𝑥2
+ 𝐷𝐻2𝐴
𝑑2[ 𝐴2−]
𝑑𝑥2
= 0                (5A.36) 
𝐷𝑂𝐻−
𝑑2[𝑂𝐻−]
𝑑𝑥2
+ 𝐷𝐵
𝑑2[𝐵]
𝑑𝑥2
+ 𝐷𝐻2𝐴
𝑑2[ 𝐴2−]
𝑑𝑥2
= 𝐷𝐻+
𝑑2[𝐻+]
𝑑𝑥2
+ 𝐷𝐵
𝑑2[𝐵𝐻2
2+]
𝑑𝑥2
𝐷𝐻2𝐴
𝑑2[𝐻2𝐴]
𝑑𝑥2
            (5A.37) 
Integrate equations 5A.35 to 5A.37 once, gives: 
𝐷𝐵
𝑑[𝐵]
𝑑𝑥
+ 𝐷𝐵
𝑑[𝐵𝐻+]
𝑑𝑥
+ 𝐷𝐵
𝑑[𝐵𝐻2
2+]
𝑑𝑥
= 𝐶1                 (5A.38) 
𝐷𝐻2𝐴
𝑑[𝐻2𝐴]
𝑑𝑥
+ 𝐷𝐻2𝐴
𝑑[𝐻𝐴−]
𝑑𝑥
+ 𝐷𝐻2𝐴
𝑑[ 𝐴2−]
𝑑𝑥
= 𝐶2                    (5A.39) 
𝐷𝑂𝐻−
𝑑[𝑂𝐻−]
𝑑𝑥
+ 𝐷𝐵
𝑑[𝐵]
𝑑𝑥
+ 𝐷𝐻2𝐴
𝑑[ 𝐴2−]
𝑑𝑥
= 𝐷𝐻+
𝑑[𝐻+]
𝑑𝑥
+ 𝐷𝐵
𝑑[𝐵𝐻2
2+]
𝑑𝑥
+ 𝐷𝐻2𝐴
𝑑[𝐻2𝐴]
𝑑𝑥
+ 𝐶3          (5A.40) 
By charge neutrality:  
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𝐷𝑂𝐻−
𝑑[𝑂𝐻−]
𝑑𝑥
+ 𝐷𝐻2𝐴
𝑑[𝐻𝐴−]
𝑑𝑥
+ 2𝐷𝐻2𝐴
𝑑[ 𝐴2−]
𝑑𝑥
= 𝐷𝐻+
𝑑[𝐻+]
𝑑𝑥
+ 𝐷𝐵
𝑑[𝐵𝐻+]
𝑑𝑥
+ 2𝐷𝐵
𝑑[𝐵𝐻2
2+]
𝑑𝑥
          (5A.41) 
By combining equations 5A.38 to 5A.41, it can be shown that:  
𝐶3 = 𝐶2 − 𝐶1                     (5A.42) 
Integrating equations 5A.38 to 5A.40, gives: 
𝐷𝐵[𝐵] + 𝐷𝐵[𝐵𝐻
+] + 𝐷𝐵[ 𝐵𝐻2
2+] = 𝐶1𝑥 + 𝐶4                     (5A.43) 
𝐷𝐻2𝐴[𝐻2𝐴] + 𝐷𝐻2𝐴[𝐻𝐴
−] + 𝐷𝐻2𝐴[ 𝐴
2−] = 𝐶2𝑥 + 𝐶5               (5A.44) 
𝐷𝑂𝐻−[𝑂𝐻
−] + 𝐷𝐵[𝐵] + 𝐷𝐻2𝐴[ 𝐴
2−] = 𝐷𝐻+[𝐻
+] + 𝐷𝐵[ 𝐵𝐻2
2+] + 𝐷𝐻2𝐴[𝐻2𝐴] + 𝐶3𝑥 + 𝐶6(5A.45) 
Based on equations 5.33 and 5.34, the concentrations of the nonionized drug and coformer at the 
dissolving surface can be written to include in the following boundary conditions: 
At x = 0:        at x = h: 
[B] =
√𝐾𝑠𝑝(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
   [B] = 0 (sink condition) 
[𝐻2𝐴] = (
𝐷𝐵
𝐷𝐻2𝐴
)2/3
√𝐾𝑠𝑝(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )
  [𝐻2𝐴] = 0 (sink condition) 
[𝐵𝐻+] = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝐵𝐻+] = 0 (sink condition) 
[𝐵𝐻2
2+] = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝐵𝐻2
2+] = 0 (sink condition) 
[𝐻𝐴−] = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝐻𝐴−] = 0 (sink condition) 
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[𝐴2−] = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝐴2−] = 0 (sink condition) 
[𝐻+] = [𝐻+]0        [𝐻
+] = [𝐻+]ℎ 
[𝑂𝐻−] = [𝑂𝐻−]0       [𝑂𝐻
−] = [𝑂𝐻−]ℎ 
Evaluation of interfacial pH 
Applying the above boundary conditions to equations 5A.43 to 5A.45, at x = 0: 
𝐷𝐵
√𝐾𝑠𝑝(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
+ 𝐷𝐵[𝐵𝐻
+] + 𝐷𝐵[ 𝐵𝐻2
2+] = 𝐶4             (5A.46) 
𝐷𝐻2𝐴(
𝐷𝐵
𝐷𝐻2𝐴
)2/3
√𝐾𝑠𝑝(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )
+ 𝐷𝐻2𝐴[𝐻𝐴
−] + 𝐷𝐻2𝐴[ 𝐴
2−] = 𝐶5  (5A.47) 
𝐷𝑂𝐻−[𝑂𝐻
−]0 + 𝐷𝐵
√𝐾𝑠𝑝(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
+ 𝐷𝐻2𝐴[ 𝐴
2−] = 𝐷𝐻+[𝐻
+]0 +
𝐷𝐵[ 𝐵𝐻2
2+] + 𝐷𝐻2𝐴(
𝐷𝐵
𝐷𝐻2𝐴
)2/3
√𝐾𝑠𝑝(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )
+ 𝐶6             (5A.48) 
and at x = h, assuming sink conditions, equations 5A.43 to 5A.45 can be written as: 
0 = 𝐶1ℎ + 𝐶4                     (5A.49) 
0 = 𝐶2ℎ + 𝐶5                     (5A.50) 
𝐷𝑂𝐻−[𝑂𝐻
−]ℎ = 𝐷𝐻+[𝐻
+]ℎ + 𝐶3ℎ + 𝐶6                            (5A.51) 
 175 
 
Combining equations 5A.46 to 5A.51 and algebraically solving for interfacial pH, [H+]0, yields the 
following equation: 
𝐴𝑥8 + 𝐵𝑥7 + 𝐶𝑥6 + 𝐷𝑥5 + 𝐸𝑥4 + 𝐹𝑥3 + 𝐺𝑥2 + 𝐻𝑥 + 𝐼 = 0              (5A.52) 
where: 
𝐴 = 4𝐷𝐵
2𝐾𝑠𝑝 − 𝐷𝐻+
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ; 
 
𝐵 = 4𝐷𝐵𝐾𝑠𝑝 (𝐷𝐵𝐾𝑎1
𝐵 + 2𝐷𝐵𝐾𝑎1
𝐻2𝐴 − 𝐷𝐵
2
3𝐷𝐻2𝐴
1
3𝐾𝑎1
𝐻2𝐴) − 𝐷𝐻+
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴 + 𝐾𝑎1
𝐵 ) −
2𝐷𝐻+𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ); 
 
𝐶 = 𝐷𝐵
2𝐾𝑠𝑝 (𝐾𝑎1
𝐵 2 + 8𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 8𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 4𝐾𝑎1
𝐻2𝐴
2
) − 2𝐷𝐵
5
3𝐷𝐻2𝐴
1
3𝐾𝑠𝑝 (2𝐾𝑎1
𝐻2𝐴
2
+
3𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 4𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴) − 2𝐷𝐻+𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)( 𝐾𝑎1
𝐻2𝐴 + 𝐾𝑎1
𝐵 ) −
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)
2 − 𝐷𝐻+
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) +
2𝐷𝑂𝐻−𝐷𝐻+𝐾𝑤𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
; 
 
𝐷 = 2𝐷𝐵
2𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 (𝐾𝑎1
𝐵 + 4𝐾𝑎2
𝐻2𝐴 + 2𝐾𝑎1
𝐻2𝐴) − 2𝐷𝐵
5
3𝐷𝐻2𝐴
1
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴 (2𝐾𝑎2
𝐻2𝐴 + 2𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 +
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 2 + 4𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 6𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 ) + 2𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
(2𝐾𝑎2
𝐻2𝐴 +
𝐾𝑎1
𝐵 ) + 8𝐷𝐵
2𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎2
𝐻2𝐴 + 2𝐷𝑂𝐻−𝐷𝐻+𝐾𝑤𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴 + 𝐾𝑎1
𝐵 ) − 2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ −
𝐷𝐻+[𝐻
+]ℎ)(𝐷𝐻+𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐷𝐻+𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐷𝐻+𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 − 𝐷𝑂𝐻−𝐾𝑤) −
𝐷𝐻+
2𝐾𝑎1
𝐵 2𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴) − 𝐾𝑎1
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)
2(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐵 +
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ); 
 
𝐸 = 𝐷𝐵
2𝐾𝑠𝑝𝐾𝑎1
𝐵 2 (2𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴
2
) − 2𝐷𝐵
5
3𝐷𝐻2𝐴
1
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴 (9𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 +
2𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 2𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 2 + 4𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
2
+ 4𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 2 + 𝐾𝑎1
𝐵 2𝐾𝑎2
𝐵 ) +
𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
(𝐾𝑎1
𝐵 2 + 2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 4𝐾𝑎2
𝐻2𝐴
2
+ 8𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 ) − (𝐷𝑂𝐻−𝐾𝑤)
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 +
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)(𝐷𝑂𝐻−𝐾𝑤𝐾𝑎1
𝐻2𝐴 + 𝐷𝑂𝐻−𝐾𝑤𝐾𝑎1
𝐵 − 𝐷𝐻+𝐾𝑎1
𝐵 𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 −
𝐷𝐻+𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) + 2𝐷𝑂𝐻−𝐷𝐻+𝐾𝑤𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) −
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)
2(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) +
4𝐷𝐵
2𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
(2𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎2
𝐻2𝐴
2
) − 𝐷𝐻+
2(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴; 
 
𝐹 = 2𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎1
𝐵 (2𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 + 4𝐾𝑎2
𝐻2𝐴𝐾𝑎2
𝐵 + 4𝐾𝑎2
𝐻2𝐴
2
+ 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) −
2𝐷𝐵
5
3𝐷𝐻2𝐴
1
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎1
𝐵 (6𝐾𝑎2
𝐻2𝐴
2
+ 6𝐾𝑎2
𝐻2𝐴𝐾𝑎2
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 3𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 + 2
𝐾𝑎2
𝐻2𝐴
𝐾𝑎1
𝐻2𝐴
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) −
 176 
 
(𝐷𝑂𝐻−𝐾𝑤)
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴 + 𝐾𝑎1
𝐵 ) + 2𝐷𝑂𝐻−𝐾𝑤𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ −
𝐷𝐻+[𝐻
+]ℎ)(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) + 2𝐷𝑂𝐻−𝐷𝐻+𝐾𝑤𝐾𝑎1
𝐵 2𝐾𝑎1
𝐻2𝐴 (𝐾𝑎2
𝐻2𝐴𝐾𝑎2
𝐵 + 𝐾𝑎2
𝐵 2) −
𝐾𝑎1
𝐵 2𝐾𝑎1
𝐻2𝐴(𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)
2 (𝐾𝑎2
𝐻2𝐴𝐾𝑎2
𝐵 + 𝐾𝑎2
𝐵 2) − 2𝐷𝐻+(𝐷𝑂𝐻−[𝑂𝐻
−]ℎ −
𝐷𝐻+[𝐻
+]ℎ)𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2 + 2𝐷𝐵
2𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 (𝐾𝑎1
𝐵 + 2𝐾𝑎2
𝐻2𝐴); 
 
𝐺 = 𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎1
𝐵 (𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 2 + 8𝐾𝑎2
𝐻2𝐴
2
𝐾𝑎2
𝐵 + 8𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 4𝐾𝑎2
𝐻2𝐴
2
𝐾𝑎1
𝐵 ) −
2𝐷𝐵
5
3𝐷𝐻2𝐴
1
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 (4𝐾𝑎2
𝐻2𝐴𝐾𝑎2
𝐵 + 3𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 2𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 ) −
(𝐷𝑂𝐻−𝐾𝑤)
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) +
2𝐷𝑂𝐻−𝐾𝑤𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 2𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)(𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎2
𝐵 ) +
2𝐷𝑂𝐻−𝐷𝐻+𝐾𝑤𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2 − (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)
2𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2 +
𝐷𝐵
2𝐾𝑠𝑝(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 )2; 
 
𝐻 = 4𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 2𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 ) −
(𝐷𝑂𝐻−𝐾𝑤)
2𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 2𝐾𝑎2
𝐵 (𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎2
𝐵 ) + 2𝐷𝑂𝐻−𝐾𝑤𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2(𝐷𝑂𝐻−[𝑂𝐻
−]ℎ −
𝐷𝐻+[𝐻
+]ℎ) − 4𝐷𝐵
5
3𝐷𝐻2𝐴
1
3𝐾𝑠𝑝(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 )2𝐾𝑎2
𝐵 ; 
 
𝐼 = 4𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2 − (𝐷𝑂𝐻−𝐾𝑤)
2𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2. 
 
Evaluation of flux of the cocrystal components   
Combine equations 5A.46 and 5A.49, and solve for −𝐶1 for the total flux of cocrystal in terms of 
drug species across the diffusion layer: 
𝐽𝑐𝑐 =
𝐷𝐵
ℎ
√𝐾𝑠𝑝(1 +
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1 +
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )                    (5A.53) 
Substituting equation 5A.22 into equation 5A.53, the rotating flux of cocrystal can be written as:  
𝐽𝑐𝑐 = 0.62𝐷𝐵
2/3
𝜔1/2𝑣−1/6√𝐾𝑠𝑝(1 +
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1 +
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )            (5A.54) 
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APPENDIX 5B  
This appendix provides the mass transport analysis for the dissolution of cocrystals based 
on the interfacial equilibrium model and as well as the comparison in interfacial pH and flux 
predictions between the surface saturation and interfacial equilibrium models.   
Mass transport analysis based on interfacial equilibrium model 
According to the interfacial equilibrium model, the concentrations of the cocrystal 
components have to increase in order to maintain constant solubility product at the dissolving 
surface at all time.  For the dissolution of a 1:1 cocrystal with dibasic drug and diacidic coformer, 
the concentrations of the components at the dissolving surface can be written based on the 
interfacial equilibrium model as:  
[𝐵]𝑇 = [𝐵] + [𝐵𝐻
+] + [𝐵𝐻2
2+] = (
𝐷𝐻2𝐴
𝐷𝐵
)1/3𝑆𝑐𝑐       (5B.1) 
[𝐻2𝐴]𝑇 = [𝐻2𝐴] + [𝐻𝐴
−] + [𝐴2−] = (
𝐷𝐵
𝐷𝐻2𝐴
)1/3𝑆𝑐𝑐       (5B.2) 
Based on these two equations, the following boundary conditions can be written: 
At x = 0:        at x = h: 
[𝐵] = (
𝐷𝐻2𝐴
𝐷𝐵
)1/3
√𝐾𝑠𝑝(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
  [𝐵] = 0 (sink condition) 
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[𝐻2𝐴] = (
𝐷𝐵
𝐷𝐻2𝐴
)1/3
√𝐾𝑠𝑝(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1+
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )
(1+
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )
  [𝐻2𝐴] = 0 (sink condition) 
[𝐵𝐻+] = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝐵𝐻+] = 0 (sink condition) 
[𝐵𝐻2
2+] = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝐵𝐻2
2+] = 0 (sink condition) 
[𝐻𝐴−] = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝐻𝐴−] = 0 (sink condition) 
[𝐴2−] = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛       [𝐴2−] = 0 (sink condition) 
[𝐻+] = [𝐻+]0        [𝐻
+] = [𝐻+]ℎ 
[𝑂𝐻−] = [𝑂𝐻−]0       [𝑂𝐻
−] = [𝑂𝐻−]ℎ 
Evaluation of interfacial pH 
Applying the above boundary conditions to equations 5A.43 to 5A.45 and follow the steps 
shown in Appendix 5A, the following equation can be written to predict the interfacial pH: 
𝐴𝑥8 + 𝐵𝑥7 + 𝐶𝑥6 + 𝐷𝑥5 + 𝐸𝑥4 + 𝐹𝑥3 + 𝐺𝑥2 + 𝐻𝑥 + 𝐼 = 0     (5B.3) 
where: 
𝐴 = 4𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝 − 𝐷𝐻+
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ; 
 
𝐵 = 4𝐷𝐵𝐷𝐻2𝐴
2
3𝐾𝑠𝑝 (𝐷𝐵
1
3𝐾𝑎1
𝐵 + 2𝐷𝐵
1
3𝐾𝑎1
𝐻2𝐴 − 𝐷𝐻2𝐴
1
3𝐾𝑎1
𝐻2𝐴) − 𝐷𝐻+
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴 + 𝐾𝑎1
𝐵 ) −
2𝐷𝐻+𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ); 
 
𝐶 = 𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝 (𝐾𝑎1
𝐵 2 + 8𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 8𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 4𝐾𝑎1
𝐻2𝐴
2
) − 2𝐷𝐵𝐷𝐻2𝐴𝐾𝑠𝑝 (2𝐾𝑎1
𝐻2𝐴
2
+
3𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 4𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴) − 2𝐷𝐻+𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)( 𝐾𝑎1
𝐻2𝐴 + 𝐾𝑎1
𝐵 ) −
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𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)
2 − 𝐷𝐻+
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) +
2𝐷𝑂𝐻−𝐷𝐻+𝐾𝑤𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 𝐷𝐻2𝐴
4
3𝐷𝐵
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
; 
 
𝐷 = 2𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 (𝐾𝑎1
𝐵 + 4𝐾𝑎2
𝐻2𝐴 + 2𝐾𝑎1
𝐻2𝐴) − 2𝐷𝐵𝐷𝐻2𝐴𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴 (2𝐾𝑎2
𝐻2𝐴 +
2𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 2 + 4𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 6𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 ) +
2𝐷𝐻2𝐴
4
3𝐷𝐵
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
(2𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐵 ) + 8𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎2
𝐻2𝐴 +
2𝐷𝑂𝐻−𝐷𝐻+𝐾𝑤𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴 + 𝐾𝑎1
𝐵 ) − 2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)(𝐷𝐻+𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 +
𝐷𝐻+𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐷𝐻+𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 − 𝐷𝑂𝐻−𝐾𝑤) − 𝐷𝐻+
2𝐾𝑎1
𝐵 2𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴) −
𝐾𝑎1
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)
2(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ); 
 
𝐸 = 𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝𝐾𝑎1
𝐵 2 (2𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴
2
) − 2𝐷𝐵𝐷𝐻2𝐴𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴 (9𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 +
2𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 2𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 2 + 4𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
2
+ 4𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 2 + 𝐾𝑎1
𝐵 2𝐾𝑎2
𝐵 ) +
𝐷𝐻2𝐴
4
3𝐷𝐵
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
(𝐾𝑎1
𝐵 2 + 2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 4𝐾𝑎2
𝐻2𝐴
2
+ 8𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 ) − (𝐷𝑂𝐻−𝐾𝑤)
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 +
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)(𝐷𝑂𝐻−𝐾𝑤𝐾𝑎1
𝐻2𝐴 + 𝐷𝑂𝐻−𝐾𝑤𝐾𝑎1
𝐵 − 𝐷𝐻+𝐾𝑎1
𝐵 𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 −
𝐷𝐻+𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) + 2𝐷𝑂𝐻−𝐷𝐻+𝐾𝑤𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) −
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)
2(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) +
4𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
(2𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎2
𝐻2𝐴
2
) − 𝐷𝐻+
2(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴; 
 
𝐹 = 2𝐷𝐻2𝐴
4
3𝐷𝐵
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎1
𝐵 (2𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 + 4𝐾𝑎2
𝐻2𝐴𝐾𝑎2
𝐵 + 4𝐾𝑎2
𝐻2𝐴
2
+ 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) −
2𝐷𝐵𝐷𝐻2𝐴𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎1
𝐵 (6𝐾𝑎2
𝐻2𝐴
2
+ 6𝐾𝑎2
𝐻2𝐴𝐾𝑎2
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 3𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 + 2
𝐾𝑎2
𝐻2𝐴
𝐾𝑎1
𝐻2𝐴
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) −
(𝐷𝑂𝐻−𝐾𝑤)
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴 + 𝐾𝑎1
𝐵 ) + 2𝐷𝑂𝐻−𝐾𝑤𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ −
𝐷𝐻+[𝐻
+]ℎ)(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) + 2𝐷𝑂𝐻−𝐷𝐻+𝐾𝑤𝐾𝑎1
𝐵 2𝐾𝑎1
𝐻2𝐴 (𝐾𝑎2
𝐻2𝐴𝐾𝑎2
𝐵 + 𝐾𝑎2
𝐵 2) −
𝐾𝑎1
𝐵 2𝐾𝑎1
𝐻2𝐴(𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)
2 (𝐾𝑎2
𝐻2𝐴𝐾𝑎2
𝐵 + 𝐾𝑎2
𝐵 2) − 2𝐷𝐻+(𝐷𝑂𝐻−[𝑂𝐻
−]ℎ −
𝐷𝐻+[𝐻
+]ℎ)𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2 + 2𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 (𝐾𝑎1
𝐵 + 2𝐾𝑎2
𝐻2𝐴); 
 
𝐺 = 𝐷𝐻2𝐴
4
3𝐷𝐵
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎1
𝐵 (𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 2 + 8𝐾𝑎2
𝐻2𝐴
2
𝐾𝑎2
𝐵 + 8𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 4𝐾𝑎2
𝐻2𝐴
2
𝐾𝑎1
𝐵 ) −
2𝐷𝐵𝐷𝐻2𝐴𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 (4𝐾𝑎2
𝐻2𝐴𝐾𝑎2
𝐵 + 3𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 2𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 ) −
(𝐷𝑂𝐻−𝐾𝑤)
2𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 + 𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 ) +
2𝐷𝑂𝐻−𝐾𝑤𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 2𝐾𝑎2
𝐵 (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)(𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎2
𝐵 ) +
2𝐷𝑂𝐻−𝐷𝐻+𝐾𝑤𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2 − (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐻+[𝐻
+]ℎ)
2𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2 +
𝐷𝐵
4
3𝐷𝐻2𝐴
2
3𝐾𝑠𝑝(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 )2; 
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𝐻 = 4𝐷𝐻2𝐴
4
3𝐷𝐵
2
3𝐾𝑠𝑝𝐾𝑎1
𝐻2𝐴
2
𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 (𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 + 2𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 ) −
(𝐷𝑂𝐻−𝐾𝑤)
2𝐾𝑎1
𝐻2𝐴𝐾𝑎1
𝐵 2𝐾𝑎2
𝐵 (𝐾𝑎2
𝐻2𝐴 + 𝐾𝑎2
𝐵 ) + 2𝐷𝑂𝐻−𝐾𝑤𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2(𝐷𝑂𝐻−[𝑂𝐻
−]ℎ −
𝐷𝐻+[𝐻
+]ℎ) − 4𝐷𝐵𝐷𝐻2𝐴𝐾𝑠𝑝(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 )2𝐾𝑎2
𝐵 ; 
 
𝐼 = 4𝐷𝐻2𝐴
4
3𝐷𝐵
2
3𝐾𝑠𝑝(𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2 − (𝐷𝑂𝐻−𝐾𝑤)
2𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴(𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )2. 
Evaluation of flux of the cocrystal components   
Applying the above boundary conditions to equation 5A.43 from Appendix 5A and solve 
for −𝐶1 for the total flux of cocrystal in terms of drug species across the diffusion layer: 
𝐽𝑐𝑐 =
𝐷𝐻2𝐴
1
3𝐷𝐵
2
3
ℎ
√𝐾𝑠𝑝(1 +
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1 +
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )     (5B.4) 
Substitute equation 5A.22 from Appendix 5A into equation 5B.4, the rotating flux of cocrystal can 
be written as:  
𝐽𝑐𝑐 = 0.62(𝐷𝐵𝐷𝐻2𝐴)
1/3𝜔1/2𝑣−1/6√𝐾𝑠𝑝(1 +
𝐾𝑎1
𝐻2𝐴
[𝐻+]0
+
𝐾𝑎1
𝐻2𝐴𝐾𝑎2
𝐻2𝐴
[𝐻+]0
2 )(1 +
[𝐻+]0
𝐾𝑎2
𝐵 +
[𝐻+]0
2
𝐾𝑎1
𝐵 𝐾𝑎2
𝐵 )      (5B.5) 
Comparison between the surface saturation and interfacial equilibrium models  
 In order to evaluate the superiority between the surface saturation and interfacial 
equilibrium models, interfacial pH and flux of the cocrystals were predicted using both models 
and compared in Figure 5B.1 to 5B.3 for the three KTZ cocrystals.  The surface concentration of 
the drug for the interfacial equilibrium model is greater than that for the surface saturation model 
because it has to raise above the stoichiometric solubility of the cocrystal in order to maintain 
constant Ksp at the surface at all times during dissolution.  While the surface coformer 
concentration for the interfacial equilibrium model is lower than the drug concentration, it is still 
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higher than that for the surface saturation model.  The different concentrations of the cocrystal 
components at the dissolving surface result in the slight difference in interfacial pH predictions 
between the two models.  As shown in Figure 5B.1 to 5B.3, the predicted interfacial pH values at 
low bulk pH from the interfacial equilibrium model for all three cocrystals are slightly higher than 
those from the surface saturation model.  This is due to the higher drug concentration at the 
dissolving surface predicted from the interfacial equilibrium model, which leads to greater 
basicity.  On the other hand, the higher coformer concentration at the dissolving surface for the 
interfacial equilibrium model results in slightly lower interfacial pH predictions at high bulk pH 
compared to the surface saturation model.  Although the theoretical flux predictions from both 
models follow the same trend as the experimental data, the predictions from the interfacial 
equilibrium model for all three cocrystals are greater than those from the surface saturation model 
as shown in Figure 5B.1 to 5B.3. The better agreement between the experimental data and 
theoretical flux predictions has again demonstrated the superiority of the surface saturation model 
over the interfacial equilibrium model. 
(a)                                                                      (b)                                                  
 
Figure 5B.1.  Comparison of interfacial pH (a) and flux predictions (b) for KTZ-FUM between the 
interfacial equilibrium model (dotted line) and surface saturation model (solid line).  The solid 
circles are the experimental flux values.   
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(a)                                                                      (b) 
 
Figure 5B.2.  Comparison of interfacial pH (a) and flux predictions (b) for KTZ-SUC between the 
interfacial equilibrium model (dotted line) and surface saturation model (solid line).  The solid 
circles are the experimental flux values.   
 
(a)                                                                         (b) 
 
Figure 5B.3.  Comparison of interfacial pH (a) and flux predictions (b) for KTZ-ADP between the 
interfacial equilibrium model (dotted line) and surface saturation model (solid line).  The solid 
circles are the experimental flux values.   
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CHAPTER 6  
EFFECT OF BUFFERING AGENTS ON THE DISSOLUTION OF COCRYSTALS 
Abstract  
 Buffers are commonly encountered in drug development as they are frequently used in 
preparing dissolution media and sometimes even in drug formulations.  The human GI tract also 
contains bicarbonate buffer to maintain the GI pH.  It is well known that the properties and 
concentrations of buffers can have significant impact on the dissolution rates of ionizable drugs.  
Since cocrystals usually contain ionizable components, the influence of buffering agents on the 
dissolution rates of these cocrystalline materials should also be emphasized.  The purpose of this 
study is to evaluate the effect of acetate and phosphate buffers on the dissolution of a 1:1 cocrystal 
with nonionizable drug and acidic coformer, carbamazepine-salicylic acid (CBZ-SLC).  The mass 
transport model previously developed for this cocrystal has been extended to include the buffer 
properties for evaluating the buffer effect on interfacial pH and dissolution rates.  The mass 
transport analyses have demonstrated the importance of pKa value, diffusion coefficient and 
concentration of buffering agents in determining the interfacial pH.  By modeling interfacial pH, 
the flux of cocrystal can be accurately predicted as a function of buffer concentration.  In this 
study, the dissolution rate of CBZ-SLC increases with increasing buffer concentration and this 
increase is due to the elevation in interfacial pH by both acetate and phosphate buffers.   
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Introduction  
 The composition of dissolution media, such as pH and buffering agents can have significant 
impact on the dissolution rates of ionizable drugs1-3.  For the dissolution of ionizable compounds, 
the pH at the dissolving surface is extremely important and this interfacial pH can be quite different 
from the pH of the bulk solution1-3.  The presence of buffer species in the dissolution media can 
influence the interfacial pH and consequently alters the dissolution rates of ionizable drugs2-6.  
There has been studies in the literature demonstrating the influence of buffering agents on the 
dissolution rates of ionizable drugs2-6.  In these studies, the dissolution rates of ionizable drugs 
increase as buffer concentration increases and the rate of increase is dependent on the properties 
and concentrations of the buffer in solutions2-6.  The interfacial pH of naproxen has been shown to 
increase with increasing phosphate buffer concentration4.  As the buffer capacity in the bulk 
solution exceeds the self-buffering capacity of naproxen, the interfacial pH becomes similar to the 
bulk pH4.  Interfacial pH determines the dissolution behavior of naproxen in the presence of 
phosphate buffer and the dissolution rate of naproxen increases with increasing buffer 
concentration4.  Both interfacial pH and dissolution behavior of ionizable drugs under the influence 
of buffer can be accurately predicted using mass transport analyses for dissolution with 
simultaneous chemical reactions in the hydrodynamic boundary layer adjacent to the dissolving 
surface2-6.   
The primary buffer species in human GI tract is bicarbonate and the buffer concentrations 
can vary depending on the location in the GI tract and other factors such as food and stress7-9.  
Physiological relevant dissolution media such as fasted state simulated intestinal fluid (FaSSIF) 
and fed state simulated intestinal fluid (FeSSIF) also contain phosphate buffer as the main 
buffering agent10, 11.  Besides dissolution media, buffering agents have also been used in 
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formulations to prevent GI irritation and/or to promote dissolution of acidic drugs12-14.  Buffering 
agents can be encountered both in vivo and in vitro, so it is essential to understand the mechanism 
of how they influence the dissolution rates of ionizable drugs.      
The impact of pH on the dissolution rates of cocrystals under unbuffered conditions has 
been evaluated in previous chapters in this thesis.  The purpose of this chapter is to evaluate the 
dissolution rates of cocrystals under the influence of buffering agents.  The model cocrystal used 
in this study is carbamazepine-salicylic acid (CBZ-SLC) and the buffering agents are phosphate 
and acetate buffers.  The mass transport analyses for this cocrystal based on the surface saturation 
model15 were extended to include the chemical reactions of the coformer with the buffer species 
from the bulk solution.  This new mass transport model can be used to predict the interfacial pH 
and flux of 1:1 cocrystals with non-ionizable drugs and acidic coformers as a function of pH and 
buffer concentration. 
Materials and methods 
Materials   
Anhydrous carbamazepine (CBZ), salicylic acid (SLC), sodium lauryl sulfate (SLS), 
potassium phosphate monobasic, sodium acetate anhydrous and potassium phosphate dibasic 
anhydrous were purchased from Sigma Chemical Company (St. Louis, MO) and used as received.  
Acetonitrile, methanol and sodium phosphate monobasic were purchased from Fisher Scientific 
(Pittsburgh, PA).  Sodium phosphate dibasic heptahydrate was purchased from Acros Organics 
(Pittsburgh, PA).  Acetic acid was purchased from Mallinckrodt Baker (Phillipsburg, NJ).  Water 
used in this study was filtered through a double deionized purification system (Milli Q Plus Water 
System) from Millipore Co. (Bedford, MA).   
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Cocrystal synthesis   
Cocrystals were prepared by reaction crystallization method16 at room temperature.  CBZ-
SLC was prepared by adding 1:1 molar ratio of CBZ and SLC in acetonitrile solution containing 
0.1 M SLC.  Solid phases were characterized by X-ray powder diffraction (XRPD) and differential 
scanning calorimetry (DSC). 
Cocrystal dissolution measurements  
Constant surface area dissolution rates of CBZ-SLC were determined using a rotating disk 
apparatus.  Cocrystal powder (~150 mg) was compressed in a stainless steel rotating disk die with 
a tablet radius of 0.50 cm at approximately 85 MPa for 2 minutes using a hydraulic press.  The die 
containing the compact was mounted onto a stainless steel shaft attached to an overhead, variable 
speed motor.  The disk was exposed to 150 mL of the dissolution medium in a water jacketed 
beaker with temperature controlled at 25°C and a rotation speed of 200 rpm was used.  Dissolution 
media containing different buffer concentrations in 150 mM SLS were prepared on the day of the 
experiment.  The bulk solution pH did not change significantly throughout the experiment.  Sink 
conditions were maintained throughout the experiments by ensuring the concentrations at the last 
time point of the dissolution were less than 10% of the cocrystal solubility.  Solution 
concentrations were measured using HPLC and solid phases after dissolution were analyzed by 
XRPD.   
HPLC   
Waters HPLC equipped with a photodiode array detector was used for all analysis.  The 
mobile phase was composed of 55% methanol and 45% water with 0.1% trifluoroacetic acid and 
the flow rate of 1 mL/min was used.  Separation was achieved using Waters, Atlantis, T3 column 
 187 
 
(5.0 µm, 100 Å) with dimensions of 4.6 x 250 mm.  The sample injection volume was 20 µL.  The 
wavelengths for the analytes were as follows: 284 nm for CBZ and 303 nm for SLC.    
XRPD   
XRPD diffractograms of solid phases were collected with a benchtop Rigaku Miniflex X-
ray diffractometer using Cu-Kα radiation (λ = 1.54 Å), a tube voltage of 30 kV, and a tube current 
of 15 mA.  Data was collected from 5 to 40° at a continuous scan rate of 2.5°/min. 
DSC   
Crystalline samples were analyzed by DSC using a TA instrument 2910 MDSC system 
equipped with a refrigerated cooling unit.  All experiments were performed by heating the samples 
at a rate of 10 °C/min under a dry nitrogen atmosphere.  Temperature and enthalpy of the 
instrument were calibrated using high purity indium standard.   
Theoretical 
The present model here describes the dissolution of 1:1 cocrystals with nonionizable drugs 
and monoacidic coformers in buffered media containing surfactant.  This model is an extension 
from the previous model developed based on the surface saturation model with simultaneous 
chemical reactions in the hydrodynamic boundary layer adjacent to the dissolving surface15.  
Besides the chemical reactions with water and hydroxide ion, the acidic coformer also reacts with 
the basic components of the buffer in the dissolution medium.  Although the mass transport model 
developed here is for the monoprotic buffer systems, it is also applicable to diprotic or even 
triprotic buffer systems as long as the pKa value used is close to the bulk pH of the dissolution 
medium.  This assumption has been tested for both diprotic and triprotic buffer systems3.  By using 
relevant pKa values, the flux predictions from the monoprotic model have been shown to be 
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identical to those from the diprotic and triprotic models 3.  These findings suggest that the transport 
mechanism of buffer is governed by the dissociation of the dominated buffer species in solution3.  
The chemical equilibria and the equations for equilibrium constants during the dissolution 
of 1:1 cocrystal, RHA with R as the nonionizable drug and HA as the weakly acidic coformer in 
buffered solution containing surfactant with B as the basic and BH+ as the conjugate acidic buffer 
species, can be described as follows: 
(𝑅𝐻𝐴)𝑠𝑜𝑙𝑖𝑑 ⇋ 𝑅𝑎𝑞 + 𝐻𝐴𝑎𝑞             (6.1) 
𝐾𝑠𝑝 = [𝑅]𝑎𝑞[𝐻𝐴]𝑎𝑞              (6.2) 
𝑅𝑎𝑞 + 𝑚 ⇋ 𝑅𝑚              (6.3) 
𝐾𝑠
𝑅 =
[𝑅]𝑚
[𝑅]𝑎𝑞[𝑚]
               (6.4)   
𝐻𝐴𝑎𝑞 + 𝑚 ⇋ 𝐻𝐴𝑚              (6.5) 
𝐾𝑠
𝐻𝐴 =
[𝐻𝐴]𝑚
[𝐻𝐴]𝑎𝑞[𝑚]
              (6.6) 
𝐻𝐴𝑎𝑞 ⇋ 𝐻3𝑂
+ + 𝐴𝑎𝑞
−               (6.7) 
𝐾𝑎
𝐻𝐴 =
[𝐻3𝑂
+][𝐴−]𝑎𝑞
[𝐻𝐴]𝑎𝑞
              (6.8)   
𝐻𝐴𝑎𝑞 + 𝑂𝐻
− ⇋ 𝐻2𝑂 + 𝐴𝑎𝑞
−              (6.9) 
𝐾1 =
[𝐴−]𝑎𝑞
[𝐻𝐴]𝑎𝑞[𝑂𝐻−]
            (6.10) 
𝐵𝐻𝑎𝑞
+ ⇋ 𝐵𝑎𝑞 + 𝐻
+            (6.11) 
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𝐾𝑎
𝐵 =
[𝐻+][𝐵]𝑎𝑞
[𝐵𝐻+]𝑎𝑞
            (6.12) 
𝐵𝐻𝑎𝑞
+ + 𝑂𝐻− ⇋ 𝐵𝑎𝑞 + 𝐻2𝑂           (6.13) 
𝐾2 =
[𝐵]𝑎𝑞
[𝐵𝐻+]𝑎𝑞[𝑂𝐻−]
            (6.14) 
𝐻𝐴𝑎𝑞 + 𝐵𝑎𝑞 ⇋ 𝐵𝐻𝑎𝑞
+ + 𝐴𝑎𝑞
−            (6.15) 
𝐾3 =
[𝐵𝐻+]𝑎𝑞[𝐴
−]𝑎𝑞
[𝐵]𝑎𝑞[𝐻𝐴]𝑎𝑞
=
𝐾𝑠
𝐻𝐴
𝐾𝑎
𝐵            (6.16) 
where 𝐾𝑠𝑝 is the solubility product of the cocrystal, 𝐾𝑠
𝑅 is the solubilization constant of R and 𝐾𝑠
𝐻𝐴 
is the solubilization constant of HA, m is the micellar concentration in solution and is equal to the 
total surfactant concentration minus the critical micellar concentration (CMC), 𝐾𝑎
𝐻𝐴 and 𝐾𝑎
𝐵 are 
the ionization constants of HA and B.  Subscript aq denotes the aqueous phase and m denotes the 
micellar phase.   The underlying assumption in this analysis is that the buffer species and ionized 
form of coformer are not solubilized by surfactant. 
 In the presence of surfactant, the stoichiometric solubility of RHA can be predicted using 
the following equation: 
𝑆𝑐𝑐 = √𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(1 +
𝐾𝑎
𝐻+
+ 𝐾𝑠𝐻𝐴[𝑚])        (6.17) 
Detailed derivations of the mass transport analyses based on the surface saturation model15 
developed previously to describe the dissolution of cocrystals are provided in Appendix 6A.  The 
mass transport analyses are based on the following assumptions: chemical reactions and solute 
solubilization within the diffusion layer occur instantaneously, free solutes and micelles are in 
equilibrium throughout the diffusion layer, the ionized form of the coformer and buffer species are 
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not solubilized by surfactant, aqueous diffusivities of the ionized and non-ionized forms are the 
same.  For simplification of the interfacial pH prediction, the effective diffusivity of the coformer 
is assumed to be the same as the aqueous diffusivity because it is not significantly solubilized by 
the surfactant.  In this study, the effect of surfactant concentration on the viscosity of dissolution 
media was not accounted for the mass transport analyses.  Although the viscosity of the dissolution 
media may approximately double at high surfactant concentration (eg: 300 mM)17, its impact on 
the hydrodynamic boundary layer is small.  The viscosity of dissolution media is not expected to 
significantly affect the diffusion of free species as they are assumed to be diffusing through the 
aqueous phase where the surfactant concentration is equal to the CMC and the viscosity is not 
substantially different from water18. The effect of viscosity on the diffusion coefficient of the 
micelles incorporates the effect of viscosity changes.    
Results and discussion 
Physicochemical properties 
In this study, the effect of buffer on the dissolution of CBZ-SLC was evaluated using 
acetate and phosphate buffers in 150 mM SLS solutions.  This surfactant concentration was 
maintained constant for all dissolution studies in order to rule out the surfactant effect on the 
dissolution rates of the cocrystal.  In the absence of buffering agent, 150 mM SLS is sufficient to 
stabilize CBZ-SLC from the conversion back to the stable drug form during dissolution at bulk pH 
up to 815.  However, this concentration may not be sufficient for stabilizing the cocrystal in certain 
buffer concentrations due to the ability of buffer in elevating the interfacial pH.  Consequently, 
solid phase transformation may be observed in some of the dissolution experiments.  
Physicochemical properties of CBZ-SLC and its components are required for the predictions of 
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interfacial pH and flux.  The solubility product of CBZ-SLC was determined to be 0.40 mM2, and 
the solubilization constant of CBZ is 0.43 mM-1 and SLC is 0.060 mM-1 in 150 mM SLS15.   The 
pKa values and diffusion coefficients for the cocrystal components and buffer species are 
summarized in Table 6.1.  Although phosphoric acid has three pKa values, only the second one 
was used in this study because the pH of the dissolution media were around this value.  Therefore, 
the relevant buffer species in solutions are monobasic phosphate and dibasic phosphate.   
Table 6.1.  pKa values and diffusion coefficients of cocrystal components and buffer species. 
Compound pKa Diffusion Coefficient (x 10-6 cm2/sec) 
Carbamazepine - 1.48a 
Salicylic Acid 3.0a 7.66a 
Acetate 4.8b 10.9d 
Phosphate 6.6c 8.1c 
a) From reference 15;  
b) From reference 2; 
c) From reference 3; 
d) From reference 4. 
 
Influence of buffer on interfacial pH 
 The pH at the dissolving surface is important for determining the dissolution rates of 
cocrystals with ionizable components and this interfacial pH can be predicted using equation 
6A.36 from Appendix 6A.  The influence of buffering agents on the interfacial pH of CBZ-SLC 
as a function of bulk pH is shown in Figure 6.1.  As shown in Figure 6.1, interfacial pH is 
influenced by both the properties and concentrations of the buffering agents.  The buffer effect on 
interfacial pH is effective at bulk pH around the pKa values of the buffers.  The pKa value of acetate 
buffer is 4.8, so the interfacial pH starts to deviate from the unbuffered system at bulk pH 4 and 
these deviations increase with increasing buffer concentration.  The pKa value of phosphate buffer 
is 6.6, so the deviations in interfacial pH from the unbuffered system do not start until at bulk pH 
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above 5.  In both buffered systems, interfacial pH is elevated due to the chemical reactions between 
the acidic coformer and basic components of the buffers at the dissolving surface, which decrease 
the concentration of hydrogen ion and increase the interfacial pH.  The relative acidity and basicity 
between the buffer and coformer can also play a role on influencing the interfacial pH2.  The 
equilibrium constant from equation 6.16 for acetate and SLC is 63, while for phosphate and SLC 
is 3981.  This means that the phosphate buffer is a lot more basic compared to SLC than acetate 
buffer to SLC.  The lower basicity of acetate could not suppress the self-buffering ability of the 
coformer and allows it to self-buffer the interfacial pH similar to the unbuffered conditions for the 
buffer concentrations studied here.  The self-buffering ability of the coformer vanishes in the more 
basic phosphate buffer system.  Instead of plateauing, the interfacial pH in phosphate buffer 
solutions increases with bulk pH in an attempt to maintain a surface pH as close as to the bulk 
solution pH.                              
(a)                                                                           (b) 
  
Figure 6.1.  Theoretical predictions of interfacial pH for CBZ-SLC as a function of bulk pH in 
different acetate buffer (a) and phosphate buffer (b) concentrations at 150 mM SLS.  No buffer: 
; 15 mM: ; 25 mM: ; 50 mM: .  Interfacial pH were predicted using equation 6A.36 
from Appendix 6A with the physicochemical properties shown in Table 6.1.  
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Evaluation of crital stabilization concentration (CSC)  
 Critical stabiliztion concentration (CSC) is defined as the surfactant concentration required 
to achieve equivalent solubility of the cocrystal and parent drug19-21.  This concentration is pH 
dependent for cocrystals with ionizable components19-21.  Due to the elevation in interfacial pH by 
buffer, the CSC values of CBZ-SLC should be evaluated at the bulk pH of dissolution experiments 
to determine if they are below the SLS concentration (150 mM) used in this study.  The CSC  
values of CBZ-SLC for all the dissoluiton conditions studied in this work are summarized in Table 
6.2.  As shown in this table, the CSC values are below 150 mM SLS for most of the conditions, 
expect for 25 mM phosphate buffer at bulk pH 6.79, 50 mM phosphate buffer at bulk pH 6.78 and 
50 mM acetate buffer at bulk pH 4.85.  Since the CSC values in these conditions are above 150 
mM SLS used in the dissolution experiments, solid phase transformation may occur during 
dissoltuion.  
Table 6.2.  Estimated CSC for CBZ-SLC in different bulk pH, phosphate and acetate buffer 
concentrations. 
Buffer 
Conc. (mM) 
Phosphate buffer Acetate buffer 
pH CSCb 
(mM) 
pH CSCb 
(mM) Bulk Interfaciala Bulk Interfaciala 
15 6.84 4.5 148 - - - 
25 
6.79 4.8 289 
4.80 4.4 120 
6.03 4.1 63 
50 
6.78 5.3 861 4.85 4.6 181 
6.03 4.5 127 3.97 3.8 36 
a) Calculated using equation 6A.36 from Appendix 6A with the physicochemical properties shown 
in Table 6.1. 
b) Calculated using previously developed equation20. 
 
Influence of buffer on dissolution  
 Effect of buffer on the dissolution rates of CBZ-SLC was evaluated by performing 
dissolution studies in 150 mM SLS at different buffer concentrations and bulk pH.  For acetate 
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buffer, the dissolution profiles of CBZ-SLC in terms of components’ concentrations are shown in 
Figure 6.2.  Among the three dissolution conditions, only the 50 mM acetate buffer at bulk pH 
4.85 was expected to have cocrystal conversion during dissolution as predicted by the CSC value 
shown in Table 6.2.  This conversion was confirmed by the nonlinear dissolution behavior shown 
in Figure 6.2 and a mixed phase of CBZ-SLC and the dihydrated form of CBZ after dissolution by 
XRPD analysis.  Theoretically, the dissolution of CBZ-SLC in 50 mM acetate buffer at bulk pH 
4.85 should be faster than in 25 mM acetate buffer at bulk pH 4.80 due to the evaluation in 
interfacial pH.  However, the dissolution rates of CBZ-SLC in these conditions are nearly the same 
as shown in Figure 6.2 due to the conversion of the cocrystal in 50 mM acetate buffer at bulk pH 
4.85.  The dissolution profiles of CBZ-SLC in terms of components’ concentrations for phosphate 
buffer are shown in Figure 6.3 and 6.4.  In Figure 6.3, the dissolution experiments were performed 
in 15, 25 and 50 mM phosphate buffer at bulk pH around 6.8.  Among these conditions, CBZ-SLC 
is only stable in 15 mM phosphate buffer and these results are consistent with the CSC predictions 
shown in Table 6.2.  The solid phase transformation of CBZ-SLC in both 25 and 50 mM phosphate 
buffer was demonstrated by the nonlinear dissolution behavior shown in Figure 6.3 and the XRPD 
analyses after dissolution.  The dissolution rate of CBZ-SLC was only slightly higher in 50 mM 
phosphate buffer during the early dissolution time points and this did not last very long as the 
concentrations of both components became lower than those in 25 mM phosphate buffer by 10 
minutes.  These dissolution profiles suggest that the conversion rate of CBZ-SLC is much faster 
in 50 mM phosphate buffer than in 25 mM phosphate buffer.  As shown in Table 6.2, the CSC for 
CBZ-SLC in 50 mM phosphate buffer is 5.7x larger than 150 mM SLS, while for 25 mM phosphate 
buffer is only 1.9x.  The higher supersaturation generated with respect to the parent drug during 
the dissolution of CBZ-SLC in 50 mM phosphate buffer leads to faster conversion rate compared 
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to that in 25 mM phosphate buffer.  In order to capture the true dissolution rates of CBZ-SLC, 
linear regressions were fitted using the first 4 data points for 25 mM phosphate buffer and first 3 
data points for 50 mM phosphate buffer.  The dissolution experiments of CBZ-SLC in 25 and 50 
mM phosphate buffer at bulk pH 6 are shown in Figure 6.4.  There was no solid phase 
transformation observed during dissolution for these two conditions, which is expected because 
the CSC values are below 150 mM SLS.            
(a)                                                                          (b) 
 
Figure 6.2.  Dissolution profiles of CBZ-SLC in terms of CBZ concentrations (a) and SLC 
concentrations (b) in 150 mM SLS at different bulk pH and acetate buffer concentrations.  25 mM 
acetate buffer at pH 4.80: ; 50 mM acetate buffer at pH 4.85: ; 50 mM acetate buffer at pH 3.97:
.  The solid circles are the experimental data and the lines are the fitted linear regressions. 
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(a)                                                                          (b)  
  
Figure 6.3.  Dissolution profiles for CBZ-SLC in terms of CBZ concentrations (a) and SLC 
concentrations (b) in 150 mM SLS at different bulk pH and phosphate buffer concentrations.  15 
mM phosphate buffer at pH 6.84: ; 25 mM phosphate buffer at pH 6.79: ; 50 mM phosphate 
buffer at pH 6.78: .  The solid circles are the experimental data and the lines are the fitted linear 
regressions. 
 
(a)                                                                            (b) 
 
Figure 6.4.  Dissolution profiles for CBZ-SLC in terms of CBZ concentrations (a) and SLC 
concentrations (b) in 150 mM SLS at different bulk pH and phosphate buffer concentrations.  25 
mM phosphate buffer at pH 6.03: ; 50 mM phosphate at pH 6.03: .  The solid circles are the 
experimental points and the lines are the fitted linear regressions. 
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Evaluation of the mass transport model 
 To evaluate the predictive power of the mass transport model, the flux of CBZ-SLC in 
different buffer concentrations were calculated from the dissolution rates and compared to the 
theoretical predictions.  The influence of pH and buffer concentration on the dissolution of CBZ-
SLC is shown in Figure 6.5.  The dissolution pH dependence of CBZ-SLC relies on the interfacial 
pH rather than bulk pH.  Buffering agents have the ability to alter the interfacial pH and this ability 
is dependent on the properties and concentrations of the buffer.   Therefore, the dissolution pH 
dependence of CBZ-SLC can vary depending on the types and concentrations of the buffer.  As 
buffer concentration increases, interfacial pH increases due to the consumption of hydrogen ion at 
the dissolving surface and consequently, the flux of CBZ-SLC would increase because of the 
acidity of the coformer.  Due to the rapid conversion of the cocrystal back to the parent drug, the 
concentration profile of CBZ-SLC in pH 6.78, 50 mM phosphate buffer shown in Figure 6.3 (a) 
represents the drug dissolution more than the cocrystal dissolution.  Therefore, the flux of CBZ-
SLC at this condition was calculated using the first 3 data points from the dissolution concentration 
profile in terms of SLC shown in Figure 6.3 (b) and compared to the theoretical flux in Figure 6.5.  
As shown in Figure 6.5, the theoretical predictions agree reasonably well with the experimental 
data.  Some large deviations, such as at bulk pH 4.85, 50 mM acetate buffer and pH 6.78, 50 mM 
phosphate buffer, are due to the conversion of the cocrystal during dissolution.  The precipitation 
of the dihydrated form of CBZ at the dissolving surface impeded the dissolution of CBZ-SLC and 
resulted in lower flux.  The mass transport model in this study has not considered the cocrystal 
conversion, so the flux predictions would be overestimated when conversion happens during 
dissolution.   
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(a)                                                                          (b) 
 
Figure 6.5.  Flux of CBZ-SLC at 150 mM SLS as a function of bulk pH in acetate buffer (a) and 
phosphate buffer (b) solutions.  50 mM buffer: ; 25 mM buffer: ;15 mM buffer: ; and 0 
mM buffer: .  Solid circles are experimental flux values of CBZ-SLC in terms of CBZ, except 
for pH 6.78, 50 mM phosphate buffer, which is in terms of SLC.  Solid lines are theoretical flux 
predictions.  The theoretical and experiment flux in 0 mM buffer are from reference 15.  The flux 
in the presence of buffer were calculated using equation 6A.40 from Appendix 6A based on the 
interfacial pH predicted in Figure 6.1.  
 
Conclusions 
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the interfacial pH predictions, the flux of CBZ-SLC can be adequately predicted as a function of 
buffer concentration.  Due to the acidity of the coformer, the flux of CBZ-SLC increases as a 
function of buffer concentration because interfacial pH is evaluated by the presence of buffer.  This 
study emphasizes the importance of including any parameters that can influence the pH at the 
dissolving surface in the mass transport analyses in order to obtain accurate flux predictions for 
ionizable compounds.     
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APPENDIX 6A  
The flux of all the species across the diffusion layer includes both the diffusion and 
chemical reactions happening during dissolution.  At steady state, the diffusion and simultaneous 
chemical reactions of the individual species within the diffusion layer can be written using Fick’s 
law as follows:  
𝜕[𝑅]𝑎𝑞
𝜕𝑡
= 𝐷𝑅𝑎𝑞
𝜕2 [𝑅]𝑎𝑞
𝜕𝑥2
+ 𝜙1 = 0         (6A.1) 
𝜕[𝑅]𝑚
𝜕𝑡
= 𝐷𝑅𝑚
𝜕2 [𝑅]𝑚
𝜕𝑥2
+ 𝜙2 = 0         (6A.2) 
𝜕[𝐻𝐴]𝑎𝑞
𝜕𝑡
= 𝐷𝐻𝐴𝑎𝑞
𝜕2 [𝐻𝐴]𝑎𝑞
𝜕𝑥2
+ 𝜙3 = 0         (6A.3) 
𝜕[𝐴−]𝑎𝑞
𝜕𝑡
= 𝐷𝐴𝑎𝑞−
𝜕2 [𝐴−]𝑎𝑞
𝜕𝑥2
+ 𝜙4 = 0         (6A.4) 
𝜕[𝐻𝐴]𝑚
𝜕𝑡
= 𝐷𝐻𝐴𝑚
𝜕2 [𝐻𝐴]𝑚
𝜕𝑥2
+ 𝜙5 = 0         (6A.5) 
𝜕[𝑂𝐻−]
𝜕𝑡
= 𝐷𝑂𝐻−
𝜕2 [𝑂𝐻−]
𝜕𝑥2
+ 𝜙6 = 0         (6A.6) 
𝜕[𝐻+]
𝜕𝑡
= 𝐷𝐻+
𝜕2 [𝐻+]
𝜕𝑥2
+ 𝜙7 = 0         (6A.7) 
∂[BH+]𝑎𝑞
∂t
= DBH+
∂2 [BH+]𝑎𝑞
∂x2
+ ϕ8 = 0         (6A.8) 
∂[𝐵]𝑎𝑞
∂t
= D𝐵
∂2 [B]𝑎𝑞
∂x2
+ ϕ9 = 0          (6A.9) 
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where ϕ1-9 are the reaction rate functions.  At equilibrium, the reaction rate of the reactant should 
be the opposite of the product.  Based on the chemical equilibria, the followings can be written: 
𝜙1 = −𝜙2                     (6A.10) 
𝜙3 = −𝜙4 − 𝜙5                    (6A.11) 
ϕ8 = −ϕ9                     (6A.12) 
Because of A- is a product of the reactions between HA, B and BH+, so reaction rate of A- can be 
reflected by the reaction rate of B, H+ and OH-, therefore, 
𝜙4 = 𝜙7 − 𝜙6 − 𝜙9                    (6A.13) 
Based on equation 6A.13, equation 6A.11 can be written as:  
𝜙3 = 𝜙6 + 𝜙9 − 𝜙5 − 𝜙7                   (6A.14) 
Based on the equations 6A.10, 6A.11, 6A.12 and 6A.14, the following mass balance equations can 
be written:  
𝐷𝑅𝑎𝑞
𝑑2 [𝑅]𝑎𝑞
𝑑𝑥2
= −𝐷𝑅𝑚
𝑑2 [𝑅]𝑚
𝑑𝑥2
                   (6A.15) 
𝐷𝐻𝐴𝑎𝑞
𝑑2 [𝐻𝐴]𝑎𝑞
𝑑𝑥2
= −𝐷𝐴𝑎𝑞−
𝑑2[𝐴−]𝑎𝑞
𝑑𝑥2
− 𝐷𝐻𝐴𝑚
𝑑2 [𝐻𝐴]𝑚
𝑑𝑥2
                (6A.16) 
𝐷𝐻𝐴𝑎𝑞
𝑑2 [𝐻𝐴]𝑎𝑞
𝑑𝑥2
= 𝐷𝑂𝐻−
𝑑2 [𝑂𝐻−]
𝑑𝑥2
+ 𝐷𝐵𝑎𝑞
𝑑2 [𝐵]𝑎𝑞
𝑑𝑥2
− 𝐷𝐻+
𝑑2[𝐻+]
𝑑𝑥2
− 𝐷𝐻𝐴𝑚
𝑑2 [𝐻𝐴]𝑚
𝑑𝑥2
            (6A.17) 
𝐷𝐵𝑎𝑞
𝑑2 [𝐵]𝑎𝑞
𝑑𝑥2
= −𝐷𝐵𝐻𝑎𝑞+
𝑑2 [𝐵𝐻+]𝑎𝑞
𝑑𝑥2
                  (6A.18) 
Integrating equations 6A.15 to 6A.18 once gives: 
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𝐷𝑅𝑎𝑞
𝑑[𝑅]𝑎𝑞
𝑑𝑥
= −𝐷𝑅𝑚
𝑑 [𝑅]𝑚
𝑑𝑥
+ 𝐶1                  (6A.19) 
𝐷𝐻𝐴𝑎𝑞
𝑑 [𝐻𝐴]𝑎𝑞
𝑑𝑥
= −𝐷𝐴𝑎𝑞−
𝑑[𝐴−]𝑎𝑞
𝑑𝑥
− 𝐷𝐻𝐴𝑚
𝑑 [𝐻𝐴]𝑚
𝑑𝑥
+ 𝐶2               (6A.20) 
𝐷𝐻𝐴𝑎𝑞
𝑑 [𝐻𝐴]𝑎𝑞
𝑑𝑥
= 𝐷𝑂𝐻−
𝑑 [𝑂𝐻−]
𝑑𝑥
+ 𝐷𝐵𝑎𝑞
𝑑 [𝐵]𝑎𝑞
𝑑𝑥
− 𝐷𝐻+
𝑑[𝐻+]
𝑑𝑥
− 𝐷𝐻𝐴𝑚
𝑑 [𝐻𝐴]𝑚
𝑑𝑥
+ 𝐶3            (6A.21) 
𝐷𝐵𝑎𝑞
𝑑 [𝐵]𝑎𝑞
𝑑𝑥
= −𝐷𝐵𝐻𝑎𝑞+
𝑑 [𝐵𝐻+]𝑎𝑞
𝑑𝑥
+ 𝐶4                  (6A.22) 
Since 𝐴𝑎𝑞
−  is the product of the reaction between HA, B and OH-, so its flux can be reflected by B, 
OH- and H+: 
−𝐷𝐴𝑎𝑞−
𝑑[𝐴−]𝑎𝑞
𝑑𝑥
= 𝐷𝑂𝐻−
𝑑 [𝑂𝐻−]
𝑑𝑥
+ 𝐷𝐵𝑎𝑞
𝑑 [𝐵]𝑎𝑞
𝑑𝑥
− 𝐷𝐻+
𝑑[𝐻+]
𝑑𝑥
               (6A.23) 
With this mass balance relationship, it can be seen that  
𝐶2 = 𝐶3                     (6A.24) 
Since the concentration of buffer is conserved, the total flux of buffer should be equal to zero, 
therefore,  
𝐶4 = 0                      (6A.25) 
Integrating equations 6A.19 to 6A.22 once gives:  
𝐷𝑅𝑎𝑞[𝑅]𝑎𝑞 = −𝐷𝑅𝑚[𝑅]𝑚 + 𝐶1𝑥 + 𝐶5                 (6A.26)   
𝐷𝐻𝐴𝑎𝑞[𝐻𝐴]𝑎𝑞 = −𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚−𝐷𝐴𝑎𝑞− [𝐴
−]𝑎𝑞 + 𝐶2𝑥 + 𝐶6               (6A.27) 
𝐷𝐻𝐴𝑎𝑞[𝐻𝐴]𝑎𝑞 = 𝐷𝑂𝐻−[𝑂𝐻
−] + 𝐷𝐵𝑎𝑞[𝐵]𝑎𝑞 − 𝐷𝐻+[𝐻
+]−𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚 + 𝐶3𝑥 + 𝐶7            (6A.28) 
𝐷𝐵𝑎𝑞[𝐵]𝑎𝑞 + 𝐷𝐵𝐻𝑎𝑞+ [𝐵𝐻
+]𝑎𝑞 = 𝐶8                  (6A.29) 
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Boundary conditions 
Based on the surface saturation model and solubility of cocrystal under surfactant conditions, the 
following boundary conditions for each species can be written: 
At x = 0:        at x = h: 
[𝑅]𝑎𝑞,0 =
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+𝐾𝑠
𝑅[𝑚]
   [𝑅]𝑎𝑞,ℎ = 0 (under sink condition) 
[𝐻𝐴]𝑎𝑞,0 = (
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)2/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚]
  [𝐻𝐴]𝑎𝑞,ℎ = 0 (under sink condition) 
[𝑅]𝑚,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛      [𝑅]𝑚,ℎ = 0 (under sink condition) 
[𝐻𝐴]𝑚,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛      [𝐻𝐴]𝑚,ℎ = 0 (under sink condition) 
[𝐴−]𝑎𝑞,0 = 𝑢𝑛𝑘𝑛𝑜𝑤𝑛      [𝐴
−]𝑎𝑞,ℎ = 0 (under sink condition) 
[𝐵]𝑎𝑞 = [𝐵]0       [𝐵]𝑎𝑞 = [𝐵]ℎ 
[𝐵𝐻+]𝑎𝑞 = [𝐵𝐻
+]0      [𝐵𝐻
+]𝑎𝑞 = [𝐵𝐻
+]ℎ 
[𝐻+] = [𝐻+]0       [𝐻
+] = [𝐻+]ℎ 
[𝑂𝐻−] = [𝑂𝐻−]0      [𝑂𝐻
−] = [𝑂𝐻−]ℎ 
Evaluation of interfacial pH   
Applying the above boundary conditions to equations 6A.27 to 6A.29, at x = 0:  
𝐷𝐻𝐴𝑎𝑞(
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)2/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚]
= −𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚,0−𝐷𝐴𝑎𝑞− [𝐴
−]𝑎𝑞,0 + 𝐶6         (6A.30) 
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𝐷𝐻𝐴𝑎𝑞(
𝐷𝑅𝑒𝑓𝑓
𝐷𝐻𝐴𝑒𝑓𝑓
)2/3
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚]
= 𝐷𝑂𝐻−[𝑂𝐻
−]0 + 𝐷𝐵𝑎𝑞[𝐵]0 −
𝐷𝐻+[𝐻
+]0−𝐷𝐻𝐴𝑚[𝐻𝐴]𝑚,0 + 𝐶7                  (6A.31) 
𝐷𝐵𝑎𝑞[𝐵]0 + 𝐷𝐵𝐻𝑎𝑞+ [𝐵𝐻
+]0 = 𝐶8                  (6A.32) 
and at x = h, since sink conditions are assumed, 6A.27 to 6A.29 can be written as: 
𝐶2ℎ + 𝐶6 = 0                     (6A.33) 
0 = 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ + 𝐷𝐵𝑎𝑞[𝐵]ℎ − 𝐷𝐻+[𝐻
+]ℎ + 𝐶3ℎ + 𝐶7               (6A.34) 
𝐷𝐵𝑎𝑞[𝐵]ℎ + 𝐷𝐵𝐻𝑎𝑞+ [𝐵𝐻
+]ℎ = 𝐶8                  (6A.35) 
Combining equations 6A.30 to 6A.35 and algebraically solving for interfacial pH, [H+]0, yields the 
following equation: 
𝐴[𝐻+]0
7
+ 𝐵[𝐻+]0
6
+ 𝐶[𝐻+]0
5
+ 𝐷[𝐻+]0
4
+ 𝐸[𝐻+]0
3
+ 𝐹[𝐻+]0
2
+ 𝐺[𝐻+]0 + 𝐻 = 0 (6A.36) 
where 
𝐴 = (𝐷𝐻+𝐷𝐵𝐻𝑎𝑞+ )
2(1 + 𝐾𝑠
𝐻𝐴[𝑚]); 
𝐵 = 2𝐷𝐻+𝐷𝐵𝐻𝑎𝑞+ [𝐷𝐻+DBaqKa
B + 𝐷𝐵𝐻𝑎𝑞+ (DBaq[B]h − 𝐷𝐻+[𝐻
+]ℎ + 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)](1 +
𝐾𝑠
𝐻𝐴[𝑚]); 
𝐶 = 2𝐷𝐻+𝐷𝐵𝐻𝑎𝑞+ [DBaqKa
B (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐵𝐻𝑎𝑞+ [𝐵𝐻
+]ℎ − 𝐷𝐻+[𝐻
+]ℎ) − 𝐷𝑂𝐻−𝐾𝑤𝐷𝐵𝐻𝑎𝑞+ ] (1 +
𝐾𝑠
𝐻𝐴[𝑚]) + (1 + 𝐾𝑠
𝐻𝐴[𝑚]) [𝐷𝐻+DBaqKa
B + 𝐷𝐵𝐻𝑎𝑞+ (DBaq[B]h − 𝐷𝐻+[𝐻
+]ℎ + 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)]
2
+
2Ka
HA𝐷𝐻+𝐷𝐵𝐻𝑎𝑞+ [𝐷𝐻+DBaqKa
B + 𝐷𝐵𝐻𝑎𝑞+ (DBaq[B]h − 𝐷𝐻+[𝐻
+]ℎ + 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)]; 
𝐷 = 2 [𝐷𝐻+DBaqKa
B + 𝐷𝐵𝐻𝑎𝑞+ (DBaq[B]h − 𝐷𝐻+[𝐻
+]ℎ +
𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)] [DBaqKa
B (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐵𝐻𝑎𝑞+ [𝐵𝐻
+]ℎ − 𝐷𝐻+[𝐻
+]ℎ) − 𝐷𝑂𝐻−𝐾𝑤𝐷𝐵𝐻𝑎𝑞+ ] (1 +
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𝐾𝑠
𝐻𝐴[𝑚]) − 2𝐷𝐻+𝐷𝐵𝐻𝑎𝑞+ 𝐷𝑂𝐻−𝐾𝑤DBaqKa
B(1 + 𝐾𝑠
𝐻𝐴[𝑚]) +
2𝐷𝐻+𝐷𝐵𝐻𝑎𝑞+ Ka
HA [DBaqKa
B (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐵𝐻𝑎𝑞+ [𝐵𝐻
+]ℎ − 𝐷𝐻+[𝐻
+]ℎ) − 𝐷𝑂𝐻−𝐾𝑤𝐷𝐵𝐻𝑎𝑞+ ] +
[𝐷𝐻+DBaqKa
B + 𝐷𝐵𝐻𝑎𝑞+ (DBaq[B]h − 𝐷𝐻+[𝐻
+]ℎ + 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)]
2Ka
HA; 
𝐸 = [DBaqKa
B (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐵𝐻𝑎𝑞+ [𝐵𝐻
+]ℎ − 𝐷𝐻+[𝐻
+]ℎ) − 𝐷𝑂𝐻−𝐾𝑤𝐷𝐵𝐻𝑎𝑞+ ]
2
(1 +
𝐾𝑠
𝐻𝐴[𝑚]) − 2𝐷𝑂𝐻−𝐾𝑤DBaqKa
B [𝐷𝐻+DBaqKa
B + 𝐷𝐵𝐻𝑎𝑞+ (DBaq[B]h − 𝐷𝐻+[𝐻
+]ℎ +
𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)] (1 + 𝐾𝑠
𝐻𝐴[𝑚]) − 2𝐷𝐻+𝐷𝐵𝐻𝑎𝑞+ 𝐷𝑂𝐻−𝐾𝑤DBaqKa
BKa
HA + 2 [𝐷𝐻+DBaqKa
B +
𝐷𝐵𝐻𝑎𝑞+ (DBaq[B]h − 𝐷𝐻+[𝐻
+]ℎ + 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)] [DBaqKa
B (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐵𝐻𝑎𝑞+ [𝐵𝐻
+]ℎ −
𝐷𝐻+[𝐻
+]ℎ) − 𝐷𝑂𝐻−𝐾𝑤𝐷𝐵𝐻𝑎𝑞+ ] Ka
HA − (𝐷𝐴𝑎𝑞−
1/3
𝐷𝑅𝑒𝑓𝑓
2/3
DBaqKa
HA√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚]))
2; 
𝐹 = Ka
HA [DBaqKa
B (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐵𝐻𝑎𝑞+ [𝐵𝐻
+]ℎ − 𝐷𝐻+[𝐻
+]ℎ) − 𝐷𝑂𝐻−𝐾𝑤𝐷𝐵𝐻𝑎𝑞+ ]
2
−
2𝐷𝑂𝐻−𝐾𝑤DBaqKa
B [DBaqKa
B (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ − 𝐷𝐵𝐻𝑎𝑞+ [𝐵𝐻
+]ℎ − 𝐷𝐻+[𝐻
+]ℎ) −
𝐷𝑂𝐻−𝐾𝑤𝐷𝐵𝐻𝑎𝑞+ ] (1 + 𝐾𝑠
𝐻𝐴[𝑚]) − 2𝐷𝑂𝐻−𝐾𝑤DBaqKa
BKa
HA [𝐷𝐻+DBaqKa
B + 𝐷𝐵𝐻𝑎𝑞+ (DBaq[B]h −
𝐷𝐻+[𝐻
+]ℎ + 𝐷𝑂𝐻−[𝑂𝐻
−]ℎ)] − 2Ka
B(𝐷𝐴𝑎𝑞−
1/3
𝐷𝑅𝑒𝑓𝑓
2/3
DBaqKa
HA√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚]))
2; 
𝐺 = (𝐷𝑂𝐻−𝐾𝑤DBaqKa
B)2(1 + 𝐾𝑠
𝐻𝐴[𝑚]) − 2𝐷𝑂𝐻−𝐾𝑤DBaqKa
BKa
HA [DBaqKa
B (𝐷𝑂𝐻−[𝑂𝐻
−]ℎ −
𝐷𝐵𝐻𝑎𝑞+ [𝐵𝐻
+]ℎ − 𝐷𝐻+[𝐻
+]ℎ) − 𝐷𝑂𝐻−𝐾𝑤𝐷𝐵𝐻𝑎𝑞+ ] − (𝐷𝐴𝑎𝑞−
1/3
𝐷𝑅𝑒𝑓𝑓
2/3
DBaqKa
HAKa
B√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚]))
2; 
𝐻 = Ka
HA(𝐷𝑂𝐻−𝐾𝑤DBaqKa
B)2. 
Evaluation of flux of the cocrystal components:   
Applying the boundary conditions to equation 6A.26, at x = 0: 
𝐷𝑅𝑎𝑞
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+𝐾𝑠
𝑅[𝑚]
= −𝐷𝑅𝑚𝐾𝑠
𝑅[𝑚]
√𝐾𝑠𝑝(1+𝐾𝑠
𝑅[𝑚])(1+
𝐾𝑎
𝐻0
++𝐾𝑠
𝐻𝐴[𝑚])
1+𝐾𝑠
𝑅[𝑚]
+ 𝐶5           (6A.37) 
and at x = h, assuming sink conditions: 
0 = 𝐶1ℎ + 𝐶5                                (6A.38) 
Combining the above equations and solving for −𝐶1 for the flux of the cocrystal in terms of drug: 
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𝐽𝑅 =
𝐷𝑅𝑒𝑓𝑓
ℎ𝑅
√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(1 +
𝐾𝑎
𝐻0
+ + 𝐾𝑠
𝐻𝐴[𝑚])                (6A.39) 
By substituting the thickness of the hydrodynamic boundary layer for rotating disk (ℎ =
1.612𝐷
1
3𝑣
1
6𝜔−
1
2)1, equation 6A.39 becomes: 
𝐽𝑅 = 0.62𝐷𝑅𝑒𝑓𝑓
2/3
𝜔1/2𝑣−1/6√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(1 +
𝐾𝑎
𝐻0
+ + 𝐾𝑠
𝐻𝐴[𝑚])              (6A.40) 
The flux of the cocrystal in terms of coformer can be also solved in a similar manner by applying 
the boundary conditions to equation 6A.27: 
𝐽𝐻𝐴 =
𝐷𝐻𝐴𝑒𝑓𝑓
1
3 𝐷𝑅𝑒𝑓𝑓
2
3
ℎ𝐻𝐴
√𝐾𝑠𝑝(1 + 𝐾𝑠𝑅[𝑚])(1 +
𝐾𝑎
𝐻0
+ + 𝐾𝑠
𝐻𝐴[𝑚])               (6A.41) 
By substituting the boundary layer thickness into equation 6A.41, it can be shown to equal to 
equation 6A.40.  This is expected since the flux of drug and coformer should be the same for a 1:1 
cocrystal even though they have different diffusivities.   
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CHAPTER 7 
CONCLUSIONS AND FUTURE DIRECTIONS 
The fundamental frameworks have been built in this dissertation to understand the 
dissolution behavior of cocrystals under different solution conditions.  Unlike the empirical 
approaches that are based on experimental observations, this thesis relies on the mass transport 
phenomenon to explain the dissolution behavior of cocrystals.  The mechanism of cocrystal 
dissolution has been investigated through the development of mass transport models by applying 
Fick’s law of diffusion to dissolution with simultaneous chemical reactions in the hydrodynamic 
boundary layer adjacent to the dissolving cocrystal solid surface.  These mass transport models 
have emphasized the importance of physicochemical properties of the cocrystal components and 
solution conditions in determining the rates of cocrystal dissolution.  Overall, this dissertation has 
provided the fundamental knowledge of cocrystal dissolution that is important for the cocrystal 
selection process and formulation development.         
 Based on the differential diffusion between the cocrystal components and the solubility 
product behavior of the cocrystals, two models, the surface saturation and interfacial equilibrium 
models have been developed to describe the dissolution process of cocrystals.  The major 
differences between the two models are related to the boundary conditions of the cocrystal 
components at the dissolving solid-liquid interface due to the different ability of the models in 
maintaining the solubility product of the cocrystal.  The different boundary conditions of the two 
models lead to different mass transport analyses that would result in different theoretical 
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predictions in interfacial pH and flux of the cocrystals.  The better agreement between the 
experimental and theoretical flux makes the surface saturation model superior to the interfacial 
equilibrium model.  Consequently, the surface saturation model was primarily used in this 
dissertation to perform mass transport analyses for evaluating the dissolution behavior of 
cocrystals in different solution conditions.   
By validating the surface saturation model, the common coformer effect on the dissolution 
rates of cocrystals was also evaluated in this thesis.  Similar to pharmaceutical salts, cocrystals 
also exhibit solubility product behavior.  Therefore, the dissolution rates of cocrystals would 
decrease in the presence of excess coformer.  These findings have provided useful insights for the 
effect of differential permeation between the cocrystal components on oral absorption.  The higher 
drug permeation can potentially result in excess coformer in the intestine that can decrease the 
dissolution rate of the continually dissolving cocrystal and consequently, result in lower oral 
absorption.   
One of the important findings of this thesis is that the interfacial pH is the significant factor 
that determines the dissolution rates of cocrystals with ionizable components.  By cocrystallizing 
with different coformers, interfacial pH can be modulated to different extents compared to the 
parent drugs.  For example, CBZ is nonionizable, so it has no ability to alter the pH at the dissolving 
surface and this means that the interfacial pH is the same as the bulk pH.  However, when it 
cocrystallizes with acidic coformers, SAC and SLC, interfacial pH is significantly different from 
the bulk solution pH.  For both cocrystals, interfacial pH decrease as coformers start to ionize and 
reach constant values at bulk pH ranges from 4 to 8 due to the self-buffering ability of the 
cocrystals.  Similarly, KTZ cocrystals with acidic coformers also lower the interfacial pH 
compared to the basic KTZ.  Besides the physicochemical properties of the cocrystals and their 
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components, solution composition, such as buffering agents can also affect the interfacial pH.  The 
presence of acetate and phosphate buffers elevates the interfacial pH of CBZ-SLC due to the 
chemical reactions between the acidic coformer and basic buffer components at the dissolving 
surface.  The mass transport models developed in this thesis are able to capture the interfacial pH 
behavior and allow accurate flux predictions for cocrystals under different solution conditions.  
Cocrystallization can not only modulate the interfacial pH, but also the dissolution pH dependence 
of the parent drugs.     
Besides solubility advantage, cocrystals can also exhibit diffusivity advantage over the 
parent drug in the presence of surfactant.  The effective diffusion coefficients of CBZ as a function 
of SLS were found to be smaller than those of the cocrystals.  These differential diffusion 
coefficients could be potentially due to the different solubility dependence on SLS between the 
drug and cocrystals.  Having higher diffusion coefficients, cocrystals would require lower or even 
no solubility advantages to maintain higher dissolution rates compared to the parent drugs.  One 
of the challenges for current cocrystal development is the potential instability of the highly soluble 
cocrystals in solution.  Therefore, the ability of identifying the conditions in which the cocrystals 
can exhibit both thermodynamic stability and dissolution advantage is important for formulation 
development.        
The important physicochemical parameters have been established in this dissertation to 
predict the in vitro dissolution behavior of cocrystals.  Moving forward with this project, in vivo 
predictive dissolution is the next logical direction.  The dissolution conditions in this thesis did not 
accurately reflect the physiological environment of the human GI tract.  Therefore, future 
dissolution studies should consider using biorelevant media, such as Fasted and Fed State 
Simulated Intestinal Fluids (FaSSIF and FeSSIF) at body temperature.  Both FaSSIF and FeSSIF 
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contain physiologically relevant surfactants (such as bile salts and phospholipids) and buffer 
species that can influence the dissolution behavior of cocrystals.  Although the mass transport 
models in this dissertation have considered both of these parameters, the power of these models in 
predicting the dissolution behavior of cocrystals in biorelevant media still remains to be explored.  
In order to be more physiologically relevant, future dissolution studies should also consider using 
powder dissolution instead of the current rotating disk dissolution.  Although there are more 
parameters, such as particle sizes and surface areas that need to be considered for modeling the 
powder dissolution, the current mass transport analyses have provided the theoretical frameworks 
for the transition from rotating disk to powder dissolution.   
The rates of dissolution and permeation are important for determining the bioavailability 
of oral drugs.  The drug permeability can be different from the coformer permeability, and there is 
a lack of studies to evaluate the effect of this differential permeation on the oral absorption of 
cocrystals.  Chapter 4 has shown that the presence of excess coformer can decrease the dissolution 
rate of cocrystal.  Therefore, it is essential to investigate whether the slower permeation of the 
coformer would result in excess concentration that could alter the dissolution rate of the 
continually dissolving cocrystal.  A dissolution/permeation system would be useful to 
simultaneously evaluate the dissolution and permeation of the cocrystal components to access the 
oral absorption mechanisms of cocrystals.  
The mass transport models in this dissertation were developed with assumptions to keep 
the analyses simple.  However, there are other factors that can influence the cocrystal dissolution 
rate have not been considered, such as ionic strength, viscosity, diffusion of the ionized 
components, solution mediated phase transformation, et al.  Future mass transport analyses should 
consider all these factors to provide more rigorous mass transport models for cocrystal flux 
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predictions.  There is also a lack of studies to demonstrate which model, surface saturation or 
interfacial equilibrium, is more physically realistic.  Future studies should explore more in this 
area.    
